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Introduction: Obesity is a significant risk factor in the development of endometrial cancer 
and poses a serious health threat. Furthermore, morbidities related to obesity are associated 
with a significantly increased risk of mortality for women who develop endometrial cancer. 
Obesity is associated with altered levels of many hormones including leptin, insulin, insulin-
like growth factor-1 (IGF-I) and adiponectin. The role of these hormones in the progression of 
endometrial cancer is largely unknown. In this study, it was hypothesised that these obesity-
related hormones including as leptin, insulin and IGF-I would promote cancer growth, while 
adiponectin would inhibit cancer growth. 
Objectives: The aim of this study was to use a number of selected cells lines to determine if 
obesity-related hormones leptin, insulin, IGF-I and adiponectin have effects on cell 
proliferation, secretion of vascular endothelial growth factor (VEGF) which is a protein 
associated with the development of blood vessels used to support the growth of cancers, and 
the expression of specific proteins associated with different cell signalling cascades. These are 
the phosphatidylinositol 3-kinase (PI-3K)/ Protein kinase B (Akt)/ mammalian target of 
rapamycin (mTOR) pathway (PI-3K/Akt/mTOR), Janus kinase family and signal transducers 
and activators of transcription-3 (JAK/STAT3) and 5' adenosine monophosphate-activated 
protein kinase (AMPK) protein.  
Materials and Methods: To examine these hypotheses, two endometrial cell lines, Ishikawa 
and HEC-1A, a breast cancer cell line, MFC-7 and an ovarian cancer cell line, SKOV-3 were 
used in this study. Cell lines were cultured and the cells exposed to selected range of leptin, 
insulin, IGF-I and adiponectin concentrations, both individually and in combinations. In some 
culture conditions, the addition of pharmacological inhibitors were used to investigate the 
hormone-stimulated cellular responses including proliferation, secretion of VEGF, and 
activation of selective signalling molecules using Western blots, flow cytometry and 
immunofluorescent imaging with an optical sectioning microscope. 
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Results:  In chapter 3, the aim of the experiments was to investigate the effects of leptin, 
insulin, IGF-I and adiponectin on cell growth and secretion of VEGF in the endometrial 
cancer cell line, Ishikawa. It was shown that leptin (20-100 ng/ml), insulin (116-2900 ng/ml), 
and IGF-I (20-500 ng/ml) increased the proliferation of the Ishikawa endometrial cancer cells. 
On the other hand, adiponectin inhibited cell proliferation at high concentrations (50 - 100 
ng/ml) while increasing it at a lower concentration (20 ng/ml). The combinations of leptin, 
insulin or IGF-I with adiponectin showed different responses, and there was a lack of 
evidence for additive growth effects in the combinations. For instance, addition of adiponectin 
(20 ng/ml) to leptin or insulin increased cell numbers. However, the combination of 
adiponectin (20 ng/ml) and IGF-I reduced cell numbers to the control (no growth factor) 
levels. These findings suggest that IGF-I uses a different pathway to that used by leptin and 
insulin to increase cell proliferation. 
In chapter 3, the secretion of VEGF was also investigated. Ishikawa cells did not increase 
VEGF secretion in response to leptin, insulin or IGF-I compared to control cells. In contrast, 
the VEGF secretion was increased by adiponectin (20-100 ng/ml).  
In chapter 4, the aim of the experiments was to compare the effects of these hormones 
on alternative cancer cell lines with endometrial cancer cell line Ishikawa. The selected cell 
lines were the endometrial cancer cell line, HEC-1A, a breast cancer cell line MCF-7 and an 
ovarian cancer cell line, SKOV-3. Cell proliferation, level of apoptosis and VEGF secretion 
were determined in these cell lines, and the results showed that the effects of the hormones on 
these parameters were cell line-dependent. For example, cell numbers were increased by 
leptin, insulin and IGF-I in HEC-1A cells, but insulin did not increase cell numbers in the 
MCF-7 cell line. In addition, none of these three hormones affected SKOV-3 cell numbers. 
In chapter 5, experiments aimed to investigate the mechanism by which leptin 
stimulates proliferation of Ishikawa cells. Leptin was shown to trigger oncogenic signalling 
proteins including PI-3K/Akt/mTOR, JAK/STAT3 and AMPK, thus suggesting that leptin 
stimulated cell proliferation by triggering PI-3K and JAK activation. This was confirmed by 
the inhibition of these two proteins using specific inhibitors. The results also suggested that 
there is a cross-talk between JAK/STAT3 and PI-3K/Akt/mTOR pathways, and that JAK is 
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the upstream protein for these two pathways. Leptin’s ability to reduce the secretion of VEGF 
was not affected by these two inhibitors. Thus, these results also suggest that cell proliferation 
and VEGF secretion are independently regulated by leptin because leptin increased cell 
proliferation using JAK/PI-3K pathways and reduced VEGF secretion by reduction in AMPK 
pathway. It is interesting to note that levels of AMPK and phosphorylated AMPK (p-AMPK), 
which are often associated with or have been reported to be responsible for VEGF secretion in 
cancer cells, did not show a significant change in leptin-treated cells. This may explain the 
reduction in VEGF secretion in the presence of leptin. 
In chapter 6, experimental aims were to investigate the effects of two concentrations (20 
ng/ml and 100 ng/ml) of adiponectin on cell proliferation and secretion of VEGF from the 
Ishikawa cell line. The lower concentration of adiponectin increased cell proliferation and 
VEGF secretion. Furthermore, it also increased the levels of Akt, p-Akt, STAT3, p-STAT3, 
AMPK, and p-AMPK as detected by Western blotting. These results suggest that low 
concentrations of adiponectin stimulated cell proliferation in a similar manner to leptin except 
for the AMPK protein expressions, and that adiponectin was triggering the PI-3K/Akt and 
JAK/STAT3 pathways. Moreover, that these low concentrations of adiponectin increased 
AMPK and p-AMPK proteins expression and also increased the VEGF secretion, which was 
unexpected. However, this increase in VEGF secretion was produced only in 20 ng/ml 
adiponectin, stimulating conditions. This may suggest that 20 ng/ml adiponectin is a more 
highly tumorigenic stimulator than leptin. Higher concentration of adiponectin (100 ng/ml) 
reduced Ishikawa cell proliferation. The reduction of cell proliferation was not via the 
inhibition of any of the stimulatory pathways. This suggests that high adiponectin 
concentration may exert its inhibitory effects via different pathways other than the stimulatory 
pathways.   
In chapter 7, the aim of the experiments was to investigate the stimulatory effects on 
growth of insulin and IGF-I in Ishikawa cells. Results showed that both insulin and IGF-I 
increased cell numbers but reduced secretion of VEGF. The level of Akt and p-Akt were 
elevated but AMPK expression was not changed, and p-AMPK was significantly reduced. 
Collectively, these results suggest that insulin and IGF-I activate cell proliferation through a 
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PI-3K/Akt pathway. Again, it was interesting to note that low AMPK was linked to the low 
secretion of VEGF that was observed in the presence of insulin and IGF-I. 
Conclusions: Initially, it was hypothesised that leptin, insulin and IGF-I promote cancer 
growth, while adiponectin inhibits it. The results were generally consistent with the initial 
hypothesis in some cases. For example, all of the so-called tumorigenic hormones, (that is, 
leptin, insulin and IGF-I) increased proliferation in Ishikawa cells, however, these hormones 
reduced the secretion of angiogenic signal VEGF, moreoever, responses to these hormones 
varied between cell lines, with the hormones stimulating proliferation in the endometrial cell 
line and the breast cell line but not in the ovarian cell line. 
On the other hand, in Ishikawa cells it was found that while higher concentrations of 
adiponectin reduced proliferation of tumour cells and increased VEGF secretion, as expected, 
lower concentrations of adiponectin resulted in a surprising increase in cell proliferation as 
well as an increase in VEGF secretion.  
Investigation of the expression of certain intracellular mediators in Ishikawa cells would 
suggest that leptin-induced cell proliferation but not VEGF secretion is stimulated via the PI-
3K/Akt/mTOR pathway and that the JAK/STAT3 pathway is an important mediator of this. 
Leptin, insulin and IGF-I all increased proliferation and decreased VEGF secretion from 
Ishikawa cancer cells. While it was demonstrated that activation of the PI-3K/Akt/mTOR 
pathway occurred, there were some differences in response, especially when in combination 
with adiponectin, that suggested the utilisation of different pathways or receptors. 
From these experiments, it is impossible to determine the effect of these hormones in vivo. 
While it is somewhat unexpected that VEGF secretion was normally reduced with increasing 
cell proliferation, these findings are consistent with the hypothesis that obesity-related 
hormones, and particularly the combination of higher levels of leptin combined with lower 
levels of adiponectin, have an impact on tumour growth in obese women with low grade 
endometrial cancer. 
Further in vivo and clinical studies are required to determine the clinical importance of these 
relationships and to explore the therapeutic potential of targets within the identified pathways.  
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New observations in this study; While it is recognised that there is a significant literature of 
the potential impact of leptin and adiponectin on cancer growth, I have attempted to perform a 
systematic study of the chosen hormones on Ishikawa cells and to compare these findings 
with those of other cell lines. The studies performed for this thesis contribute to an 
understanding of this subject in the following areas. 
 Using Ishikawa cells, I have described the contradictory increase in proliferation 
but decrease in VEGF secretion under the influence of leptin, insulin and IGF-I. Using 
these cells, I have also described how low concentrations of adiponectin increase cell 
proliferation while higher concentrations inhibit proliferation but increase VEGF 
secretion. I have also described how these effects compare with the effects of these 
hormones in a selection of other cell lines. 
 I have documented the presence of the receptors of leptin (Ob-R), insulin (InsR), 
IGF-I (IGFR) and adiponectin (AdipoR) in the cell membrane, cytoplasm and nucleus.  
 I also described serine phosphorylation of STAT3 in Ishikawa cells in the 
presence of leptin and low adiponectin and provided evidence that cross-talk occurred 
between PI-3K/Akt/mTOR and JAK/STAT3 pathways in Ishikawa endometrial cancer 
cells. In addition, an increase in AMPK and p-AMPK in association with increased 
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1.1.1. Obesity, an overview 
Obesity is a major concern in developed and developing societies [1, 2]. Body fatness is 
usually assessed using body mass index (BMI), which is calculated as a person’s weight in 
kilograms divided by the square of their height in metres. This provides a simple index of 
weight relative to height that can be measured easily in population studies. A BMI of 20–24.9 
kg/m2 is considered normal, a BMI of 25–29.9 kg/m2 is classed as overweight and a BMI of 
30 kg/m2 or more as obese. Waist circumference (WC) is another simple measure of adiposity 
[3]. However, for a given WC value, overweight and obese subjects and normal-weight 
subjects have similar health risks. Nevertheless, BMI remains a significant predictor of health 
risk whether or not WC is normal or high [4]. 
Obesity is a significant public health problem among children and adults [5, 6], and has 
adverse impacts on society at large [7]. Rates of obesity have increased three-fold or more 
since 1980 in many areas including North America, the United Kingdom, Eastern Europe, the 
Middle East, the Pacific Islands, Australasia and China [5, 6]. Worldwide, more than one 
billion adults have been categorised as overweight, and 300 million categorised as obese [5, 
6]. The number of deaths resulting from obesity were calculated to be between 100,000 to 
300,000 per year from a wide variety of causes [3, 8, 9].  
The Organisation for Economics, Co-operation and Development (OECD) report in 
2014 titled ‘Obesity and the Economics of Prevention: Fit not Fat’ [10], reported that New 
Zealand has the third highest percentage of overweight and obese children in the OECD after 
Greece and Italy [10, 11]. One third of New Zealand children are considered overweight or 
obese, in contrast only one quarter of Australian children are in this category [10, 11]. By 
comparison, 64% of the population of the United States of America (USA) was overweight or 




Obesity has been associated with the incidence of several types of cancer in both 
women and men, including cancer of the oesophagus, colon, pancreas, endometrium, and 
kidney, as well as postmenopausal breast cancer [2, 3, 12]. A World Health Organisation 
(WHO) 2014 report concluded that obesity is the most important risk factor worldwide for 
cancer [3]. Alterations of metabolic profiles associated with obesity (e.g. excess circulating 
free fatty acids), some genetic factors and lifestyle factors may also increase cancer risk [3, 
13]. The risk of endometrial cancer progressing to later stages is significantly reduced by an 
increase in physical activity by obese women [14] and for several cancers, avoidance of 
weight gain reduces the risk [3, 15, 16].  This thesis, therefore, focuses on the links between 
obesity and the progression of endometrial cancer. 
Although the mechanisms through which obesity increases cancer risk are only partially 
understood, it is likely that the influence of obesity is partly mediated through hormonal 
mechanisms, consistent with observations of the effects of exogenous and endogenous 
hormones such as oestrogen and progesterone [3]. Nevertheless, hormonal effects appear to 
vary between different cancer types and sites [3]. For breast and endometrial cancers, the 
increase in cancer risk associated with obesity in postmenopausal women is possibly related 
to the increase in circulating oestrone, in turn due to increased formation of oestrogens from 
precursor hormones in the adipose tissue. Obesity also increases the risk of endometrial 
cancer in premenopausal women, and this may be due to anovulation and reduced production 
of progesterone [3]. 
There are several further inter-related and confounding factors connecting obesity to 
cancer risk, including physical activities, diet, and energy balance, but links between these 
factors and cancer risk have not been sufficiently investigated from an epidemiological 
standpoint. The effect of abnormal metabolism, including metabolic disorders within 
overweight people, might be a key. In one extensive population study [17], improved 
metabolic health diminished the risk of obesity-related cancer. The cellular and molecular 
pathways linking weight gain with established [18] hallmarks of cancer [19] remain unclear. 
These pathways, however, remain under the spotlight of current research [20]. Altered 




insulin-like growth factor and adiponectin, are also differentially controlled in the obese state 
[20].  
Obesity is recognized as a chronic inflammatory condition that influences 
cardiovascular disease, and has been linked to approximately 20% of all cancers [3, 4]. 
Obesity’s influences vary with gender and cancer-type [2]. One aspect of obesity’s influence 
involves the accumulation of macrophages in adipose tissue which establishes pro-
inflammatory feedback loops among macrophages, pre-adipocytes and adipocytes, leading to 
the generation of inflammatory cytokines and free radicals [3, 21]. The size of the adipose 
tissue stores, referred to as adiposity, increases in periods of food intake and relaxation, and 
declines when energy expenditure is in excess of intake [22]. This increased adiposity 
bestows a higher risk of developing certain cancers in obese individuals such as endometrial 
and breast cancers [23-25] (Figure 1.1). Notably, the risk of endometrial cancer increases 





Figure 1.1 The relationship between body mass index and the risk of developing 
cancers of the endometrium, ovary and breast. The dashed line indicates a 
relative risk of 1 which means that at that level, obesity does not significantly 
alter the risk. Data are from reference [3]. (Illustrated with permission from the 
copyright holder). 
  
There are direct effects of obesity and adiposity on the secretion of pro-inflammatory 
cytokines and adipokines, and there are also indirect effects such as insulin resistance and 
high insulinaemia (an excessive increase in insulin concentration in the blood) that are 
commonly associated with obesity or an increase in the levels of steroid hormones. Obese 
women with endometrial cancer also have significantly higher death rates from other obesity-
related health problems, such as type II diabetes and heart disease, when compared to healthy 
women [26, 27]. In this project, I investigate the effects of four hormones that may be 




dysregulated in obesity. These hormones are leptin, insulin, insulin-like growth factor-I (IGF-
I) and adiponectin.  
1.1.2. The white adipose tissue   
White adipose tissue (WAT) mass, which is one of the two types of adipose tissue 
found in mammals (the other kind is brown adipose tissue), is characteristically increased in 
obese individuals [22, 23]. Indeed, WAT has many key roles in mammalian physiology such 
as glucose homeostasis, energy expenditure, source of many hormones, thermal insulator etc. 
[28]. Previous research indicates that WAT acts as a long-term fuel reserve, and this reserve 
can provide other organs with fatty acids for oxidation in cases of food deprivation.  
A change in our understanding of WAT function came with the discovery of the 
cytokine-like factor, leptin [29], which revealed an active, endocrine role for WAT [19]. 
Leptin hormone is secreted principally from adipocytes (fat cells) within the WAT, and it acts 
in central organs, particularly the hypothalamus, and in peripheral organs. Neurons in the 
brain such as neuropeptide Y (NPY) and melanocyte-stimulating hormone (MSH) neurons 
release peptides in response to leptin secretion from adipose tissue and increased food intake 
by the humans [28]. However, leptin is not the only adipokine secreted by WAT, with 
adiponectin being another example [28, 30-32].  
Obesity is associated with both systemic and local inflammation of WAT. Similarly, 
WAT from obese patients is infiltrated by leukocytes, including macrophages and T 
lymphocytes [12, 33], which may create a microenvironment that favours tumour growth and 
metastasis [12, 34]. Thus, it has been observed that WAT influences tumour progression 
including endometrial, oesophageal, colorectal and renal cancers [22, 23]. 
1.1.3. Obesity and the level of hormones 
The levels of peripheral hormones, including leptin, adiponectin, insulin, and insulin-
like growth factor-1 (IGF-I) are different between obese and lean individuals [16, 35]. Leptin 
concentrations are markedly lower in women with low BMI and higher in women with 




obese women than in normal weight subjects [38]. In the obese state, there is an increase in 
the size and number of adipocytes. This change in the composition of the adipose tissue is 
part of the reason for the increased secretion of leptin and a decrease in the secretion of 
adiponectin [16]. Obesity is also associated with an elevation of the insulin concentration [39, 
40]. In contrast, IGF-I levels are markedly lower in obese subjects compared to lean, age-
matched, controls [41]. It seems likely that over nutrition and excessive secretion of insulin 
(hyperinsulinaemia) in obese subjects modulates regulated growth response through the 
insulin stimulated production of IGF-1, and through the  suppression of the secretion of 
hepatic insulin-like growth factor binding proteins (IGFBP-1 and IGFBP-2) [42]. Thus, as a 
consequence of their disrupted regulation, these hormones may have a crucial role in the 
carcinogenesis of endometrial cancer [16, 43] and possibly other cancers [12, 44]. 
1.2. Hormones of obesity and cancer 
A number of hormones have been studied in relation to the development and 
progression of cancer. These include insulin, glucocorticoids, tumour necrosis factor α (TNF 
α), and reproductive hormones such as progesterone, testosterone and estradiol [45]. The most 
well-studied of these, and a key player in the development of various cancers, is oestrogen 
[46]. 
Oestrogens exhibit a broad spectrum of physiological functions ranging from regulation 
of the menstrual cycle and reproduction to modulation of bone density, brain function, and 
cholesterol mobilization. Despite the beneficial actions of endogenous oestrogen, sustained 
exposure to exogenous oestrogen is a well-established risk factor for various cancers [46-50]. 
However, other obesity-related hormones have rarely been investigated in a systematic way. 
Of the obesity-related hormones selected for study in this project, leptin, insulin and IGF-I 
have been reported to promote cancer proliferation [51-61]. Furthermore, adiponectin is 
secreted from the same tissue as leptin and is believed to inhibit the proliferation of cancer 
cells [62-64]. The effects of these four hormones on cell proliferation, vascular endothelial 
growth factor (VEGF) secretion, and apoptosis will be investigated in this project, and these 





Leptin (derived from Greek λεπτός, leptos, meaning "thin") is a protein hormone that 
plays a key role in regulating energy intake and expenditure, including appetite/hunger, 
metabolism, and the behaviour of cancer cells [31, 65-67]. Leptin’s sequence is highly 
conserved among mammalian species, and the disruption of leptin regulation can lead to 
obesity [68]. Thus, leptin was discovered in 1994 [29, 65] through the identification of a 
mutated gene which was responsible for the development of obesity in obese (ob/ob) / mice, 
and so leptin is sometimes also called Ob protein. Very low leptin concentrations are found in 
the plasma of ob/ob mice, and these animals eat excessively [69]. Similar studies in another 
mutant, the obese (fa/fa) Zucker rat that exhibits hyperleptinaemia, hyperinsulinemia, and 
hyperlipidemia, led to the identification of the leptin receptor [70]. In humans, the leptin gene 
(Lep(ob)) is located on chromosome 7 [71] and encodes a protein with a molecular weight of 
18 kDa. This protein contains a signal sequence which is cleaved to produce the mature leptin 
hormone of molecular weight 16 kDa [29], and leptin’s sequence is highly conserved among 
mammalian species [68]. The human leptin receptor gene is found within the 5.1 cM interval 
[46]. Ob-Rb (full-length and functional isoform, 48 kDa) and Ob-Ra (a short isoform, 42 
kDa) are the main isoforms [72, 73].  
Most recently, leptin receptors were found to have an association with human puberty 
[74]. The association between fat mass and pubertal timing is partly facilitated via the 
activities of the metabolic hormone leptin, which is considered as the key player in weight 
control [75]. It is well established that humans and mice lacking leptin (ob/ob) or the leptin 
receptor (db/db) are unable to reach puberty they are also likely to be infertile [76]. Genome-
wide association studies (GWAS) of pubertal timing revealed that leptin cell signalling has a 
cross-talk with many genes that are involved with BMI, such as FTO, SEC16B, TMEM18 and 
NEGR1 [77]. On the other hand, a medical condition self-limited delayed puberty (DP), which 
is a highly heritable trait that often segregates in an autosomal dominant pattern, was found to 
be correlated with low leptin concentrations (hypoleptinaemia) in boys [78]. Disruption of 
neither leptin nor the leptin receptor did not exhibit a clear association with polymorphisms 




partly involved in the mechanism by which energy homeostasis regulates reproductive 
progression [79]. 
The level of circulating leptin is directly correlated with the total amount of fat in the 
body [12, 80-82], and leptin levels in obese individuals are higher than in lean individuals 
(26.9 ± 3.9 and 5.9 ± 0.7 µg/L) respectively [83]. Previous studies suggested that leptin was 
only synthesised in WAT, but it has now been established that the hormone is produced in a 
broad range of tissues and organs including the brown adipose tissue, stomach, placenta, 
mammary gland, ovarian follicles, certain fetal organs such as the heart and bone or cartilage, 
and perhaps even the brain [28, 66]. Primarily, leptin functions as an appetite reduction signal 
[84]. Fasting leads to a rapid inhibition of ob gene expression in WAT leading to a fall of 
leptin levels circulating in the blood. However, a reduction in the level of circulating leptin 
follows re-feeding [85]. These observations were supported by treating mice with leptin. Mice 
were either fed or injected with leptin in order to reduce food intake, with these treatments 
causing significant weight reductions [86-89]. Several central neuroendocrine systems also 
interact with leptin, and this interaction may further control food intake [90, 91]. For example, 
in case of fullness, leptin activates the NPY in the hypothalamus which leads to the inhibition 
of NPY-induced food intake or stimulation of MSH that leads to reduced food intake [85, 92-
94]. In humans, the normal fasting leptin concentration in plasma ranges widely between 1.2 
and 97.9 ng/ml, and it is about three times higher in women than in men [82]. 
Leptin is thought to function through the insertion of fatty acid channels into adipose 
tissue, limiting triacylglycerol deposition in other tissues [95]. Furthermore, leptin affects 
energy consumption, and acts as a major signal to the reproductive system particularly in 
relation to sexual maturation in females. Leptin may also be a key factor in angiogenesis and 
for the immune system [89, 96-98]. It influences a wide range of metabolic processes ranging 
from inhibition of insulin secretion to sugar transport stimulation [99-101].  
1.2.1.1. The role of leptin in the tumour microenvironment 
Leptin, the adipocytokine, is upregulated in overweight people, and many malignancy 




confidently established this association [102]. Leptin is a key player in immunoregulation and 
may exhibit a connection whereby macronutrient intake and differences in the energy balance 
may have an impact on immune mechanism activation [103]. Leptin gene expression by 
adipose stromal cells (ASCs) may be enhanced by oestrogen [104]. Moreover, leptin is known 
to play a key role in oestrogen signalling in breast cancer cells via the activation of aromatase 
gene expression [104]. Cancer cell progression can be activated via leptin binding to 
oestrogen receptor (ERα) in ovarian, endometrial, and breast cancer cells [105]. Leptin is 
believed to increase cancer growth by a pathway which is via human telomerase reverse 
transcriptase (hTERT) expression. This was inhibited by treatment with activated vitamin D3 
via induction of miR-498 in cell line models [20, 106]. 
1.2.2. Insulin  
Insulin is a peptide hormone composed of 51 amino acids and having a molecular 
weight of 5808 Da. It is produced in the islets of Langerhans in the pancreas: insulin’s name 
comes from the Latin insula for "island". The structure and sequence of insulin varies only 
slightly among species of mammals [107]. Insulin’s function is studied predominantly in 
regard to the physiological control of glucose metabolism. When glucose levels in the blood 
increase, the pancreatic β-cells will respond by releasing insulin. The effect of insulin 
secretion subsequently reduces glucose concentrations by suppressing gluconeogenesis, 
which takes place in the liver and other intermediate pathways. Insulin levels in obese persons 
were two-fold higher than in lean individuals (11.7 + 1.3 and 5.6 + 0.6 mU/L) respectively 
[83]. In addition, glycogenolysis taking place in muscle and fat tissue is blocked by the 
presence of insulin and that will reduce bioavailability of glucose in blood. Thus, insulin 
function is important to energy balance and adipocyte regulation [108]. In humans, insulin 
plays a crucial role in the regulation of glucose levels, and reduced insulin levels will lead to 
the development of hyperglycaemia [109]. In 1939, Himsworth and Kerr observed that obese 
and elderly patients had a low insulin response to increased glucose levels in the blood 
circulation even though the pancreas had increased the secretion of insulin. Their description 
was in line with what is now referred to as "insulin resistant syndrome" [110, 111]. However, 




hormone synthesis and inhibits sex hormone binding protein which leads to increased 
oestrogenic and growth factor activities [40]. 
Insulin elicits its effects on cells via a tyrosine kinase receptor, the insulin receptor 
(InsR), and a hybrid insulin/IGF-I receptor. These receptors are highly expressed in cancer 
cells [41, 112-114]. Insulin binding to its receptor activates insulin receptor substrate-1 (IRS-
1) and a series of chemical reactions and pathways inside cancer cells [115]. The two main 
pathways which are activated by insulin binding to insulin receptors are the mitogen-activated 
protein kinase (MAPK) and phosphoinositol-3 kinase/Akt (PI-3K/Akt) pathway [115]. 
It has been reported that insulin resistance, hyperinsulinemia, and type II diabetes, three 
pathologies which are related to obesity, may also correlate with endometrial cancer [116]. 
Once insulin binds to its receptor, it induces proliferative activities on several cell types 
especially cancer cells [58]. Other non-receptor mechanisms may occur such as changing 
expression of IGF-I and its binding proteins, or blocking of anti-proliferative activity of 
progesterone [117]. The mitogenic activity of insulin has been shown to be due to the action 
of insulin on suppressing the expression of IGFBP-I. Therefore, hyperinsulinemia may result 
in downregulation of IGFBP-I which may stimulate proliferation even in the presence of 
progesterone [116, 117]. 
1.2.3. Insulin-like growth factor-1 (IGF-I) 
Insulin-like growth factor-1 (IGF-I), also known as somatomedin C, is a protein 
encoded by the IGF-I gene in humans [118, 119]. IGF-I is a hormone with a structure closely 
related to that of insulin. There are two types of insulin-like growth factors, IGF-I and -II, 
with amino acid sequences that are highly homologous. IGF-I is composed of 70 amino acid 
residues and IGF-II is composed of 73 [119]. IGF-I consists of a single chain with three 
intramolecular disulphide bridges. There are three protein receptors for IGF-I, which are 
insulin like growth factor-1 receptor (IGF-IR), insulin-like growth factor-II receptor (IGF-IIR) 
and insulin receptor (InsR) [87-89]. These different receptors may help IGFs to exert their 
function under specific circumstances [120-122]. Insulin shares some receptor-binding 




IGF-I is a growth factor that is central to a number of biological processes and its 
production is sensitive to nutritional state including glucose levels [123-125]. Accumulating 
evidence suggests dysfunction of IGF regulation underlies numerous pathologies, and the IGF 
system is involved in many pathophysiological activities in tumorigenic processes [122, 125]. 
IGF-I plays a critical role in growth in children and adults. An antagonistic peptide of IGF-I, 
mecasermin, is used for the treatment of abnormal growth during childhood development 
[126]. 
The correlation of endometrial cancer with obesity, type II diabetes and oestrogen led to 
an initiative to study the role of IGF-I in the biology of endometrial cancer. A significant 
number of random cases of type I endometrial cancer have been shown to develop upon 
stimulation with endogenous and exogenous oestrogens [127]. The effect of oestrogens, 
especially oestradiol (E2), as a cell proliferation stimulator is thought to be partly due to the 
induction of autocrine synthesis of IGF-I and upregulation of its receptor in the uterus [128]. 
However, expression of IGF-I encoding gene was detected mostly in the follicular and early 
luteal phase of menstrual cycle [127, 129]. As a consequence to the E2-dependent activation 
of IGF-I, mitogenic effects of IGF-I on the endometrium occur. Oestrogen also stimulates the 
synthesis of 17β-hydroxysteroid dehydrogenase and oestrogen sulfotransferase that contribute 
to the proliferation of endometrial cells [116, 127]. As a result of their expression, E2 is 
converted to a less active oestrone (E1) and oestrone sulfates, which are quickly expelled 
from the cells and the body. Progesterone on the other hand, counteracts these proliferative 
effects. In addition, the activity of progesterone contributes in the IGF-I binding protein 
(IGFBP-I) synthesises. IGFBP-I blocks the proliferative properties of IGF-I in the 
endometrium via controlling its availability for the cellular receptors [116]. Abnormal 
proliferation of endometrial cells occurs as a result of the excess production of oestrogen-
induced IGF-I, and the absence of IGFBP-I synthesis which depends on the expression of 






Adiponectin was identified in the mid-1990s. It is another protein hormone that is 
secreted from the adipose tissue [131], but it is also secreted from the placenta during 
pregnancy [132]. Human adiponectin is a 244 amino acid polypeptide [95] with molecular 
weight approximately 30 kDa [133], and it circulates in human plasma mainly as a 180 kDa, 
low molecular weight (LMW) hexamer and a high molecular weight (HMW) of 360 kDa 
[134]. However, while LMW adiponectin is the most important form in the circulation, HMW 
adiponectin is the more abundant form of intracellular adiponectin in cells such as adipose 
tissue [135]. AdipoR1 and AdipoR2 represent the two types of adiponectin receptor that have 
been identified. The two proteins are plasma membrane receptors with an internal N and 
external C terminals and so, interestingly, the location of N and C terminals are opposed to 
the topology of reported G protein-coupled receptors [136]. AdipoR1 and AdipoR2 occur on 
the cell membrane and in the cytoplasm of normal and malignant endometrial tissue [35].   
Adiponectin plays a role in the suppression of the metabolic disruptions that may result 
in atherosclerosis [137], non-alcoholic fatty liver disease (NAFLD) and be an independent 
risk factor for metabolic syndrome [138]. Several studies observed that there is a strong 
negative association between adiponectin concentration and obesity [12], inflammation, 
insulin resistance, metabolic syndrome, cardiovascular disease, and cancer [139-141]. 
Adiponectin is found in the highest concentration of all hormones in human plasma [131] 
with a range from 3 to 30 µg/ml which accounts for up to 0.05% of total plasma proteins [142, 
143]. In contrast to other hormones, adiponectin serum levels are found to be higher in lean 
women compared to obese (13.3 + 1.8 and 8.6 + 0.8 mg/L) respectively [83]. Adiponectin is 
considered to be an insulin-sensitising adipocytokine which means that adipocytes (low lipid 
storage, packed with fatty acids), suppress transcription of the adiponectin gene by secreting 
various pro-inflammatory, prothrombotic and angiogenic factors [144-146]. Additionally, 
oestrogen elevates adiponectin in the circulation of women in a manner that is independent of 
fat mass [135]. Also, in men, an inhibition of adiponectin HMW isoform in adipose tissue 
may occur due to the presence of testosterone [142, 147]. Reduction in adiponectin 
concentrations in the blood are closely related to the progression of type 2 diabetes and 




association with cancer development [150]. Plasma adiponectin levels can be increased if 
obese individuals lose weight by following a diet regimen or through physical exercises [131, 
151]. 
1.2.5. Leptin, insulin, IGF-I and adiponectin and the growth of cancers 
Leptin, insulin, IGF-I and adiponectin have been observed to exhibit different effects on 
cancer cells. Measurements demonstrated that the proliferation of cancer cells was increased 
by leptin, insulin and IGF-I but not by the presence of adiponectin [139, 141, 143, 152-157]. 
The secretion of VEGF from cancer cells also increased in the presence of the leptin, insulin 
and IGF-I but not in the presence of adiponectin [158]. On the other hand, apoptosis has been 
shown to be suppressed by leptin, insulin and IGF-I but apoptosis was enhanced in the 
presence of adiponectin in different types of cancer [152-157]. 
Increasing epidemiological data and numerous in vitro studies have suggested a strong 
link between leptin and several types of cancer. An increase in the expression of leptin and its 
receptor (Ob-R) has been reported in many cancer types including gliomas, adenocarcinomas, 
and melanomas [159]. Increased proliferation as a result of leptin treatments have also been 
reported following in vitro experiments with gastric [160], breast [161-163], ovarian [164], 
prostate [165] and endometrial cancer cell lines [12, 166]. In contrast, leptin treatments show 
an inhibitory effect on the growth of pancreatic carcinoma cells in vitro, suggesting that 
leptin’s response is tissue-dependent [165].  
Recent studies have reported that circulating adiponectin levels are inversely associated 
with the risk of malignancies associated with obesity [12] and insulin resistance [167]. In 
preclinical models, adiponectin inhibited the proliferation of several types of cancers [12, 
168-170] including endometrial cancer [12, 137, 171], postmenopausal breast cancer [12, 
169], leukaemia [172] and colon cancer [12, 173]. Moreover, low adiponectin levels have 
been associated with an increased incidence of gastric cancer [174], prostate cancer [175], and 
colon cancer [173]. Furthermore, a recent meta-analysis showed that low circulating 
adiponectin concentrations are correlated with an increased risk of endometrial cancer [43]. It 




148, 176, 177], and lower adiponectin concentrations are found in obese individuals [148, 
178]. Moreover, a study assessing the relationship between adiponectin concentration and 
BMI concluded that women with higher BMI and low adiponectin levels have a 6.5-times 
higher incidence of endometrial cancer than women with normal BMI and high adiponectin 
concentration [179]. Additionally, it has been suggested that tumours that grow in a low 
adiponectin environment are more likely to demonstrate a biological aggressive phenotype 
[180]. Adiponectin has also been shown to induce apoptosis in endometrial and hepatocellular 
cancer cells [12]. 
Several studies have shown that insulin signalling proteins, specifically the insulin 
receptor (InsR) and insulin receptor substrate-1 (IRS-1), may also be involved in the 
development of various tumours [181]. Insulin is not only implicated with an increase of 
colon cancer incidence [182, 183] but is also associated with colon cancer mortality [182-184] 
with the effects mediated by insulin resistance, hyperinsulinemia and high glucose diets [185]. 
Additionally, insulin was found to be associated with increases of pancreatic [186, 187] and 
breast [188, 189] cancer incidence and mortality [190, 191].   
Obesity, diabetes, and insulin resistance are high-risk factors for the development of 
type 1 endometrial cancer [192]. Epidemiological studies have concluded that IGFs play an 
important role in tumour development. These studies have suggested that the high 
concentrations of IGFs and/or lower levels of IGF binding proteins present in cancer patients' 
serum are involved in the increased risk of enhancement of several types of cancer including 
premenopausal breast [193, 194],  prostate [195-197], lung [198-200], colorectal [201-203], 
endometrial [204], and bladder cancer [205]. IGF proteins and mediating signalling molecules 
are highly expressed in endometrial cancer [18, 206].  
However, a recent in vivo study showed that there was no link between the risk for 
endometrial cancer and serum IGF-I levels. The study also found no statistically significant 
differences between serum IGF-I concentration in endometrial cancer as compared to healthy 
women, regardless of their menopausal status at the time of blood collection (most women 




The four hormones that will be studied in this thesis, leptin, insulin, IGF-I and 
adiponectin, have all been shown to be associated with oncogenic activity, although the 
mechanisms of action are yet to be clearly defined. For example there are conflicting 
conclusions on the effects that varied IGF-I levels have in connection to cancer incidence 
[204, 207, 208] with some studies reporting a positive correlation and others an inverse effect. 
Similarly, the parameters that may be involved in the regulation of the properties exhibited by 
adiponectin on cancer development are uncertain [12, 209, 210], and while insulin 
concentrations are raised in obese women with endometrial cancer [208, 211] it is unclear 
whether the connection between obesity to diabetes underlies this association [208]. In the 
case of leptin [212, 213] it is challenging to separate its association with increased cancer risk 
from its links with obesity since leptin is synthesised mainly by adipose tissue. However, 
leptin concentrations were found to have a strong positive association in women with 
endometrial cancer in both lean and obese patients [214]. The mechanisms that drive these 
endocrine-oncogenic associations are potentially complex [62] but the literature is without a 
definitive assessment of the plasma concentrations of these hormones in women with the 
various cancer and normal phenotypes.  
1.3. Cancer progression and obesity 
1.3.1. Cancer cell biology 
In the process of cell division, all somatic cells undergo proliferation through a highly 
conserved cell cycle [215]. In order to produce new cells, the cell cycle involves five different 
phases: quiescence (G0), Gap1 (G1), DNA replication/synthesis (S), Gap2 (G2) and mitosis 
(M). G1 phase involves proteins and RNA synthesis in addition to DNA repair [216]. During 
these activities, cells may fall into quiescence entering the G0 or resting phase [217]. 
Following quiescence, cells may re-enter the cycle when needed or differentiate into G0 [216, 
217].  
DNA synthesis occurs during S phase and cells with newly-replicated DNA enter G2 




harmonised progression through the different phases of cell cycle, facilitated by cyclins and 
cyclin dependent kinases [219], is crucial to maintain genome stability [216]. Typically, cell 
proliferation is strictly monitored via different regulatory pathways where cell numbers are 
controlled via cell cycle checkpoints that, for example, pause the cell cycle and/or promote 
programmed cell death [215, 219]. Mutations in cancer cells may cause dysregulation of the 
cell cycle proteins and checkpoint genes leading to sustained cell proliferation that evades cell 
death signals. This is translated into continuous, uncontrolled cell division and proliferation 
and leads to the formation of tumours [216] (Figure 1.2). As a consequence to prolonged, 
active replication, dysfunctional apoptosis [216, 218], chromosome damage and, eventually, 
malignant transformation occurs [216, 218]. 
1.3.2. Cancer cells progression and proliferation 
Cancer cells have the ability to maintain prolonged proliferation and escape growth 
suppression. These cancer cells exhibit a number of so-called hallmarks in their growth, 
including sustained proliferative signalling, the evasion of growth suppression, resistance to 
cell death enabling replicative immortality, the induction of angiogenesis, and the activation 
of invasion and metastasis [19, 220]. These cancer hallmarks and other characteristics have 
been proposed to be in association with cancers [18, 19]. The signals for these behaviours are 
carried by molecules with growth factor activity. In obesity, there is dysregulation of a 
number of endocrine factors that have been established to have growth-promoting properties. 
In addition, the hormones alter the regulation of other systems such as VEGF, which are 
involved in supporting tumour survival. The hormones trigger a cascade of signal 
transduction molecules which, in cells with oncogenic mutations, lead to cancer development 
[19]. Thus, tumour growth depends, to a large extent, on the increased and dysregulated 
proliferation of cancer cells. However, another component that plays a role in cell 
proliferation is the reduction of cell demise through the inhibition of the apoptosis processes. 
In obese women, the microenvironment is rich with growth factors e.g. leptin [20, 105], that 





Leptin is a proliferative hormone, and high leptin concentrations in the 
microenvironment will increase cell growth and proliferation [20, 105, 222]. Increased 
proliferation increases the opportunity for mistakes to be made during DNA replication [105, 
222, 223]. As a result, the cells will become more prone to the accumulation of oncogenic 
mutations and more prone to become cancerous within the conducive microenvironment [20, 
105, 223]. It has not yet been established as to which of the two steps, proliferation or 
mutation, occurs first. However, the dysregulation of hormones due to obesity may be 
contributing to cancer progression  [20]. 
In summary, although cancer may develop along with obesity, it has not been reported 
that obesity can cause cancer. It should be noted though that obesity might initiate cancer if 
there are already oncogenic mutations or DNA replication mistakes [222, 223]. However, the 
work presented in this thesis investigates the effect of obesity-related hormones on already 
established cancer cells.  
The tumorigenic process is a multistage process that involves a combination of gene 
mutations and changes in the microenvironment. One consequence is that cell proliferation 
takes place in an uncontrolled manner. Other phenotypic changes occur and tumours form 
[18]. Subsequently, the mutant cancer cells multiply and penetrate the wall of blood vessels as 
well as lymphatic tissue. Tumour cells metastasise to other tissue sites and regrow at new 





Figure 1.2 Tumorigenic processes of conversion of normal cells to tumour and carcinoma (The figure is based on a diagram in ‘Davidson’s Principle and Practice of 
Medicine’, 21st edition, ISBN Number 9780702050350, Edited by Brian R. Walker, Nicki R Colledge, Stuart H. Ralston, and Ian Penman, 2010) [193] and has been 




1.3.3. Gene expression profiles and cancer risk in the obese 
The molecular characterisation of tumours, in which tumour classification depends on 
the genetic profiling, currently promises improvement in clinical oncology studies because the 
process can subgroup patients in regards to prognosis and susceptibility to specific 
medications [224, 225]. It is thought that a similar signature might be recognised for the obese 
phenotype, along with various malignancy sites, as a step towards understanding of 
pathogenesis of obesity-related cancers and also for revealing possible novel treatment targets 
[20]. In this regard, gene microarray data showed different gene expression signatures for 
obese and lean patients with cancerous precursor cells for endometrial cancer [226]. Loss of 
the gene encoding tumour suppressor phosphatase and tensin homolog (PTEN), cancer 
suppressor, is correlated with developed progression-free survival. PTEN loss resulted in 
different protein alterations: canonical PI-3K pathway activation was exhibited only in the 
controls, while a reduction in the expression of the gene encoding b-CATENIN (CTNNB1) 
and phosphorylated FOXO3A were obvious in obese patients [226]. The upregulation and 
activation of the PI-3K pathway in non-obese patients suggested that various targets may 
apply to different patient populations at the same disease site [227].  
Breast tumours from obese patients have widespread differences in gene expression, 
including specific mutations, in comparison with overweight or lean patients, and an obesity-
associated transcriptional signature of 662 genes was found using whole-genome analysis [20, 
228]. In multiple, public gene expression data sets from breast cancers, this manifestation of 
the obesity signature patterns correlated with a gene expression signature for IGF signalling 
and, to a lesser extent, with lower levels of oestrogen receptors (ER) [20], and the presence of 
this obesity signature also correlated with a shorter time to metastases [228]. However, 
primary microarray data determined that mutations in 52 proteins from a smaller sample of 
tumours did not show any significant differences in mutations between obese and non-obese 
subjects, once modifications had been made for false discovery rates. This prevents 




1.3.4. Inflammation as a protumorigenic mechanism  
The adjusted tumour microenvironment was central to research into the increased 
progression of tumours in obese subjects, and connected local and general inflammation with 
the developing hallmarks of cancer [19]. Chronic inflammation defines an abnormally 
extended or dysregulated defensive response that reflects the loss of tissue homeostasis [230], 
and which has been associated with the fundamental mechanisms of tumorigenesis [34, 231]. 
Intracellular signalling mechanism associated with inflammation include signal transducer 
and activator of transcription 3 (STAT3) and nuclear factor-kB (NF-kB), and these can be 
enhanced by somatic alteration or inflammatory incentives [231]. Cyclins are upregulated by 
STAT3 which in turns stimulates the cellular proliferation, and reduces cell death via 
activating anti-apoptotic proteins [232]. NF-kB stimulation might be caused by proliferative, 
inflammatory, and pro-survival gene expression, and may not be correlated with the 
regulation of cellular senescence [233]. Invasion and attaining metastatic potential and 
genomic instability of cancer cells due to the response to impaired DNA repair mechanisms 
and increased DNA damage [222, 223] were associated with epithelial-to-mesenchymal 
transition (EMT) [20]. Until now, it is uncertain which serum biomarkers for inflammation 
such as CRP, TNF-α, and IL-6 are linked with obesity-related cancer development [20, 234] . 
1.3.5. Cellular instability and changes in cellular energetics linked with 
obesity 
One of the initial hallmarks of cancer is genomic instability [17]. This refers to the 
increased tendency of the genome to gain changes because of dysfunction during the 
processes of genome replication [235]. There are two mechanisms that can generate genomic 
instability, with these being the microsatellite instability (MIN) and chromosomal instability 
(CIN) pathways. Screening for the levels of MIN in tissues provides microsatellite-stable 
(MSS) or microsatellite-instable (MSI) profiles. Colorectal cancer in women has provided 
evidence of an association between obesity and an increased risk of microsatellite-instable 
high (MSI-H) [236]. In endometrial cancer, an MSI profile was associated with a high BMI 




compared with non-obese patients with endometrial cancer, providing further evidence 
linking genomic instability with the overweight state [238].  
1.4. Cancer of the endometrium 
In obese patients, there is a greatly increased risk for cancer in the uterus. For this 
reason, this project selected the endometrium as its focus and cancer cell lines from other 
tissues were studied for comparison. 
1.4.1. Aetiology of endometrial cancer  
1.4.1.1. Reproductive risk factors 
The theory that infertility is a risk factor for endometrial cancer is in line with studies 
indicating higher risks for married, nulliparous women than for unmarried women. Thus, 
some researchers have discovered that infertile women encounter a three-to eightfold increase 
in risk [239, 240]. Mechanisms that may mediate this risk might variously be related to 
infertility-involved anovulatory menstrual cycles (i.e., prolonged exposure to oestrogens 
without adequate progesterone), high serum levels of androstenedione (i.e., an abundance of 
androstenedione is available for change to oestrone), and the absence of monthly sloughing of 
the endometrial lining (i.e., residual tissue may develop toward becoming hyperplastic). 
Moreover, nulliparity has been correlated with low levels of serum sex-hormone-binding 
globulin (SHBG), and this may lead to increase bioavailable oestrogen [241]. 
It has been known for a long time that the risk of endometrial malignancy decreases 
with growing parity, particularly among premenopausal women [242, 243]. Recently, 
consideration of this topic has concentrated on the ages at which these births happened. 
Research has identified a decreased risk with either older ages at last birth or shorter times 
since the last birth, and it has been suggested that this may reveal a defensive impact of 
mechanical clearance of initiated cells [244, 245]. An understanding of the actions of 
infertility on cancer risk must consider connections regarding specific birth control strategies 




decrease in cancer risk among subjects using intrauterine devices, as revealed by a later meta-
analysis [246]. The nature of this clear, protective effect has not been explained despite the 
fact that it is conceivable that the devices may influence risk by causing structural or 
biochemical changes to the endometrium or circulating hormones. Another area of interest is 
the impact of using fertility drugs, given that many studies have suggested that women using 
ovulation-inducing drugs have a higher chance of endometrial cancers [247, 248]. Further, the 
relationship of risk to breast feeding remains dubious, and while some studies propose that 
lactation may offer protection [249], this has not been noted in all research [47, 245]. 
1.4.1.2. Menstrual risk factors 
Most research has shown that age at menopause is specifically linked with the risk of 
uterine disease. Around 70% of all women determined to have endometrial cancer are 
postmenopausal. Most research indicates that there is an approximate two-fold increase in risk 
for women with natural menopause after the age of 52 years compared with menopause 
before the age of 49 years [250]. It has been suggested that the effect of increased age at 
menopause on the risk of cancer developing may reflect longer exposure of the uterus to 
oestrogen that influence the action in the absence of ovulation and progesterone. Overall, 
however, the interplay between menstrual factors, age, and weight are complicated, as are the 
biologic systems of these factors working in the pathogenesis of uterine malignancy [47]. 
1.4.1.3. Exogenous hormones 
Exogenous hormones term refer to oral contraceptive, menopausal hormones and 
tamoxifen. Studies have demonstrated that the impacts of hormonal treatment, both 
unopposed oestrogens (that is, acting alone) and in combination treatments, may differ 
depending on the characteristics of the user, most notably with a woman's BMI. Various 
studies have suggested that the antagonistic impacts of unopposed oestrogens were most 
noteworthy in non-obese subjects and that the clinically useful impacts of combined treatment 
were most prominent in obese women [48-50]. Most information with respect to effects of 
hormones are derived from research on consumers of pills. It is uncertain, however, as to 




associations of risk with even low-dose oestrogens, it is conceivable that these regimens may 
present some increase in the chances of risk [47]. 
1.4.1.4. Anthropometry and physical activity 
Obesity is a well-recognised risk factor promoting uterine tumours and may represent 
up to 25% of cases [251]. Very overweight women seem to have extraordinarily high risks 
compared to normal weight women  [50]. Obesity seems to influence both premenopausal and 
postmenopausal endometrial cancer [47]. 
Much research has focused on the role of physical activity in the aetiology of 
endometrial tumours. A potential relationship is naturally engaging, given that physical 
activity can lead to changes in the menstrual cycle, body fat distribution, and levels of 
endogenous hormones. Evidence shows a defensive effect of physical activity on uterine 
cancer risk, and no associations with body weight [47]. A current meta-analysis of prospective 
studies exhibited a reduced risk of endometrial cancer with medium to heavy physical 
exercise, and  no association with known potential confounders such as obesity, menopausal 
hormone treatment utilize, and parity [252]. For the most part, studies that have assessed 
occupational and recreational physical activity have revealed decreased risks [47]. 
1.4.1.5. Smoking 
A reduction in endometrial cancer risk among smokers has been reported, with current 
smokers having about half the risk of non-smokers [253-255]. Cigarette smoking has been 
connected to an early age of menopause in some communities and to reduced levels of 
endogenous oestrogens. Decreased risks might be more notable in overweight or obese 
patients [47, 256]. Currently, biological mechanisms underlying the negative association of 
smoking and endometrial cancer risk remain unclear. Adjustments in endogenous hormones 
or metabolic pathways are likely involved. One report [257] revealed that the negative 
association of smoking with endometrial cancer risk became strongly associated to higher 
serum androstenedione levels compared to lower serum oestrogen levels among overweight 





1.4.1.6. Medical Conditions 
Multiple clinical studies have connected polycystic ovary syndrome (PCOS) to the 
elevated risk of endometrial cancer incidence, especially among younger females. It is 
unclear, however, whether this increased risk is related to obesity or not. A recent systematic 
review and meta-analysis suggested that women with PCOS had a three-fold higher risk of 
endometrial cancer [47, 258]. Various investigations have also noticed a high risk of 
endometrial malignancy among diabetic patients. A question that needs to be addressed, 
however, is whether this association is related to weight. Several research groups [259, 260] 
have proposed that the relationship holds when comparisons are confined to non-obese 
women or are adjusted for weight, but a strong association between diabetes and endometrial 
cancer risk among obese women in several studies has provoked interest for the aetiologic 
part of specific metabolic abnormalities such as hyperinsulinemia [47, 261, 262]. 
Other diseases, including hypertension, arthritis, thyroid conditions, anemia, and 
cholecystectomy, have all been proposed to influence the incidence of endometrial cancer, in 
spite of the fact that little reliable evidences has been presented [263, 264]. More recent 
research has also focused on the impacts of non-hormonal drugs on the risk of endometrial 
cancer development. Given speculation that the inflammatory process may be an essential part 
in the development of endometrial cancer [265], a number of papers have evaluated the 
associations of nonsteroidal anti-inflammatory drugs with endometrial cancer development 
but with conflicting outcomes [47, 263, 266, 267]. 
1.4.1.7. Familial factors 
It is well established that 5% of the endometrial cancer incidence occurs in young 
subjects [268] as a result of family history of uterine cancer [269]. Moreover, subjects with a 
family history of colon growth are at increased risk [268]. Various investigations have 
concentrated on relationship of uterine cancer risk with mutual single nucleotide 
polymorphisms (SNPs), including those with obesity [270], hormone biosynthesis, 




association studies (GWAS) were used in a study conducted in 2011, to identify the most 
important genes involved in increased risk of endometrial cancer [274]. This study revealed 
that a susceptibility locus close to HNF1B (rs4430796), that had a positive association with 
prostate cancer risk and inversely with T2D, was a significant predictor of endometrial cancer 
risk [274]. GWAS also identified that the SNP rs1202524, near the CAPN9 gene on 
chromosome 1q42.2, may host an endometrial cancer susceptibility locus [47, 275]. 
1.4.1.8. Environmental and occupational risk factors 
Geographic variations in rates of endometrial cancer, with higher rates in certain 
industrial areas, has prompted the suggestion that specific environmental agents may 
influence risk. Given the well-recognised effect of hormones on the disease, there has been 
specific concerns about the potential effects of certain endocrine disruptors, including 
dichlorodiphenyltrichloroethane (DDT). Several studies have addressed this issue by looking 
at dichlorodiphenyldichloroethylene (DDE) levels, the active form of DDT, in the sera of 
cancer patients and controls, but have found no significant differences [276-278]. By contrast, 
few studies have focused on impacts of electromagnetic radiation as a risk factor for 
endometrial cancer but observations in regards to electric blanket or mattress covers have 
delivered mixed outcomes [47, 279, 280]. 
1.4.1.9. Hormones underlying risk factor associations  
Few studies have reported on whether different endogenous hormones are associated 
with endometrial cancer risk. Key and Pike [281] suggested that endometrial carcinogenesis is 
reliant on uterine mitosis, which is increased by oestrogens and decreased by progesterone. A 
few studies have also suggested a positive correlation between endometrial cancer risk with 
serum androstenedione and testosterone levels [47, 127, 282, 283]. 
Obesity, which is suggested to cause elevated oestrogen levels, appears to represent a 
key risk factor for both uterine carcinoma and endometrial hyperplasia, yet the underlying 
mechanisms are not clear. A case-control analysis of serum oestrogen levels [283] revealed 
that the risk associated with obesity was not totally mediated by oestrogens in premenopausal 




oestrogen levels seemed to represent the main risk factor related to obesity [284]. A potential 
role for insulin and insulin-like growth factors (IGFs) in cancer risk has been suggested, 
although studies have not generally provided clear evidence of the role of either C-peptide, is 
a short 31-amino-acid polypeptide that connects insulin's A-chain to its B-chain in 
the proinsulin molecule, [285] or IGF levels [47, 211].  
It is already known that oestrogen has a strong influence and is the key driver of the 
development of several cancers, including endometrial cancer but the possibility that some 
other factors may also be operating alongside oestrogen remains poorly researched [47-50]. In 
this project, therefore, I have investigated the potential of four hormones, leptin, insulin, IGF-
I and adiponectin that are dysregulated in obesity for their ability to alter cancer cell 
behaviour. 
1.4.2. Anatomy and physiology of endometrial cancer 
The uterus is composed of myometrium (uterine muscle) and epithelial endometrium 
(the mucous membrane lining its cavity). The endometrium consists of groups of glands and 
stroma. Under the influence of ovarian oestrogen in the first half of the menstrual cycle, the 
endometrium proliferates and expands. Following this proliferative phase, ovulation occurs in 
a fertile cycle. In the second half of the cycle, the endometrium changes and develops 
secretory characteristics, including increasing levels of ovarian progesterone production. 
Later, the reduction of progesterone levels, which were maintaining the functional layer, 
results in the sloughing off of the tissue leading to menstruation [286, 287].  
Under conditions of prolonged stimulation with E2 in the absence of progesterone, 
hyperplastic changes will take place in the endometrium and in time these may lead to the 
development of endometrial cancer. In some cases, these changes may be reversed by 
progesterone. Obese women are known to have higher levels of oestrogenic hormones and 
relatively lower progesterone levels than lean women. Indeed, the association of endometrial 
cancer and obesity is so strong that it is plausible that the changes in levels of reproductive 
steroids alone would be insufficient to generate the increased level of risk, and that effects 




1.4.3. Epidemiology of endometrial cancer 
Evidence provided by epidemiological studies and from both case control and cohort 
studies show a strong association between BMI of over 30 and endometrial cancer incidence 
[15, 289, 290], and a linear increase in the risk of endometrial cancers with increasing weight 
or BMI has been observed in most groups, [291]. In addition, an increased relative risk (6.3-
fold) in the development of endometrial cancer in obese compared to lean women may occur 
due, in part, to the conversion of androgens to oestrogen [22].  
The incidence rates of endometrial cancer have increased in a number of countries 
between the 1980s and 2010 [3], and in 2012 there were an estimated 320,000 new cases and 
76,000 deaths from the disease worldwide [3], the annual incidence being 10-20 per 
100,000 women [290, 292]. Incidence rates vary 20–30-fold between countries with close to 
two thirds of the registered new cases occurring in wealthy countries in Northern and Eastern 
Europe and North America, and with rates tending to be low in Africa and West Asia [3, 290]. 
Endometrial cancer is the sixth most common cancer in women around the world (almost 5% 
of all cancers in women). Increases in the elderly and obese in a population appear to be 
major contributing factors to this trend [3]. 
In the USA, endometrial cancer is the fourth most common type of cancer [293-296].  
In the European Union, endometrial cancer ranks second in incidence among gynaecological 
cancers at 13 cases per 100,000 people per year [297] and is the third most common cause of 
death from gynaecological cancers after ovarian and cervical cancer [298, 299].  
In New Zealand, endometrial cancer is the fifth most common cancer in women [298, 
300]. There are four main ethnic groups in New Zealand; Maori, those of European origin, 
those of Pacific origin, and an Asian ethnic group who largely migrated to New Zealand in the 
last three decades [298]. Endometrial cancer rates are significantly higher among women of 
Polynesian descent than in Maori or European women [298, 300-303].  
Most recently, a Ministry of Health of New Zealand report published in 2017 revealed 
that New Zealand was ranked third in obesity incidence in OECD, with obesity rates having 
increased notably over the past 15 years (the MOHNZ report). Moreover, the report 




Pasifika women than in Maori or European women. It is tempting to relate these trends of 
increased endometrial cancer to the trend for increase obesity in these ethnicities.  
In 2012, a similar study revealed that "Pacific and Maori women have higher incidence 
and mortality rates of uterine cancer. Women in the most deprived areas are more likely to 
present with an advanced stage of uterine cancer. Maori and Pacific women are less likely to 
present with well-differentiated tumours" [304].  
The study concluded that Maori and Pacific women, and those from lower 
socioeconomic groups, are more likely to present with advanced cancer. However, the causes 
of variation in the epidemiology of endometrial cancer in New Zealand ethnic groups are not 
yet fully explained [304].  
However, in 2016, a study was published that aimed to determine rates of which cancers 
follow changing ethnic inequalities over time in New Zealand. This study concluded that  
actions to further address the inequalities in the burden of cancer need to be developed [305]. 
These might include enhancing control of tobacco, decreasing rates of obesity and 
carcinogenic infectious agents, and focusing on increased access to effective cancer screening 
and improve health care services [305]. 
1.4.4. Characteristic of endometrial cancer 
The normal endometrium may develop malignant changes that start as a confined 
tumour. In an advanced stage this tumour invades the adjacent myometrium and penetrates 
the uterine muscle to the serosal surface of the uterus. It may extend to surrounding organs 
such as the fallopian tubes, ovary, bladder, rectum, and cervical canal [306]. Local peritoneal 
spread of the disease occurs through lymphatic drainage to pelvic and para-aortic lymph 
nodes. However, less common is haematogenous (originating in or carried by the blood) 




         
  
 
Figure 1.3 Images show the location and the progression of endometrial cancer. 
The anatomy of uterus. Abnormal growth of epithelial cell lining of endometrium 
started in a discrete area and changes into a malignancy later. (Image used with 





1.4.4.1. Grades of endometrial cancer 
The majority of endometrial tumours (80-90 %) arise within the epithelium of the 
uterine lining [290, 307, 308] and are categorised as endometrial carcinomas with the majority 
consisting of typical endometrioid adenocarcinomas [290, 309]. These typical endometrial 
carcinomas are further subdivided according to the International Federation of Gynaecology 
and Obstetrics (FIGO) classification (1988) into three architectural grades based on the 
percentage of solid tumour growth: Grade I tumours contain less than 5% solid architecture, 
grade II are those tumours with 6-50% solid architecture, while grade III tumours consist of 
more than 50% solid architecture [290, 307]. 
The remaining cases (10-20%) are rare cell types consisting of papillary serous 
carcinoma, clear cell carcinoma, papillary endometrioid carcinoma and mucinous carcinoma 
[308, 309]. Adenosquamous carcinomas are now categorized as typical endometrial 
carcinomas with squamous differentiation. The rare cell types are correlated with a later age 
of onset than grade I adenocarcinomas, have greater risk for extrauterine metastasis, and 
poorer prognosis [290, 308, 310-313].   
1.4.4.2. Cell types 
Cancer cell subtype is a good predictor of the biological response of endometrial cancer. 
Bokhman's clinical model has been the basis for categorising the pathogenesis of endometrial 
cancer [314], in which these tumours are classified into two types. Type I tumours (about 
80%) are endometrioid carcinomas that usually present as a typical hyperplasia, first as a 
result of oestrogen stimulation, then followed by changes to malignancy. Women with type I 
tumours are mainly young [308], premenopausal or perimenopausal women, and are 
associated with high BMI, hyperlipidemia, nonovulatory cycles, infertility and late 
menopause [307]. This type of tumour is a low grade [308]. The risk of cancer incidence in 
overweight women increased by 50% compared to women of normal weight [315] and 
approximately 70–90% if type I (oestrogen-dependent) endometrial cancer patients are 




It has been found that tumour progression may occur as a result of the development of 
non-endometrioid carcinomas type II tumours from pre-existing endometrioid carcinomas 
type I tumours [307, 317]. Type II tumours (20%) are non endometrioid carcinomas, or high 
grade predominantly serous and clear cell, which may arise from endometrial polyps or from 
precancerous lesions (endometrial intraepithelial carcinoma) [318, 319]. Type II tumours are 
not associated with oestrogen stimulation or hyperplasia. These tumours invade the 
myometrium and vascular spaces, and carry a high mortality rate [307]. These tumours are 
associated with high grade disease as well as more aggressive histologic subtype like papillary 
serous or clear cell carcinoma. Type II tumours are more common in older patients or those of 
African and American descent [308]. Histopathological images are provided (Figure 1.4). 
1.4.4.3. Endometrial tumour genotype 
Molecular regulation of the development of endometrioid carcinoma (type I) is different 
from those of serous carcinomas (type II) [307, 320, 321] and often exhibited microsatellite 
instability (MSI). Endometrial cells transform into endometrioid carcinoma through 
replication errors [290, 322, 323] and PTEN mutations [324, 325] and rarely exhibit p53 
mutations [326]. However, the vast majority of endometrioid serous carcinomas (type II) 
exhibit p53 mutations and loss of heterozygosity on several chromosomes, and only 
occasionally show MSI [307, 326, 327].   
Histological and morphological characteristics of type I and type II are shown in Figure 
1.4. Type I endometrial cancer is usually confined to the surface of endometrium and grows 
slowly. On the other hand, type II seems to spread and form larger tumours, and grows 
aggressively. The morphology of these two types is also different. Type I endometrial tumour 
cells have the appearance of glandular structures, which is akin to normal endometrial glands. 
Type II tumour cells have serous papillary-like appearance, similar to serous ovarian cancer 






Figure 1.4 Adenocarcinoma of the endometrium.  
(A) Endometrioid carcinoma, type I.  
(B) Nonendometrioid carcinoma, type II,  
(C) Well-differentiated (grade 1) endometrioid adenocarcinoma, type I.  
(D) Endometrioid serous carcinoma, type II. 
Image used with permission from Dr. Jamie Prat [3, 328]. 
(http://www.iarc.fr/en/publications/books/wcr/wcr-order.php).   
 
However, a wide range of mutations is responsible for tumour heterogeneity. 
Inactivation of the tumour suppressor gene PTEN may result from MSI (45%), promoter 
hypermethylation (16%), or loss of heterozygosity (24%). PTEN inactivation releases the PI-
3K/AKT pathway, inhibiting apoptosis and resulting in tumour growth advantage. The 
protein, mammalian target of rapamycin (mTOR) is a kinase that regulates cell growth and 
apoptosis [329]. mTOR inhibitors have recently been developed as potential anticancer 
agents, and PTEN-mutated tumours are particularly susceptible [3, 330]. Recent genomic and 
related analyses have indicated that most endometrioid tumours have few copy number 




and KRAS, and novel mutations in the SWI/SNF chromatin remodeling complex gene ARID5B 
[331]. β-Catenin gene mutations occur in 20% of endometrioid carcinomas, correlate with 
MMP-7 and cyclin D1 overexpression, and are associated with good prognosis. Mutation of 
the ARID1A gene and loss of the corresponding protein BAF250a have been found in 29–40% 
of endometrioid carcinomas, 18% of serous carcinomas, and 26% of clear cell carcinomas 
[332, 333]. In contrast, nonendometrioid carcinomas often show TP53 and PPP2R1A 
mutations, inactivation of p16 and E-cadherin, c-ERBB2 amplification, STK15 alterations, and 
loss of heterozygosity at multiple loci [292, 334]. 
The mutations suggested in The Cancer Genome Atlas (TCGA), 2013 paper are; POLE 
ultra-mutated (Polymerase E enzyme 7-10% endometrial cancer are mutated), micro satellite 
instability hyper-mutated (DNA repetition gene), Copy-Number Low (LCN) short tandem 
repeat typing for samples less than 200 pg of template DNA within a cell) and Copy-Number 
High (HCN) (Figure 1.5). 
In this study, Ishikawa cells are used. These are a type I endometrial cancer cell line 
which is obesity-E2-sensitive and because it has PTEN and PIK3CA mutations, it fits into 
Copy-Number-Low endometrial cancer molecular subtype. HEC-1A (also used in this study) 
is again type I endometrial cancer cell line and obesity-E2-sensitive. However, HEC-1A has 
p53 and PIK3R1 mutations and fits into Copy-Number-High endometrial cancer molecular 
subtype. 
RNAseq and microarray methods are often used to measure gene expression level. 
While similar in purpose, there are a lot of differences between the two technologies [335]. It 
is noteworthy, that these cell lines indeed had responded to the obesity hormones that have 





Figure 1.5 Non-silent mutation matrix for 13 SMGs with significantly different 
frequencies across the mutation spectra cohorts. A green bar indicates that at least 
1 non-silent SNV or indel was identified in the tumor. PTEN and TP53 
distinguished the CN-high serous-like tumors from the remaining tumors. 
PIK3CA and PIK3R1 mutations were mutually exclusive and PIK3R1 was 
mutated significantly less in the CN-high group. ARID1A and ARID5B mutations 
also appear to be mutually exclusive and both have low mutation frequency in 
CN-high group. KRAS and CTCF mutations are rarely seen in the CN-high group. 
CTNNB1 mutations appear more frequently in MSS tumors with lower mutation 
rates, than in endometrioid tumors with MSI. RPL22 mutations were almost 
exclusive to cases with MSI. FBXW7 and PPP2R1A mutations appear mutually 
exclusive, and are more common in CN-high serous-like tumors. ARID1A had a 
similar non-silent mutation frequency in MSI (36.9%) and MSS endometrioid 





1.4.4.4. Management of endometrial cancer 
Management depends on staging of the disease [336-341]. In general, treatment is 
mainly surgery and includes total hysterectomy, bilateral salpingo-oophorectomy, in case of I 
and II, with absence of visible metastasis [47]. More advanced disease required pelvic and 
para-aortic lymphadenectomy and omentectomy removing as much as possible of the tumour. 
This type of disease stage needs further postoperative adjuvant therapy such as chemotherapy, 
hormonal therapy and radiotherapy [341, 342]. Current clinical chemotherapy may include the 
use of Paclitaxel, Carboplatin, Doxorubicin and Cisplatin [342a]. Proper surgical staging 
offers better prognostic and therapeutic benefits for such women [336, 341] and may enhance 
the progress of targeted therapy and lead to better survival and less morbidity of 
overtreatment (radiation injury) and the effects of under treatment (recurrent disease, 
increased mortality) [341]. Especially in patients with type II endometrial cancer, systematic 
surgical staging requires additional omentectomy and biopsy of any suspected lesion [343]. 
Other reports also highlighted steps in clinical management of endometrial cancer [342, 344]. 
1.5. Vascular endothelial growth factor (VEGF)  
VEGF, a heparin-binding glycoprotein, is a key regulator of physiological angiogenesis, 
which is the increased vascularisation that is  necessary to transport oxygen and nutrients to 
tissues, including during embryogenesis, skeletal growth and reproductive functions [345]. 
Also, angiogenesis is essential to the development of solid tumours. VEGF-driven pathways 
have been demonstrated to play a major role in tumour angiogenesis by stimulating 
endothelial cell proliferation and inducing the budding of new blood vessels promoting the 
growth of tumour masses [346, 347]. Angiogenesis is the result of a cascade of physiological 
events that are linked to tumour neovascularisation; this process is very important for large 
tumours to obtain adequate oxygen and nutrients to maintain growth activity, and remove 
wastes. VEGF may be secreted from  adipocytes and tumour cells, and overexpression is 
associated with a poor prognosis in endometrial cancer [3, 345]. Increased production of 




increased endothelial cell proliferation and decreased apoptosis [345]. VEGF is also a potent 
permeability factor that promotes cell migration during invasion. The neovascularisation 
process for rapidly growing tumours may facilitate tumour metastasis and help in tumour 
spread [348]. The potential in cancer treatment of drugs that inhibit VEGF secretion and 
angiogenesis, such as bevacizumab and tyrosine kinase inhibitors, is being studied clinically 
in several cancer types [3, 349-355]. 
The VEGF gene is complex with several alternatively spliced isoforms, and the 
regulation of expression could differ between normal and tumour tissues [356]. The effects of 
VEGF are mediated by two high-affinity transmembrane tyrosine kinase receptors, VEGFR-1 
and VEGFR-2 [107, 109, 110], which induce dissimilar cell signalling cascades. Moreover, 
the presence of the receptors also correlates with the pathological angiogenesis that is 
associated with tumours and other disorders. 
Obesity elevates circulating VEGF secretion compared to lean individuals and high 
tumour expression of VEGF is associated with poor prognosis of obesity-related cancers [357, 
358]. Overexpression of VEGF and angiogenesis are necessary for solid tumour growth and 
metastasis [111, 359-362]. In this project regulation by obesity-related hormones [363] of this 




1.6. This Project  
Choice of Cell lines: The model at the centre of this study is the endometrial cancer cell line 
Ishikawa. This cell line was originally isolated from a woman who had low grade type I 
endometrial cancer [308]. This is the most common subtype of endometrial cancers 
(comprising approximately 65% of presenting endometrial cancers) and is hence a relevant 
model.  The Ishikawa cell line expresses active oestrogen [364], progesterone [365] and 
androgen receptors [366]. Evidence of hormonal responsiveness of Ishikawa cells in vitro by 
steroidal modification of proliferation, cellular function or gene expression is well-established 
[70]. Additionally, the activities that are exhibited by Ishikawa cells, which have a PTEN 
mutation, wild type p53 and represent type 1 subtype [367]. One additional endometrial 
cancer cell line, HEC-1A was also investigated in this study. HEC-1A has p53 mutation, a 
PTEN wildtype, K-RAS mutation, and this cell line is also representative of low grade cancer 
[331]. In this study, the responses to the individual hormones were also compared among 
cancer cells from different origins. A MCF-7 is representative of human ductal cell 
adenocarcinoma breast cancer [368]. This subtype of breast cancer has a substantially 
increased risk of developing cancer in obese women [369]. The fourth cell line, from an 
ovarian cancer, SKOV-3, is derived from metastasis ascites. Ovarian cancer onset is much 
less sensitive to obesity than either endometrium or breast tissues [370-372]. 
Hormones: The study considers the effects of four hormones, leptin, insulin, IGF-I and 
adiponectin. The first three are known as tumour-promoting hormones whereas adiponectin is 
a putatively anti-cancer peptide. Leptin is strongly associated with obesity and is the focus of 
much research investigating the effects of high BMI on metabolism and tissue function. 
Insulin also is associated with obesity and is the prominent link between diabetes and a 
number of tissue pathologies, including cancers. IGF-I has several properties similar to insulin 
and is also believed to exhibit growth-enhancing activities in the progression of many cancers. 
Thus these three peptides are known to have regulatory mechanisms that are intimately 
connected to BMI and have also been implicated in oncogenic processes. The activities of 
adiponectin are also modulated by factors associated with diabetes and is dysregulated in 




the role(s) of adiponectin in cancers have not been well-defined. Thus the interactions of this 
hormone with the other three may provide insight into interactions that potentially occur in 
vivo. 
Signalling Pathways: Also, this study attempts to document the important roles of selected 
proteins associated with PI-3K/Akt/mTOR, JAK/STAT3 pathways and AMPK protein. To 
understand these pathways in regulating cell behaviour, an inhibitor of each pathway is 
assessed. Using inhibitors will be useful to examine the cell signalling pathways that are 
involved in proliferation and VEGF secretion from cancer cells. A broad range of cell 
biological techniques will be employed in order to explore the role of the hormones in cancer 
cells.  
It has been reported that two important signalling pathways, PI-3K/Akt and 
JAK/STAT3, exhibited cross-talk in three types of cell lines (hypothalamus, 
myeloproliferative neoplasms and ovarian cancer) via insulin receptor substrate (IRS) [53, 
164, 373-375]. From these reports JAK was suggested to be the upstream molecule of these 
two pathways which provides a new target for therapeutic treatment of these diseases. Thus, I 
first hypothesised that the cross-talk of these pathways may also occur in Ishikawa 
endometrial cancer cell line. Therefore it was an initial aim to employ an in vitro model to 
investigate this proposition.   
Previous studies identified the activation of adenosine monophosphate-activated protein 
kinase (AMPK) [376, 377] as a pathway mediating adiponectin activity. Indeed adiponectin is 
recognised as a stimulator of AMPK in many cancer cell types [136, 377-379], and exposing 
cancer cells to treatment with adiponectin enhances AMPK activation in endometrium [30] as 
well as colon [365-367], breast [380-383], prostate [143, 367], and liver [349]. The conditions 
of the study will be applied to investigate this pathway.  
I acknowledge that the results found in experiments using in vitro cell lines may not 
always translate directly to the in vivo models. However, experiments designed under the right 
conditions, and with appropriate controls using properly authenticated cancer cell lines retain 
the properties of the cancers of origin [384] and certain relevant questions can be investigated 




model, will suggest that cancers are directly sensitive to dysregulated endocrinological 
processes that may alter growth patterns and VEGF secretion. In particular, signalling 
pathways associated with leptin, insulin, IGF-I and adiponectin in Ishikawa cells will be 
examined. The results may thereby suggest that an endocrinological approach could provide 
partial treatment options. Further, if the peptides have effects that vary between tissues, there 
may be advantage, in line with many contemporary views, in considering the target tissue or 
even the individual in understanding mechanisms of cancer progression in obese patients. 
High leptin, insulin, and IGF-I concentration in the microenvironment will increase cell 
growth and proliferation [20, 105, 222] henceforth increase the opportunity for mistakes 
during DNA replication to occur and be repeated [105, 222, 223]. Thus, new mutations may 
appear due to the abnormal repair of DNA. As a result the cells will be more prone to 
accumulate oncogenic mutation and become cancerous within the conducive 
microenvironment [20, 105, 223]. 
Although cancer may develop along with obesity, however, it has not been robustly 
established that obesity can cause cancer. However, it is possible to suggest that obesity might 
trigger cancer if there is already an oncogenic mutation or DNA replication mistake [222, 
223]. It is not determined yet which of the two steps, mutation or proliferation, occurs first. 
However, the dysregulation of hormones due to obesity is possibly contributing to cancer 
progression [20]. 
The hypothesis: In summary, the hypothesis of this study is that the obesity-related 
hormones, leptin, insulin, IGF-I and adiponectin can induce hormone-specific effects on 
behaviour of well-characterised cancer cell lines. In addition, these obesity-related hormones 
will elicit biological activities that will be associated with modulation of signalling pathways 
of cancer cell lines. This may provide new insight into details linking obesity with cancer 
progression and whether the hormonal effects are similar across all tissues. Also it is 
hypothesised that cross-talk between the PI-3K/Akt/mTOR and JAK/STAT3 pathways may 
also occur in Ishikawa endometrial cancer cell line. Opportunities for novel endocrinological 
treatments may emerge. Again, it must also be acknowledged that results found in in vitro cell 




concentrations of many other cellular factors and hormones that may influence the response of 
the cancer cells. 
Aims of this project are: (i) to document the proliferative and other effects of hormones on 
cancer cell lines, (ii) to study the effect of hormones on secretion of VEGF from cancer cells, 
(iii) to investigate signaling pathways that are associated with hormones modifying 















2 MATERIALS AND METHODS 
2.1. Cell Culture Media 
2.1.1.  M199 medium 
 2.2 g of sodium bicarbonate (Sigma Aldrich, Cat. No. S 5761-500 g, St Louis, MO, 
USA) and 12 g of M199 packaged medium (Gibco, Invitrogen, Cat. No. 31100-035, 
Auckland, NZ) were dissolved in 1000 ml of autoclaved Milli-Q water; then the medium was 
filtered through 0.2 µm filter membrane and stored at 4°C.  
To 196 ml prepared basal media were added 2 ml of 1% (v/v) penicillin/ streptomycin, 
(Gibco Invitrogen, Cat. No. 15140-122-100 ml), 2 ml of 1% (v/v) Glutamax-ICTS (Gibco 
Invitrogen, Cat. No. A12860), 0.4% (v/v) fungizone (Gibco Invitrogen, Cat. No. 15290-018) 
(0.8 ml in 200 ml). 
2.1.2. M199 medium with FBS 
To prepare 200 ml of M199 medium supplemented with 10% (v/v) fetal bovine serum 
(FBS) medium, (Gibco Invitrogen, Cat. No. 10091-148-500 ml), 20 ml FBS 10% (v/v) were 
added to 180 ml prepared basal medium. 
2.2. Cell Culture  
2.2.1. Maintenance of cell culture 
For experiments, cells were maintained in the M199 medium with FBS in culture flasks, 
(Corning flask 3065 (25 cm3 cell culture flask, angled neck)). To propagate cells, the medium 
was aspirated and discarded from the flask. Cells that attached to the base of the flask were 
washed with 3 ml of Phosphate Buffer Saline (PBS) (Invitrogen, Cat. No. 003002, Carlsbad, 




was added to the flask and incubated for 20 minutes at 37°C. This allowed cells to detach 
from the bottom of the flask. The resulting cell suspension was aspirated and transferred to a 
15 ml tube. The flask was then rinsed with 3 ml of PBS. The cell suspension was centrifuged 
for 5 minutes at 400g. After centrifugation, the supernatant was aspirated and discarded. 
Then, 2 ml of the medium (M199 with FBS) was added to the cell pellet and triturated with a 
1 ml pipette to disperse clumps of cells and obtain single cell suspension. An aliquot (100 μl) 
of the cell suspension was diluted with 100 μl of PBS in an Eppendorf tube prior to 
performing cell counting with a haemocytometer. Approximately 50,000 cells/well were 
seeded in a 24-well plate in M199 medium with FBS. Cells were at approximately 70% 
confluence in 37°C and 5%/95% CO2/air incubator prior to addition of treatments and 
collection.  
2.2.2. Treatment protocols 
2.2.2.1. Hormone addition 
Cells (5 x 10⁴cells/well) were seeded and grown in 24 well plates (Corning 3524 - 24 
well cell culture plate, flat bottom with a lid) in M199 medium with 10% FBS (1 ml). Cells 
were incubated for 48 hours to allow cells to attach and then medium discarded and replaced 
with M199 without FBS medium (1 ml). Cells were then incubated in FBS-free media for 24 
hours to minimise the effects of remnant hormones and growth factors which may be derived 
from FBS. After 24 hours, media was removed from cell culture wells and medium containing 
selected concentrations of hormones in M199 without FBS was placed in wells to a total 
volume of 1 ml. The working concentrations of leptin (50 ng/ml), adiponectin (20 and 100 
ng/ml), insulin (580 ng/ml), and IGF-I (100 ng/ml) were calculated from stock concentrations. 
All hormones were purchased from GenWay Biotech Inc. (San Diego, CA, USA): 
Leptin (recombinant human leptin, Cat. No. 10-783-313250), adiponectin (adiponectin 
recombinant human, Cat. No. 10-002-38001), insulin (insulin human, Cat. No. 10-663-




2.2.2.2. Signalling pathway modulation 
Pathway inhibitors were used to investigate the signalling mechanisms of the hormones. 
Phosphatidylinositol 3-kinase (PI-3K) inhibitor LY294002 (LC Laboratories, Cat. No. L-
7962, Woburn, MA, USA) was used at 20 μM. The analogue of rapamycin (mTOR) inhibitor 
everolimus (LC laboratories, Cat. No. E-4040) was used at 2 μM, and the JAK inhibitor, 
tyrphostin AG490 (Sigma-Aldrich, Cat. No. T3434-5 mg) was used at 100 μM. These 
inhibitors were included in the incubations as appropriate, concurrently with aforementioned 
growth factors. After 48 hours, the effects of experimental conditions were examined. Cells 
were collected for determination of growth activity, VEGF secretion and protein expression 
using a number of techniques including Western Blotting, flow cytometry, ELISAs, 
immunohistochemistry, and fluorescence microscopy (see following sections).  
2.3. Measurements  
2.3.1. Cell counting 
Cell suspensions were diluted so that the cells did not overlap each other on the 
haemocytometer grid, and were uniformly distributed as it assumed that the total volume in 
the chamber represents a random sample. The cell suspension was mixed thoroughly before 
taking a sample to count. The cells were counted in selected squares so that the total count 
was approximately 100 cells (the number of cells needed for a statistically robust count). 
Selecting a specific counting pattern avoided bias, and the Bio-Rad Company protocol for cell 
counting was used. In brief, the haemocytometer and cover slip surfaces were cleaned with 
lens paper and ethanol. The cover slip was placed over the counting surface prior to adding 
the cell suspension. The cell suspension was introduced so that the surface was just covered 
by the cover slip. The counting chamber was viewed at 40x (Olympus CK40, Tokyo, Japan) 
and the counts were appropriately multiplied by the dilution factors used. In a preliminary 
study, leptin was used to determine whether there was glucose-dependent response to obesity-
related peptides. This provided information for experimental design and also interpretation of 




To avoid the interference of diabetic status and oestrogen effect on cell proliferation. I 
chose M199 medium that has 5.5 mM glucose which is considered to be a normal 
physiological serum level, and compared it with DMEM-F12 that has a higher glucose 
concentration of 17.1 mM, a level associated with diabetes (see Appendices, Figure 10.1). 
In addition, M199 medium has phenol red. Phenol red is known to be a weak oestrogen. 
However, oestrogen in M199 is unlikely to have an effect on cancer cell proliferation 
compared to other media [385]. Moreover, the effect is negligible due to the fact the same 
medium is used for the control cells and in worse scenario, the oestrogenic effects of M199 
will have only a minor effect on cancer cell proliferation compared to the hormones 
investigated in the thesis. 
On the basis of these results, M199 was chosen as the more relevant medium and to 
avoid a compounding factor associated with diabetes. 
2.3.2. VEGF ELISA assay 
Conditioned media from control and treated cells were collected for determining the 
amount of secreted VEGF. The cell medium was aspirated from wells with caution so as not 
to include cells, and 75 μl was left in the well while the pipette tip did not touch the cell layer. 
The cell-free conditioned media was transferred to Eppendorf tubes and centrifuged at 6700g 
at room temperature to remove debris and non-adherent cellular material. ELISA analysis was 
performed according to the manufacturer’s instructions (VEGF ELISA kit; DuoSet ELISA 
Development R&D System human VEGF, Minneapolis, MN, USA). The kit components 
consisted of Capture Antibody, Detection Antibody, Standard, Stop solution, Streptavidin-
HRP, and Substrate solution. The cell numbers for corresponding cultures were counted and 
the level of VEGF that was secreted was determined per 106 cells. The values of absorbance 
were measured at wavelength of 450 nm. The standard curve was plotted by Prism statistical 
software (GraphPad Software, La Jolla, CA USA). The working range was 50 – 2000 pg/ml 
and minimum sensitivity of the method is less than 50 pg/ml. Samples fell within this range 




performed with six replicates (three times in duplicate) and the experiment was performed at 
least three times on independent occasions.  
2.3.3. Western blotting 
Supernatant medium was removed and cells were washed with 0.5 ml PBS and lysed 
with 100 μL RIPA lysis buffer which was freshly prepared from constituents-(50 mM Tris 
base (2-Amino-2-(hydroxymethyl)-1,3-propanediol, Roche, Cat. No, 708976, USA), 150 mM 
NaCl (MERCK, Cat. No, K 33591704506, Germany), 5 mM ethylenediaminetetraacetic acid 
(EDTA), 0.1% (SDS) (sodium dodecyl sulfate, BDH, Cat. No, 44244, UK), 1% NP-40 (acetyl 
phenol ethylene oxide, SIGMA Aldrich, Cat. No, N-6507, USA), 0.5% sodium deoxycholate, 
1 mM NaVO4, 10% glycerol (SIGMA Aldrich, Cat. No, G 6279), and 1 protease inhibitor 
cocktail tablet (Complete Mini, Roche, New Zealand), pH 7.4). The cell lysate was 
transferred to an Eppendorf tube and the total protein was measured by Bio-Rad DC protein 
assay kit (Cat. 500-0113, 500-0114 and 500-0115, CA, USA). The cell lysates were left on ice 
for a further 30 minutes. Sample buffer [0.2% (v/v) bromophenol blue, 25% (v/v) glycerol, 
10% SDS in Tris-HCl, and pH 6.8] was added and protein lysates were boiled for 10 minutes. 
Prior to loading, the cell lysates were mixed and centrifuged at 9,700 rpm for 5 minutes. A 
total of 10 µg protein lysate was loaded and separated by SDS-PAGE using a 7% stacking gel 
and a 10% separating gel.  
The SDS-PAGE was run at 120 V using Tris-glycine running buffer. The SDS-PAGE 
markers used were MagicMark™ XP Western Standard (Thermo Fisher Scientific, New 
Zealand) and Precision Plus Protein standard (Bio-Rad, Hercules, USA). Proteins were 
electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (BioRad, Cat. 
No, 162-0177, USA) in ice cold transfer buffer (25 mM Tris base, 200 mM glycerin) at 100 V 
for 60 minutes. Specific immuno-detection was carried out by incubation with relevant 
primary antibodies. Antigens were revealed using the ECL developing solution (Amersham, 
ECL Prime Western Blotting Detection Reagent, ge-9466588; GE healthcare, UK). The 
protein bands were visualized and a densitometry analysis was performed using Alliance 4.7, 





Antibodies used in this study were all provided by Santa Cruz Biotechnology (Dallas, 
TX, USA). The primary antibodies used in this study were anti-AdipoR1 (sc-99183), anti-
AdipoR2 (sc-99184), anti-Ob-R (sc-8325), anti-InsR (sc-711) and anti-IGFR (sc-7952) (Table 
2.1). The two secondary antibodies used in this study were bovine anti-rabbit IgG-HRP (sc-
2385) and bovine anti-mouse IgG-HRP (sc-2380). 
The dilution of antibodies according to the suppliers was followed. In general, 
antibodies from Santa Cruz, the optimal dilution of antibody for Western blot was around 
1/500- 1//1000. Each time before I used each antibody, I have to optimise the dilution of the 
antibodies in order to use the appropriate dilution factor of the antibody as well as the 
appropriate blocker's concentration and type by doing several experiments with different 




Table 2.1 Western Blotting antibodies 
*All the primary antibodies were purchased from Santa Cruz Biotechnology Company (Santa Cruz Biotechnology, Dallas, TX, USA), 
except for #11 which was purchased from Cell Signaling Technology (Danvers, MA, USA).  
*The same dilution of antibodies were used for Western blot and immunohistochemistry assays. 
 
 
Primary antibody Company Blocking 
Primary antibody 
dilution (10 ml) 
Secondary antibody dilution     
(13 ml):   R, rabbit; M, mouse 
Notes 
 Name kDa Ser. No.   Vol.µl  Vol.µl Source  
1.  AdipoR (H-40) 42-44 SC-99183 5% Skim milk 1/500 20 µl 1/10000 1.3 µl R  
2.  Akt 56-63 SC-8312 1% BSA 1/500 20 µl 1/10000 1.3 µl R  
3.  AMPK 63 SC-25792 1% BSA 1/250 40 µl 1/10000 1.3 µl R  
4.  GAPDH 37 SC-25778 5% Skim milk 1/1000 10 µl 1/10000 1.3 µl R  
5.  IGFR 130 Sc-7952 4%BSA 1/200 50 µl 1/10000 1.3  µl R  
6.  InsR 95 Sc-711 4% BSA 1/200 50 µl 1/10000 1.3  µl R  
7.  Ob-R (H-300) 100-125 SC-8325 Thermo-Fisher 1/500 20 µl 1/10000 1.3 µl R  
8.  p-Akt 56-63 SC-101629 1% BSA 1/500 20 µl 1/10000 1.3 µl R  
9.  p-AMPK 63 SC-33524 4% BSA 1/500 20 µl 1/10000 1.3 µl R  
10.  p-Stat3(B-7) 86-91 Sc-8059 5% BSA 1/1000 10 µl 1/5000 2.6 µl M Tyr705 epitope 
11.  p-Stat3(ser727) 86-91 9134  5% BSA 1/1000 10 µl 1/5000 2.6 µl R Ser727 epitope 
12.  Stat3 (C-20) 86-91 Sc-482 3% BSA 1/500 20 µl 1/10000 1.3 µl R  
13.  Ob-R (C-20) 100-125 Sc-1832 P Thermo-Fisher 1/500 20 µl 1/10000 1.3 µl R Blocker 
14.  Insulin Rβ (C-19) 95 Sc-711 P 4% BSA 1/200 50 µl 1/10000 1.3  µl R Blocker 




2.3.4. Immunofluorescence microscope imaging 
To prepare cells for immunofluorescence microscopy, a coverslip was sterilised in 95% 
ethanol solution then left for 30 min in a sterile area inside a 12 well plate to dry. The 
coverslip was then washed in 500 µl medium. Then M199 with FBS medium up to 1 ml 
containing 50,000 cells of cell lines was added to the cover slip which was incubated for 48 
hours to allow adherence and proliferation. 
After 48 hours, the medium was removed and the cells on the cover slip were fixed with 
4% paraformaldehyde in PBS, pH 7.4, for 45 minutes at room temperature. The cells were 
washed with cold PBS (5 times x 5 minutes) at room temperature. To permeablise the cells, 
cold methanol (95%) was added to cells for 15 min at 4ºC, (to perform actin staining 
experiment, the fixation solution was free of methanol since methanol can disrupt the actin 
during the fixation process, thus I added 0.1% Triton X-100 in PBS onto fixed cells for 15 
minutes in room temperature), and the cells were washed with cold PBS (4 times x 5 minutes) 
at room temperature. Cells were blocked with the blocker that was appropriate for each 
antibody (Table 2.1) for 60 minutes at room temperature. . Again, cells were washed with 
cold PBS (4 times x 5 minutes) at room temperature.  
Cells were incubated with primary antibody in 2.5% BSA in PBS at 4°C overnight. The 
same concentration of the antibodies used in Western blot was used for immunofluorescence. 
The cells were washed with cold PBS (4 times x 5 minutes) at room temperature. Incubation 
was performed in the dark at room temperature for 1 hour with secondary antibody 
conjugated with the fluorescent molecule Atto 594 (Sigma-Aldrich, Cat. No. 08717) to detect 
primary antibody staining and then Alexa 488 Phalloidin (CytoPainter Phalloidin iFluor 488 
reagent, Cat. No. ab176753, Abcam, Cambridge, UK) was added to detect actin 
microfilaments and incubated for 15 minutes at room temperature. The cells were covered 
with foil to protect them from light. To stain DNA, cells were incubated with Hoescht (20 
µg/ml) for 20 min at room temperature in the dark and cells were washed with a mixture of 
cold PBS and 0.05% Tween-20 (3 times x 10 minutes) at room temperature, followed by cells 




was added to the cells on cover slip. Controls for non-specific binding of primary antibody 
were performed using absorption blocking peptide where they were made available by the 
manufacturer. Controls for non-specific binding of the secondary antibody were also 
performed using just the second antibody without primary antibody.  
Localisation of protein was visualised with fluorescence microscope (Carl Zeiss, 
Imager.Z1, Oberkochen, Germany). Optical sections (0.5µm thickness) were collected using 
the ApoTome module, and 3D images and z-stack data were generated using ZEN application 
software (Carl Zeiss). All images are computer-generated from optical sectioning. 
2.3.5.  Detection of apoptotic and necrotic cells using flow cytometry  
The cells were seeded in 24-well culture plates at a density of 5 × 104 cells/well in 
M199 medium supplemented with 10 % FBS as a control medium or with treatments with the 
hormones for 48 hours. Cells were detached and collected in 1.5 ml tubes. Briefly, after 
centrifugation 10 minutes at 530g, the cell pellets were re-suspended in the Annexin assay 
buffer (200 µl). The buffer contained 10 mM PIPES, 140 mM NaCl, and 2.5 mM CaCl2 (all 
from Sigma-Aldrich) and was adjusted to pH 7.4. Volume of 5 µl of Annexin-FITC was 
added to the Eppendorf tube to detect apoptotic cells. The re-suspended cell pellets were 
kept in the buffer for 20 mins at room temperature. Cells were then incubated with 1.3 µl of 
propidium iodide (PI) for 10 mins in the dark at room temperature (because PI is light 
sensitive) to detect necrotic cells. Then Annexin assay buffer (200 µl) was added again. 200 
µl of cell suspension were added to 96-well plate in duplicate. Samples were then analyzed 
in a Cytomics FC500 MPL flow cytometer (Beckman Coulter, Brea, CA, USA).   
2.3.6. Cell lines 
Four cell lines were studied in this project. Ishikawa cell line is a well-differentiated 
human endometrial adenocarcinoma cell. It is one of the most widely used human 
endometrial-derived cell culture models. Ishikawa cell line 3-H-12 No.138 was donated by 
the National Hospital Organization, Kasumigaura Medical Centre, Japan. To make a 




from other organs were investigated. These cell lines included an ovarian cancer cell line, 
SKOV-3, a breast cancer cell line, MCF-7, and a second endometrial cancer cell line, HEC-
1A. SKOV-3 cell line was obtained from the American Tissue Culture Centre (ATCC), 
Number: HTB-77 ™; Homo sapiens, human, Ovary: Ascites, Adenocarcinoma, USA. MCF-7 
cell line was obtained from ATCC® Number: HTB-22 ™; Homo sapiens, human, Epithelial, 
Mammary Gland, Breast; Derived from Metastatic Site: Pleural Effusion, Adenocarcinoma, 
USA. HEC-1A was obtained from ATCC® Number: HTB-112 ™; Homo sapiens, human, 
Uterus/Endometrium, Adenocarcinoma, USA. All cell lines were STR profiled and cells were 
found to be mycoplasma free. 
 
2.3.7. Statistical analysis 
Data were expressed as mean ± SEM from at least three independent experiments 
performed in triplicate. Statistical analyses were performed using GraphPad Prism 7. Data 
were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s honestly 
significant difference (HSD) multiple range test or logarithmic analysis and Student's t-test or 
one-way analysis of variance (ANOVA) as appropriate. A value of P < 0.05 was considered 
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3 The effects of leptin, insulin, IGF-I and adiponectin on the 
endometrial cancer cell line, Ishikawa 
3.1. Introduction 
Obesity increases the risk of cancer incidence in overweight women by 50% compared 
to women of normal weight [315, 386], with endometrial cancer being particularly sensitive. 
The risk of endometrial cancer increases approximately 70–90% if type I patients are 
overweight [3, 15, 316]. Thus, obesity is estimated to account for 40% of endometrial cancer 
incidence [3], and as endometrial cancers are one of the most common causes of mortality 
from all types of cancer [294], obesity contributes directly to many cancer deaths.  
3.1.1. Hormones 
The manner in which obesity alters cancer risk is unclear. However, it is known that in 
obese individuals there is dysregulation of a number of factors including hormones, gene 
expression and feedback mechanisms. This project studies the effects of four obesity-related 
hormones, namely leptin, adiponectin, insulin, and IGF-I on endometrial cancer risk. 
 Leptin is a protein factor secreted primarily by white adipose tissue (WAT) but also by 
many other organs [28, 66]. There is a high correlation between plasma leptin and indices of 
body fatness including BMI [81, 82], and a correlation between elevated leptin concentrations 
and endometrial cancer has been observed [62]. This suggests that elevated amounts of leptin 
may be an important hormone in the development of endometrial cancer. Another adipokine 
hormone, adiponectin, is also primarily secreted from the adipose tissue [131]. It is believed 
to have opposite biological effects from leptin. The levels of adiponectin change in an obesity 
dependent manner with circulating plasma adiponectin levels inversely correlated with BMI 
[148, 176-178]. Adiponectin may also provide a link between obesity, insulin resistance, and 
diabetes [131, 139-141]. Recently, anti-tumour effects of adiponectin in several types of 
cancers, including endometrial cancer, have been reported [150, 168]. Insulin is a peptide 




glucose regulation [109]. Obesity, as defined by BMI, is associated with elevated insulin [39, 
40], and higher insulin levels also are associated with increased risk of endometrial cancer 
[112, 114, 387]. IGF-I plays a critical role in growth in children and adults. Many studies 
have shown a significant correlation between the presence of IGF-I and development of types 
1 and II endometrial cancer [388].  The growth of solid tumours depends on satisfactory 
nutritional support and the neovascularisation, that underpins the process, is dependent to a 
substantial extent on pathways activated by vascular endothelial growth factor (VEGF). 
VEGF is secreted from tumour cells themselves and has angiogenic, mitogenic, and vascular 
permeability-enhancing activities specific to endothelial cells [348]. Obesity elevates 
circulating VEGF secretion compared to that in lean individuals [389, 390] and high tumour 
expression of VEGF is associated with poor prognosis of obesity-related cancers [357].  
This chapter will investigate effects of these four obesity-related homones (leptin, 
adiponectin, insulin, and IGF-I) on an endometrial cancer cell line known as Ishikawa. In 
particular, the results of incubation of the cells with the hormones on cell number, level of 





3.2.1. The presence of leptin receptors 
For cancer cells to respond to leptin hormone, they should have detectable levels of 
expression of leptin receptors (Ob-Rs) to bind with the leptin ligand. Thus, the presence of 
leptin receptors (Ob-Rs) in Ishikawa cells was investigated. To ascertain this information the 
presence of Ob-Rs in endometrial adenocarcinoma Ishikawa cell lines was examined using 
immunofluorescent imaging with the collection of z-stacks on an optical sectioning 
microscope and with Western blot techniques. Immunostaining of Ob-R antigen in cell 
monolayers of Ishikawa was observed in both the plasma membrane, and cytoplasm of cells. 
This finding is in line with the localisation of substantial levels of leptin receptor in the 
cytoplasm of the cells from clinical endometrial cancer tissue [35]. 
 
Figure 3.1 Optical sectioning images in Ishikawa cells indicating the presence of 
leptin receptors. Red, Leptin receptors; Blue, Ishikawa cell nuclei; Green, actin.  




Confirmation of leptin receptor protein expression was achieved using Western blot 
immunodetection. Figure 3.2 shows the expression of Ob-Ra short form (100 kDa), and Ob-
Rb long form (125 kDa). The molecular weight was confirmed by position of the bands 




Figure 3.2 Western blot detection of leptin receptors, Ob-Rs. Protein expressions 
of Ob-Ra, short form 100 kDa and Ob-Rb, long form 125 kDa. GAPDH represents 
the reference protein. 
Whether the addition of leptin to cell culture of Ishikawa cells could alter the expression 
of leptin receptors was then investigated. As shown in Figure 3.3, the endometrial cancer cell 
line Ishikawa demonstrated a significantly increased level of leptin receptor long form, Ob-
Rb, in the presence of leptin at 50 ng/ml compared to the control. This result may suggest that 
leptin hormone could alter its own receptor in order to provide cells with the process of 
















Figure 3.3 Densitometry of the long isoform of leptin receptor, Ob-Rb, 
expression. Densitometry of Ob-Rb expression of controls (Ctrl), and cells treated 
with leptin (50 ng/ml). n = 3. Data were analyzed using logarithmic analysis and 
Student's t-test (two-tailed). Data were denoted as statistically significant (**) 
when p < 0.01 compared to controls. Data are expressed as means ± S.E.M. 
3.2.2. The effect of leptin on Ishikawa cell numbers 
To study the effect of hormones on proliferation of Ishikawa cell numbers, Ishikawa 
cells were first exposed to selected concentrations of leptin for 48 hours. After treatment cells 






Figure 3.4 Cell numbers of controls (Ctrl) and cells incubated with selected 
concentrations of leptin. n = 3. Data were analysed using one-way ANOVA. ** p 
< 0.01, and *** p < 0.001 compared to control. Data are expressed as means 
± S.E.M. 
As shown in Figure 3.4, Ishikawa cell numbers increased significantly when treated 
with leptin at 20 (p<0.01), 50 (p<0.001), and 100 (p<0.001) ng/ml. In the experimental 
conditions of this study, 50 ng/ml leptin was associated with the highest cell numbers, 
compared to 20 and 100 ng/ml. As such, at 50 ng/ml (3 nM) leptin was used in following 
experiments.  
3.2.3.  The effect of leptin on VEGF secretion 
VEGF is a potent protein molecule that plays a key role in the formation of new blood 
vessels around tumours and facilitates tumour progression. Understanding the biological 
activity and production of VEGF is of great interest. The relationship between leptin and the 
secretion of VEGF from Ishikawa cells was investigated. VEGF secretion was determined in 
the presence of the optimum concentration of leptin (50 ng/ml) which induced the greatest 





Figure 3.5 The level of VEGF secretion from control (Ctrl) and cells incubated 
with 50 ng/ml leptin was determined and normalised to 1 million cells. n = 4. 
Data were analysed using Student's t-test (two-tailed). ** p < 0.01 compared to 
control. Data are expressed as means ± S.E.M. 
As shown in figure 3.5, the secretion of VEGF was significantly reduced in the presence 
of 50 ng/ml leptin. This result suggests that leptin exerts a negative effect on VEGF secretion. 
3.2.4. The presence of adiponectin receptors in Ishikawa cells 
As previously mentioned, leptin and adiponectin show opposite roles in observations of 
biological activity. Therefore, the biological activity of adiponectin in a cell culture of 
Ishikawa is very crucial. To better understand its role, the presence of adiponectin receptor 
was investigated. 
The presence of adiponectin receptors was confirmed. Immunohistochemistry was performed 
using antibodies against AdipoR1 and AdipoR2 (Figure 3.6). Antibody specificity was 
confirmed using an absorption peptide control. Localisation included substantial levels of 
adiponectin receptors in the cytoplasm of the cell line, similarly to reports of clinical 
endometrial cancer tissue [35]. Images of the receptors and the blockers were added to 





Figure 3.6 Optical sectioning images in Ishikawa cells indicating the presence of 
the receptors for adiponectin. Red, adiponectin receptors; Blue, Ishikawa cell 
nuclei. Green actin. All images are computer-generated from optical sectioning. 
 
This result re-confirm the presence of adiponectin receptors in cell monolayers of 
Ishikawa, Western blotting was used. Ishikawa cells showed strong expression of adiponectin 
receptors at the molecular weights 42 and 49 kDa (Figure 3.7). The molecular weight was 
confirmed by position of the bands relative to the electrophoresis ladder. Bands at 49 and 42 
kDa belonged to AdipoR1 and AdipoR2, respectively.  
As leptin can elevate the level of Ob-Rb, is it possible that adiponectin may also alter 
the level of its receptor? To answer this question, cell monolayers of Ishikawa were exposed 




the receptor using Western blotting. The results (Figure 3.8) revealed that adiponectin, unlike 
leptin, did not significantly increase the level of its own receptors. This results may suggest 




Figure 3.7 Protein expression of adiponectin receptor 1, AdipoR1, and 
adiponectin receptor 2, AdipoR2 of Ishikawa cells. The band for AdipoR1 was 
observed at 49 kDa and AdipoR2 was at 42 kDa. GAPDH represents the 
reference protein. 
 
Figure 3.8 Densitometry of (A) AdipoR1 and (B) AdipoR2 protein expressions 
for Ctrl, cells treated with adiponectin (20 and 100 ng/ml) respectively. n = 3. 
Data were analysed using logarithmic analysis and one-way ANOVA. Data are 
expressed as means ± S.E.M. 
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3.2.5. The effect of adiponectin on Ishikawa cell numbers 
Next, the effect on cell growth of selected concentrations of adiponectin was 
investigated. Recombinant human adiponectin containing the globular domain (20, 50, and 
100 ng/ml) exhibited a concentration-dependent effect on cell growth (Figure 3.9). 
  
Figure 3.9 Cell numbers of Ishikawa cells were determined after treatment with 
selected concentrations of adiponectin or remaining untreated (Ctrl). n = 3. Data 
were analysed using one-way ANOVA. ** p < 0.01 and *** p < 0.001 compared 
to controls. Data are expressed as means ± S.E.M. The data are identical to 
previous figure. 
Figure 3.9 shows that an n-shaped concentration effect was observed whereby at 20 
ng/ml (0.66 nM), adiponectin was, surprisingly, stimulatory and significantly increased 
Ishikawa cell numbers and adiponectin at 50 ng/ml also increased endometrial cancer cell 
numbers. However, endometrial cancer cell numbers were reduced slightly but significantly 





3.2.6. The effect of adiponectin on VEGF secretion 
Next, the relationship between VEGF secretions elicited by high adiponectin 
concentrations (100 ng/ml), and the adiponectin concentration that is close to the minimum 
physiological concentration in human (20 ng/ml), were examined in Ishikawa endometrial 
cancer cells (Figure 3.10).  
 
Figure 3.10 The level of VEGF secretion from Ishikawa cells treated with 20 and 
100 ng/ml adiponectin (Adp20, Adp100), and control (Ctrl). Concentrations of 
VEGF were determined and normalised to 1 million cells. n = 3. Data were 
analysed using one-way ANOVA. *** p < 0.001 compared to control. Data are 
expressed as means ± S.E.M. The data are identical to previous figure. 
Figure 3.10 shows that both 20 ng/ml and 100 ng/ml of adiponectin significantly 
increased the secretion of VEGF from Ishikawa cells. Thus, a concentration-related effect of 
adiponectin similar to that on proliferation was not observed for VEGF secretion where low 
adiponectin, 20 ng/ml, increased cell proliferation and 100 ng/ml adiponectin concentration 





3.2.7. The effects of adiponectin and leptin on modulation of Ishikawa cells  
It has been recognised that at any stage of cancer development, endometrial cancer cells 
may be exposed simultaneously to more than one growth factor. Thus, the effect of the 
putative inhibitory growth factor, adiponectin, in combination with the stimulatory factor, 
leptin, was investigated. Ishikawa cells were treated with combinations of adiponectin (20 or 
100 ng/ml) with leptin.  Cell numbers and VEGF secretion were determined.  
 
Figure 3.11 Cell numbers of Ishikawa cells treated with leptin and adiponectin 
individually and combined. The effect of leptin at 50 ng/ml, adiponectin at 20 
ng/ml (Adp20), 100 ng/ml (Adp100) and combinations were compared to 
individual treatments and to untreated control cells (Ctrl). n = 3. Data were 
analysed using one-way ANOVA. * p < 0.05; ** p < 0.01 and *** p < 0.001 
compared to control. Data are expressed as means ± S.E.M. Stars without 
connections indicate comparison to control incubation. The data are identical to 
previous figure. 
Figure 3.11 shows that the combination of leptin plus adiponectin (Leptin+Adp20) 
increased cell numbers significantly, similar to the levels of individual treatments. However, 
the effect of the combination of both stimulatory hormones (Leptin+Adp20) was not an 




inhibitory concentration of 100 ng/ml to leptin (stimulatory) (Leptin+Adp100) was observed 
to counter the leptin activity. These data, together, may demonstrate that adiponectin has 
potential to influence leptin activity at its inhibitory concentrations but not at its stimulatory 
concentration. 
 
Figure 3.12 The level of VEGF secretion (ng/ml) when cells were exposed to 
Leptin, Adp20, Adp100 and a combination of Leptin+Adp20 and Leptin+Adp100 
were determined and normalised to 1 million cells. n = 4. Data were analyzed 
using one-way ANOVA. ** p < 0.01 and *** p < 0.001 compared to control. 
Data are expressed as means ± S.E.M. Stars without connections indicate 
comparison to control incubation. The data are identical to previous figure. 
Figure 3.12 shows that in incubations containing the combination of leptin (50 ng/ml) 
and adiponectin at 20 ng/ml (Leptin+Adp20) did not reduce VEGF compared to those cells 
that were stimulated with adiponectin 20 ng/ml alone. The stimulatory effect of adiponectin 
20 ng/ml on VEGF secretion remained and the inhibitory effect of leptin was largely resisted.  
On the other hand, although adiponectin at 100 ng/ml increased VEGF secretion 
significantly from Ishikawa cells, addition of leptin (50 ng/ml) to adiponectin at 100 ng/ml 
(Leptin+Adp100) led to VEGF secretion from Ishikawa cells being reduced to control level. 
This suggests that leptin may be involved in an anti-angiogenesis process via VEGF in 




The results above raised a question: were the effects of adiponectin specific to leptin or 
did adiponectin also affect other hormones? Thus, two other obesity-related hormones, insulin 
and IGF-I were also investigated. 
3.2.8. The effect of insulin on endometrial cancer cell line, Ishikawa 
The presence of insulin receptors (InsR) in Ishikawa cells has been previously 
documented by a number of studies [391-395]. As shown in Figure 3.13, Ishikawa cells are 
positive for InsR. Also, insulin receptors were demonstrated to be present in the study 
conditions (Figure 3.13) using immunohistochemistry. Antibody specificity was confirmed by 
using an absorption peptide control. 
 
Figure 3.13 Optical sectioning images of Ishikawa cells showing insulin 
receptors (Red), nucleus (Blue) and actin (Green). All images are computer-




To confirm the epifluorescence images that show that Ishikawa cells have a detectable 
level of insulin receptors (InsR), Western blotting was used. The molecular weight of 95 kDa 
was confirmed by position of the band relative to the electrophoresis ladder (Figure 3.14). The 
cytoplasmic and nucleus immunostaining of InsR in Ishikawa cells were in agreement with 
clinical samples [396].  
 
  
Figure 3.14 Protein expression of insulin receptor (InsR) in Ishikawa cells. 
GAPDH represents the reference protein.  
The effects of insulin on the Ishikawa cell proliferation and VEGF secretion were 
examined by exposing Ishikawa cells to insulin concentrations previously used which ranged 
between 0.58-580000 ng/ml [392, 397-399]. These concentrations were close to the 
physiological, nanomolar concentrations (20, 100 and 500 nM). To keep unit usage consistent 
the units were changed to ng/ml. Cell numbers were counted and the amount of VEGF that 
cells secreted into the media was determined. The final amount of VEGF was normalised to 
total cell numbers in order to obtain a measure of VEGF secretion per cell. 
 
 









Figure 3.15 Cell numbers of Ishikawa cells were determined after treatment with 
selected concentrations of insulin, 116, 580, and 2900 ng/ml or control (Ctrl). n = 
3. Data were analysed using one-way ANOVA. *** p < 0.001 compared to 
control. Data are expressed as means ± S.E.M. 
Figure 3.15 shows increased numbers for Ishikawa cells stimulated with selected 
concentrations of insulin. Insulin at 580 ng/ml (100 nM) demonstrated the maximal effect on 
increased cell number compared to control. As such, the secretion of VEGF was also 
determined at this concentration (Figure 3.16), and showed that insulin at 580 ng/ml 






Figure 3.16 The level of VEGF secretion from Ishikawa cells treated with insulin 
at 580 ng/ml (Insulin). Concentration of VEGF were determined and normalised 
to 1 million cells. n = 4. Data were analysed using Student's t-test (two-tailed). 
*** p < 0.001 compared to control. Data are expressed as means ± S.E.M.  








Figure 3.17 Cell numbers of Ishikawa cells were determined after treatment with 
insulin and adiponectin individually and combined. The effect of insulin, Adp20, 
Adp100 and combination of insulin 580 ng/ml, and adiponectin 20 or 100 ng/ml 
(Insulin+Adp20 and Insulin+Adp100) were compared to individual treatment and 
to Ctrl. n = 3. Data were analysed using one-way ANOVA. ** p < 0.01 and ***  
p < 0.001 compared to control. Data are expressed as means ± S.E.M. The data 
are identical to previous figure. 
The combination of insulin (580 ng/ml) and adiponectin at 20 ng/ml (Insulin+Adp20) 
increased cancer cell numbers significantly compared to control. The increase was not 
additive of the two peptides alone, despite both hormones having stimulatory effect on 
Ishikawa cell numbers. This result using insulin was similar to that of leptin combined with 
adiponectin at 20 ng/ml (Figure 3.11).  
The addition of 100 ng/ml adiponectin to 580 ng/ml insulin (Insulin+Adp100) did not 
reduce the stimulatory effect of insulin on cell numbers compared to the control, although it 
did compared to insulin alone (Figure 3.17). This data is clearly different from Ishikawa cells 






Figure 3.18 The level of VEGF secreted from Ishikawa cells treated with insulin 
and adiponectin individually and combined. The effect of Insulin, Adp20, 
Adp100 and combination of Insulin+Adp20, and Insulin+Adp100 were compared 
to individual treatment or untreated (Ctrl). n = 4. Data were analysed using one-
way ANOVA. ** p < 0.01, and *** p < 0.001 compared to control. Data are 
expressed as means ± S.E.M. The data are identical to previous figure. 
The results in Figure 3.18 show that the combination of insulin and 20 ng/ml 
adiponectin (Insulin+Adp20) reduced VEGF secretion from Ishikawa cells significantly 
compared to 20 ng/ml adiponectin alone, and were close to the level obtained by insulin 
alone. The combination of insulin and 100 ng/ml adiponectin (Insulin+Adp100) reduced the 
VEGF secretion to control levels. It is interesting that this result is similar to the effects of 




3.2.9. The effect of insulin-like growth factor-1 (IGF-I) on endometrial 
cancer cell line, Ishikawa 
It has been suggested that IGF-I shows biological activity in a manner similar to that of 
insulin. Therefore, it is important to investigate the effect of adiponectin and IGF-I, both alone 
and in combination. Ishikawa cells have detectable level of IGF-I receptors (Figure 3.19). 
 
Figure 3.19 Optical sectioning images of Ishikawa cells showing IGF receptors 
(Red), nucleus (Blue) and actin staining (Green). All images are computer-
generated from optical sectioning. 
Localisation included levels of IGF receptor in the cytoplasm of the cell line, similarly 
to observations in ovarian cancer tissue [400]. The protein band at about 130 kDa of the IGF 
receptor was observed using Western blotting. The molecular weight was confirmed by 






Figure 3.20 Protein expression of IGF-I receptor (IGFR) for Ishikawa cells. The 
band for IGFR was observed at 130 kDa. GAPDH represents the reference 
protein. 
Next, growth activity of Ishikawa cells in the presence of selected concentrations of 
IGF-I was determined in order to choose the most effective concentration to use in the next 
set of experiments of IGF-I. 
 
 
Figure 3.21 Cell numbers of Ishikawa cells were determined after incubation 
with selected concentrations of IGF-I at 20, 100 and 500 ng/ml or remaining 
untreated cells (Ctrl). n = 3. Data were analysed using one-way ANOVA. ***  p 
< 0.001 compared to control. Data are expressed as means ± S.E.M. 
Figure 3.21 shows that 20, 100, 500 ng/ml of IGF-I increased Ishikawa cell numbers 
significantly in comparison with the control. The normal physiological range for IGF-I in the 
circulation is dependent on age, and varies from 90 - 360 ng/ml for age 40-54 years old, and 
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71–290 ng/ml for an age older than 55 years old. Consequently, 100 ng/ml of IGF-I was used 
in the following treatment because it is physiologically relevant and demonstrated the 
maximal increase of cell numbers in Ishikawa endometrial cancer cell line. As shown in 
Figure 3.22, there was a significant reduction in VEGF secretion from Ishikawa cells induced 
by the presence of IGF-I (100 ng/ml) (13 nM). 
 
 
Figure 3.22 The level of  VEGF secretion from Ishikawa cells treated with IGF-I 
at 100 ng/ml and Ctrl. n = 4. Data were analysed using Student's t-test (two-




3.2.10. The effects of adiponectin on IGF-I modulation of Ishikawa cells. 
 
Figure 3.23 Cell numbers of Ishikawa cells were determined after treatment with 
IGF-I and adiponectin individually and combined. The effect of IGF-I, Adp20, 
Adp100 and combination of IGF-I 100 ng/ml, and adiponectin 20 and 100 ng/ml 
(IGF-I+Adp20 and IGF-I+Adp100) were compared to individual treatment and to 
Ctrl. n = 3. Data were analysed using one-way ANOVA. ** p < 0.01, and ***  p 
< 0.001 compared to control. Data are expressed as means ± S.E.M. The data are 
identical to previous figure. 
The combination of 100 ng/ml IGF-I and 20 ng/ml adiponectin (IGF-I+Adp20) 
abolished the stimulatory effects of both on cell numbers and reduced it to control levels. This 
unexpected result indicates a further, previously unrecognised complexity in the activity of 
low adiponectin concentrations. However, addition of adiponectin at 100 ng/ml to IGF-I (100 
ng/ml) (IGF-I+Adp100) led to a reduction in cancer cell numbers but to a level that was still 





Figure 3.24 The level of VEGF secreted from Ishikawa cells treated with IGF-I 
and adiponectin individually and combined. The effect of IGF-I, adiponectin at 
20 ng/ml (Adp20), adiponectin at 100 ng/ml (Adp100) and combinations, and 
untreated control cells (Ctrl) were compared. n = 4. Data were analysed using 
one-way ANOVA. ** p < 0.01, and ***  p < 0.001 compared to control. Data are 
expressed as means ± S.E.M. The data are identical to previous figure. 
When combined, the IGF-I inhibition effect on VEGF secretion from Ishikawa cells had 
no effect on the stimulatory effect of adiponectin at 20 ng/ml. The combination increased 
VEGF secretion compared to control. This is a result similar to the observation observed for 
the effect of leptin (Figure 3.12) but different to that of insulin (Figure 3.16). 
The presence of IGF-I in combination with adiponectin 100 ng/ml (IGF-I+Adp100)  
inhibited the stimulation effect of adiponectin on VEGF secretion from Ishikawa cells and the 




3.2.11. The effects of leptin, insulin, IGF-I and adiponectin on apoptosis 
levels in Ishikawa cells. 
  
The hormones may have effects on survival of the cells via modulation of the apoptotic 
pathways. The effects of the hormones on apoptosis levels in Ishikawa cells were also 
investigated individually (Figure 3.25). 
 
Figure 3.25 The level of apoptosis in Ishikawa cells without treatment or treated 
with leptin, insulin, IGF-I and adiponectin at 20 ng/ml and 100 ng/ml. n = 3. Data 
were analysed using one-way ANOVA. * p < 0.05 compared to control. Data are 
expressed as means ± S.E.M. 
It was observed that although there appeared to be a small trend, albeit not statistically 
significant, for increased levels of apoptosis in response to all of the four hormones, only the 
response to 100 ng/ml adiponectin was statistically significant. It appears that modulation of 
apoptosis is not a major process by which the hormones alter Ishikawa cell behaviour. 
Further, it was noted that the hormones had no statistically significant effect on control 






This chapter presented the effects of the presence of 20 and 100 ng/ml adiponectin in 
combinations with leptin, insulin and IGF-I, which are considered to be tumorigenic 
stimulators to endometrial cancer cells. When incubated with Ishikawa cells, leptin, insulin or 
IGF-I individually increased proliferation in agreement with previous studies [51, 159, 401]. 
In incubations with these hormones there was a decline in cell number at the highest leptin 
concentration. The reason for this is uncertain, but the onset of significant cell demise and 
detachment due to inadequate nutritional support are possible. Alternatively, a negative 
feedback process may have become prominent. Microscopic examination revealed some 
overgrowth associated with the highest concentration and such structures may have occurred 
as a result of rapid growth with resultant alteration of overall growth dynamics. Moreover, 
cells that accumulate will lose the 2D, monolayer, properties of the experiments. 
The effects of adiponection acting alone showed concentration-dependent, differential 
effect on cell growth. Thus, 100 ng/ml adiponectin decreased cell growth, consistent with 
previous reports [402-404]. In contrast, a lower adiponectin concentration (20 ng/ml) 
increased cell number. This was an unexpected result in this study, and it is the first report of 
stimulatory activity of adiponectin in regard to proliferation of endometrial cancer cells. It is 
possible to speculate that this is due to cross-talk with other stimulatory pathways [137, 379]. 
To understand the underlying signalling pathway that led to increase cell proliferation it is 
important to find a reasonable explanation for such unexpected results. Thus, this novel 
observation notably extends properties of adiponectin in endometrial cancer to being 
associated with tumorigenic as well as the previously observed anti-tumorigenic characteristic 
[402].  
The anti-tumorigenic activity of 100 ng/ml adiponectin, although not substantial, led to 
the investigation of the effects of this hormone on tumorigenc hormones. The effects of 
interactions of adiponectin, at both its lower (growth promoting) concentration and the higher 





3.3.1. Cell numbers when leptin, insulin or IGF-I are combined with 
adiponectin  
Only a few papers have discussed the responsiveness of tumour cells to the presence of 
more than one growth factor. Adiponectin was observed to reverse proliferation stimulated by 
leptin in endometrial cancer cell line, SPEC-2 [376]. Also, adiponectin reduced the 
stimulatory effect of leptin in oesophageal cancer [35, 376, 405], hepatocellular carcinoma 
cells [406], colon [366] and liver cancer cell [359]. However, leptin was shown to block the 
antiproliferative effects of adiponectin on prostate cancer cells [407]. Habeeb et al. and Li et 
al. concluded that adiponectin reduced the phosphorylation of Akt and PI-3K in colorectal 
cancer and breast cancer, respectively, leading to reduced cell proliferation [408, 409]. 
Moreover, a previous report suggested that AMPK activation by adiponectin blocks STAT3 
phosphorylation that is important for the action of the leptin stimulation effect [410]. The 
effects of leptin and adiponectin on self-receptor expression were investigated. It was noted, 
for example, that GnRH upregulates its own receptor and there is a myriad of examples of 
desensitisation and downregulation of receptors. In this study, combinations of 50 ng/ml 
leptin and 20 ng/ml adiponectin, and 50 ng/ml leptin and 100 ng/ml adiponectin were added 
to endometrial Ishikawa cancer cells. The results that showed that adiponectin at 100 ng/ml 
suppressed the effect of leptin (Figure 3.11) were in line with other researchers' findings [359, 
366, 376, 405, 408, 409].  
In contrast to effects of addition of adiponectin to leptin, the combination of 100 ng/ml 
adiponectin with insulin (Figure 3.17) had no detectable effect on the cell numbers produced 
compared to either factor added individually. This might suggest that the cell number attained 
was the maximum possible for the conditions. This seems unlikely because further 
proliferation with overgrowth has been observed on occasions in other conditions. 
Alternatively, the two factors may act via the same pathway or two pathways that converge to 
a common intermediary point where capacity of the pathway is reached. With IGF-I, a partial 
suppression was achieved by adiponectin (Figure 3.23). In this case, it is possibly a matter of 




However, when adiponectin (20 ng/ml) (in contrast to 100 ng/ml) was added to leptin 
(50 ng/ml), the effect of leptin was absent and the level of proliferation was similar to that 
associated with by adiponectin (20 ng/ml) alone (Figure 3.11). Indeed, the effect of 
adiponection is strongly dependent on its concentration; whereas 100 ng/ml had an inhibitory 
effect on cell number, 20 ng/ml was stimulatory. In combination with leptin, the cancer cell 
numbers were little different from those attained by the individual hormones. This is a notable 
finding because previously it had been hypothesised that low levels of adiponectin and high 
levels of leptin, as might be present in an obese woman [209] with endometrial cancer [411, 
412], would have a doubled proliferation rate. This result, from investigating the effect of a 
combination, suggests that might not be so.  
Similarly, 20 ng/ml adiponectin added to insulin resulted in a smaller number of cells to 
that attained by either peptide separately. Adding adiponectin (20 ng/ml) to insulin reduced 
cell number compared to each hormone individually. This suggests that there may be complex 
cross-talk between adiponectin and insulin stimulation pathways in the endometrial cancer 
cell line, Ishikawa. 
However, the combination of 20 ng/ml adiponectin and IGF-I reduced Ishikawa cell 
numbers (Figure 3.23). This may suggest that IGF-I uses a different pathway to interact with 
adiponectin that is different from the pathways that are used by leptin and insulin. As such 
this raises the intriguing question on how two stimulatory proteins can, together, have no 
effect on cell number. However, there are methods to formally test for additively, synergism, 
or antagonism (Chou-Talalay Equation), but they require more detailed measurments of 
responses than were made in this thesis. 
3.3.2. VEGF secretion following combination of leptin, insulin or IGF-I 
with adiponectin  
To understand how angiogenic support maintains growth of solid tumours, it is vital to 
determine the effects of obesity-related hormones on VEGF secretion. Thus, the three 
hormones (leptin, insulin and IGF-I) caused similar reductions in VEGF secretion, in spite of 




factors do not have a uniform mechanism of action on the processes (such as proliferation and 
VEGF-induced angiogenesis) that are believed to lead to cancer development. However, 
caution must be exercised in suggesting the parameters measured here are directly related to 
the corresponding processes in vivo. 
It has been suggested that VEGF is released by cancer cells under metabolic stress as a 
survival mechanism for the tumour [413]. Thus, the environment in which proliferation was 
being suppressed by adiponectin at 100 ng/ml (whereby a cell recognises effects deleterious to 
its survival) elicited increased VEGF secretion. Similarly, the increase in proliferation 
(indicating a low stress, favourable environment) induced by the tumorigenic hormones 
resulted in less VEGF secretion by those cells. Nevertheless, incubation with 20 ng/ml 
adiponectin which induces increased proliferation was also accompanied by increased VEGF 
secretion. This observation may suggest that the signalling pathways for proliferation and 
VEGF secretion that are activated by the adiponectin ligand (at a low physiological level) 
diverge within the cell, such that proliferation processes have a signalling switch that turns 
from positive to negative with adiponectin concentration but such a concentration-related 
switch is not present on the VEGF secretion pathway. 
In this project, an interaction between the hormones was also observed on the level of 
VEGF secretion. Whereas adiponectin (100 ng/ml) elicited increased VEGF secretion, the 
addition of leptin in combination negated the effect (Figure 3.12). Figure 3.12 shows that 
leptin caused a reduction in VEGF secretion. On the other hand, 20 ng/ml adiponectin 
increased VEGF secretion significantly. VEGF secretion from the combination showed a 
similar action to 20 ng/ml adiponectin and the effect of leptin was abolished and looks like it 
had no inhibitory effect at all. Thus, the inhibitory effect of leptin was largely resisted by the 
stimulatory effect of adiponectin. Thus, the interaction was the opposite effect to that seen on 
proliferation where increased proliferation by leptin was inhibited by adiponectin. 
Nevertheless, the results are consistent with the view that the two hormones have opposite 
influences on tumour development. To my knowledge, this is the first demonstration that 100 
ng/ml adiponectin stimulates VEGF secretion, and this is reduced by combination with 50 




It appears, also, that combination of insulin or IGF-I with adiponectin has not hitherto 
been investigated. Here, it is reported that insulin with adiponectin at 100 ng/ml reduced the 
stimulatory effect of 100 ng/ml adiponectin on VEGF secretion to control levels (Figure 
3.17). Similarly, IGF-I reduced adiponection stimulation of VEGF secretion (Figure 3.24).  
VEGF secretion from Ishikawa cells in the presence of 20 ng/ml adiponectin was also 
determined. VEGF secretion from cells exposed to 20 ng/ml adiponectin and leptin together 
was increased compared to that produced by adiponectin alone (Figure 3.12). On the other 
hand, insulin had an inhibitory effect on adiponectin’s stimulating activity on VEGF secretion 
(Figure 3.18). The response pattern for IGF-I was similar to that for leptin.  
When interaction of tumorigenic hormones with adiponectin was investigated, cells in 
most of the incubations produced the same pattern of VEGF secretion response, namely that 
the response to tumorigenic hormone was increased in the presence of adiponectin and, 
conversely, the response to adiponectin was decreased in the presence of the tumorigenic 
hormone. The exception was displayed by IGF-I when mixed with adiponectin at 20 ng/ml 
where the mixture resulted in a level of VEGF secretion that was similar to that induced by 
adiponectin alone, different from the response when adiponectin at the higher concentration 
was used. In this context it may be of oncogenic relevance that IGF-I has been observed to be 
at lower levels in obese patients than in lean individuals [41]. BMI reduction was 
independently associated with IGF-I increase. For each point of BMI reduction, the mean 
increase of serum IGF-I was 4.39 ng/ml. 
3.3.3. Summary 
Leptin, insulin and IGF-I had similar effects on cell proliferation individually, however, 
these similarities were disrupted when combined with adiponectin. This may suggest that 
leptin, insulin and IGF-I use different pathways to elicit proliferation and VEGF secretion. 
For example, in the first experiment, although 50 ng/ml leptin caused robust increases in cell 
numbers, the addition of 100 ng/ml adiponectin to leptin removed the stimulatory activity. 
This may have implications for drug treatments that will need to target several pathways: 




combination of factors described above provided evidence of potential interactions between 
obesity-related hormones.  
Overall, the results indicate that the factors do not have a uniform mechanism of action 
on the processes that are believed to lead to cancer development and progression. The effects 
of individual compounds were not additive when mixed, emphasising that in vitro data must 
be interpreted with caution as they relate to physiology and pathology, where extra regulating 
factors will also be involved. The use of combinations in this experimental in vitro study also 
confirmed that different signalling molecules were used by different hormones with respect to 
the effects on cell number and VEGF secretion. It has been suggested that in regard to the 
inhibitory activity of adiponectin on leptin the ratio might be more important than absolute 
concentrations [12, 209, 210].  
The results indicate that a number of aspects (such as interactions, pathways and 
concentrations) must be considered when extrapolating these in vitro results to possible in 
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4 The effect of hormones on endometrial (HEC-1A), breast (MCF-7) 
and ovarian (SKOV-3) cancer cell lines 
4.1. Introduction 
It was shown in the previous chapter that Ishikawa epithelial cells responded to four 
obesity-related hormones, namely leptin, insulin, IGF-I and adiponectin. These results suggest 
that because these hormones are dysregulated in obesity, they may contribute to the increased 
risk of obesity-related endometrial cancer. However, it is uncertain whether these responses 
are specific to Ishikawa cells. Consequently, these hormones will be tested on a range of 
cancer cell lines including HEC-1A, an endometrial cancer cell line with different genotype 
from Ishikawa, MCF-7 a breast tissue cancer cell line that is believed to be sensitive to 
obesity-related factors [369] and an ovarian cell line, SKOV-3, which was chosen because 
ovarian cancer is suggested to be, at most, weakly associated or perhaps not associated with 
obesity [370-372]. 
High leptin levels are strongly associated with breast cancer progression, and leptin 
caused growth potentiation in breast cell lines (ZR-1 and MCF-7) [414, 415]. Also, despite a 
weak association between obesity and ovarian cancer cells [370-372], treatment of ovarian 
cancer cell lines with leptin resulted in growth stimulation of ovarian cancer cell lines by up-
regulating genes and proteins responsible for enhancing cell proliferation [44, 416]. Further, 
raising insulin levels may be associated with the progression and development of breast [417] 
and ovarian cancers [370]. Consistent with insulin activity, IGF-I was also found to promote 
breast [414] and ovarian cancer cells [371, 418, 419]. Additionally, there was an inverse 
association between circulating adiponectin levels in vivo and the incidence of breast cancer 
linked to obesity [380, 381, 420-422] and in postmenopausal women [403]. Further, 
adiponectin has been suggested to be associated with ovarian cancer [370, 423] and 
adiponectin levels were found to be lower in capillaries of cancerous ovaries compared to 
normal ovaries [210, 424].  
In addition, results in Chapter 3 indicated that the Ishikawa cells showed decreased 




consensus that adiponectin at high concentration is considered to be anti-tumorigenic. In 
contrast, low concentration of adiponectin (20 ng/ml) (Adp20) stimulated proliferation of 
Ishikawa cells. Here, the three additional cell lines mentioned above were also investigated to 
determine whether these cells would follow a pattern of responses similar to that which was 
noted for Ishikawa cells. These observations may help to explain the link between obesity and 
progression of different types of cancer [127, 179, 425]. Thus, the cells were exposed to the 
four selected hormones. The concentrations used were the same as determined for Ishikawa 




4.2. Results  
4.2.1. Receptors 
Following the findings in Ishikawa cells, it was established by immunohistochemistry 
with optical sectioning microscopy that the three cell lines possessed receptors for the four 
hormones being studied (Figure 4.1). The information was also confirmed by Western blot 
(Figure 4.2). 
 
Figure 4.1 Images of (A) HEC-1A endometrial, (B) MCF-7 breast and (C) 
SKOV-3 ovarian cancer cell lines. Images show receptors for leptin (Ob-R), 
insulin (InsR), IGF-I (IGFR) and adiponectin (AdipoR). Red, receptors; Blue, cell 








Figure 4.2 Immunodetection bands for leptin receptor (Ob-R), insulin receptor 
(InsR), IGF-I receptor (IGFR) and adiponectin receptors (AdipoR) for HEC-1A, 
MCF-7 and SKOV-3 cancer cell lines. GAPDH is the rference protein. 
Figure 4.2 shows that the molecular sizes observed were consistent with what was seen 
before. 
4.2.2. Proliferation and VEGF secretion 
The same protocol that was used before with Ishikawa cells was used to study the 
effects on cell numbers of these cell lines. Results for HEC-1A endometrial cell line (Figure 
4.3) showed that both proliferation (A) and VEGF secretion (B) generally followed the 
pattern exhibited previously by the Ishikawa endometrial cells except that a low concentration 
of 20 ng/ml adiponectin did not increase cell number as was observed in Ishikawa cells. 
Leptin, insulin and IGF-I all increased cell numbers of HEC-1A line but none of the 












Likewise, necrosis in the cells was not affected by culture with any of the hormones and was 
similar to that in control (3.7%). 
VEGF secretion by HEC-1A cells following exposure to the four hormones was similar 
to the previously observed pattern on the Ishikawa cells (Figure 3.5, Figure 3.10, and Figure 
3.22) whereby the growth-promoting hormones leptin, insulin and IGF-I caused less VEGF 















Figure 4.3 (A) cell numbers, (B) apoptosis and (C) VEGF secretion from 
endometrial cancer cell line (HEC-1A) cells treated with selected hormones. Leptin 
50 ng/ml (Leptin), insulin 580 ng/ml (Insulin), IGF-I 100 ng/ml (IGF-I), 
adiponectin at 20 ng/ml (Adp20) and 100 ng/ml (Adp100). n = 9. Data were 
analysed using one-way ANOVA. * p < 0.05, ** p < 0.01 and ***  p < 0.001 
compared to control. Data are expressed as means ± S.E.M. The data are identical 





















Leptin and IGF-I induced higher cell numbers for MCF-7 cells compared to controls. 
However, insulin had no effect on MCF-7 cell proliferation. It can be noted that the cell line, 
nevertheless, possessed insulin receptors (Figure 4.1B and Figure 4.2). Adiponectin had no 
Figure 4.4 (A) cell numbers, (B) apoptosis and (C) VEGF secretion from breast 
cancer cell line (MCF-7) cells treated with selected hormones. Leptin, insulin, 
IGF-I, Adp20 and Adp100. n = 9. Data were analysed using one-way ANOVA.. 
** p < 0.01 and ***  p < 0.001 compared to control. Data are expressed as 





notable effect on this cell line. It is interesting to note that apoptotic MCF-7 cells were 
increased after exposure to all four hormones (Figure 4.4B). Additionally, there were no 
changes in necrosis in cells cultured with leptin or insulin compared to control (11.75%). 
However, an increase in necrosis (17.55%) was observed with IGF-I, while necrosis 
decreased with adiponectin at both 20 and 100 ng/ml (6.0%, 7.0%).  
The VEGF secretion response in MCF-7 cells was hormone dependent (Figure 4.4C). 
Again, leptin decreased VEGF secretion whereas both insulin and IGF-I caused increased 
levels of VEGF secretion. Despite MCF-7 cells having measurable level of adiponectin 
receptors, adiponectin, at either 20 ng/ml or 100 ng/ml had no effect on the VEGF secretion 
response (Figure 4.4C).  
SKOV-3 exhibited a pattern markedly different from those of HEC-1A, MCF-7 or 
Ishikawa (Figure 4.3, Figure 4.4, Figure 4.5, Figure 3.4 and Figure 3.5). In spite of all four 
hormone receptors being present, there was no enhanced proliferative response to the four 
hormones (Figure 4.5C). Adiponectin, the hormone that has been associated with anti-
tumorigenic activity, increased proliferation at 100 ng/ml although adiponectin at 20 ng/ml 
was without effect. None of the hormones incubated with SKOV-3 cells significantly 
modified apoptotic levels (Figure 4.5B) and nor were there changes in necrosis from control 
(5.5%). Insulin and IGF-I significantly increased secretion of VEGF. Adiponectin at both 





















Figure 4.5 (A) cell numbers, (B) apoptosis and (C) VEGF secretion from ovarian 
cancer cell line (SKOV-3) cells treated with selected hormones. Leptin, Insulin, 
IGF-I, Adp20 and Adp100. n = 9. Data were analysed using one-way ANOVA.  *  
p < 0.05, and *** p < 0.001 compared to control. Data are expressed as means 






4.3.1. HEC-1A - Endometrial cancer cell line 
The increase in HEC-1A cancer cell numbers in response to leptin was about half the 
number that was previously observed by Ishikawa cells. This suggests that HEC-1A cells are 
less sensitive to leptin stimulation than Ishikawa cell line. One possibility is that PTEN, a 
cancer suppressor, is a modulator of leptin activity and exhibits more suppressive activity in 
HEC-1A cells which is PTEN wild type than in Ishikawa cells which has a PTEN mutation 
[331]. Other factors, such as Ishikawa cells having half the apoptotic response compared to 
HEC-1A, however, clearly cannot be excluded from consideration. The semi-quantitative 
immunohistochemistry observations suggest the difference is not related to expression of 
leptin receptors. 
The results are in agreement with other studies in which it was observed that insulin 
increased HEC-1A cell numbers [426-428], which is possibly related to over-expression of 
insulin receptor (InsR) in HEC-1A cells [426]. These results are also consistent with reports 
that insulin has been shown to exhibit an important impact on endometrial carcinoma cells 
[429] and insulin promoted endometrial carcinoma cell proliferation [430]. Also, it was noted 
that HEC-1A responded to IGF-I as did the other endometrial cell line, Ishikawa. The increase 
in HEC-1A cell numbers elicited by culture with IGF-I parallels that previously observed by 
Bermont et al. with IGF-I (13 nM) [431].  
On the other hand, the HEC-1A endometrial cells behaved differently to those of 
Ishikawa cells in the presence of adiponectin. HEC-1A cell growth was suppressed by 
adiponectin at 20 ng/ml whereas that concentration of adiponectin provoked stimulation of 
Ishikawa cells (Figure 3.9). Similarly, growth was inhibited by adiponectin at 100 ng/ml 
(Figure 3.9). It is possible to speculate that mutational differences underlie the different 
response to adiponectin, compared to that of Ishikawa cells [150]. Recently, a study 
characterising Ishikawa and HEC-1A cells revealed that they differ greatly in gene expression 
and in their capacity for E2 formation during women’s reproductive years, and thus they 




concentration (10-40 µg/ml) on HEC-1A cell line via action on the cell cycle in vitro has been 
previously observed [150]. It is also possible that adiponectin at 100 ng/ml may inhibit 
proteins which are responsible for regulation of cell cycle phase in both Ishikawa and HEC-
1A cell lines.  
The results revealed that increased proliferation in HEC-1A cells was associated with 
reduced VEGF secretion and vice versa (Figure 4.3B). Interestingly, at the concentrations 
used, the decreased stimulation of proliferation rate by leptin and higher proliferation rate by 
insulin and IGF-I were associated with converse relative levels of VEGF secretion. 
4.3.2. MCF-7 - Breast cancer cell line 
The relationship between circulating leptin levels and breast cancer shows a positive 
association with cancer risk, and it has been suggested that leptin has an independent role in 
breast tumorigenesis [433]. Nevertheless, other researchers have concluded that it is difficult 
to explain the progression of breast cancer on the basis of serum leptin concentrations alone 
[434-436]. A recent study concluded that leptin may enhance breast cancer by enhancing the 
expression of several signalling pathways including JAK/STAT3, Erk1/2 and oestrogen that 
are responsible for increased progression in obese patients breast cancer [437]. 
Although no effect of insulin on MCF-7 growth was found, it has been suggested that 
insulin increases breast cancer growth through the modulation of the cell cycle, apoptotic 
factors and nutrient metabolism [438, 439]. However, those other studies used a concentration 
of insulin at 10 µM, which is 100 fold higher than the concentration used here. The 
observation of increased numbers of MCF-7 cells in the presence of IGF-I is in agreement 
with other investigators [440-443]. 
There was no effect on MCF-7 growth by adiponectin. However, Pfieler et al. suggested 
that there is a proliferative effect of adiponectin on breast cancer cells and that the effects of 
adiponectin on proliferation were oestrogen-dependent [444]. However, using oestrogen-




Previously, an inhibitory activity of adiponectin on MCF-7 has been reported [382, 
445]. It has been noted that circulating adiponectin levels are inversely correlated with the 
incidence of breast cancer [169, 180, 380, 381, 420, 421] and the development of breast 
cancer [169]. High adiponectin concentrations correspond with reduced proliferation of breast 
cancer cells in the in vivo milieu [169, 180, 380, 420, 421] where indirect effects such as those 
seen, for example, on Ishikawa cells (Figure 3.9) can occur. 
The patterns of VEGF secretion of MCF-7 cells did not always follow that of the other 
cell lines. The response to leptin was orthodox; insulin, while not promoting or suppressing 
proliferation, provoked increased VEGF secretion; and, IGF-I induced increased VEGF 
secretion that was associated with enhanced proliferation. Interestingly, there was no change 
in either proliferation or VEGF secretion in the presence of adiponectin. 
4.3.3. SKOV-3 - ovarian cancer cell line 
The results obtained with SKOV-3 cells are in line with others who observed that these 
cells are not affected by the presence of leptin [164] in adherent monolayer cell cultures [374, 
446]. Some studies have reported that leptin and Ob-R are increased in ovarian cancer, and 
are associated with poor progression-free survival [374, 446]. On the other hand, in studies 
using a substantially different culture model, namely floating cell aggregates of SKOV-3 
cells, leptin was observed to promote proliferation and growth [374, 447].  
Although there was no response to insulin at the same concentration that promoted 
proliferation in the other cell lines, insulin induced an increase in SKOV-3 cell numbers when 
they were grown in a different medium (DMEM-F12) [419]. The discrepancy of these results 
may be due to the differences in cell culture media and possibly the different glucose 
concentration in the medium. 
Recently, a positive role of IGF-I on progression of ovarian cancer in in vivo nude mice 
and patient tissue samples was also documented [448, 449].  
Adiponectin, the hormone in this group that has most commonly been associated with 




ng/ml was without effect. The concentrations used here again reveal the potential for 
adiponectin to have tumour-promoting activity when there are conditions, perhaps such as 
poor vascular supply, that are associated with cell stress. The link between ovarian cancer and 
adiponectin remains uncertain. A case-study concluded that BMI is higher in ovarian cancer 
patients and that adiponectin is lower [450] and a link to ovarian cancer has been suggested 
[370], although it has also been suggested that the leptin/adiponectin ratio may be more 
pertinent [12, 209, 210] and it may be important in the hormone effects measured. 
These responses to leptin, insulin and IGF-I that were observed are consistent with the 
observations in some studies [372] that ovarian cancer risk is not increased by obesity 
although a meta-analysis suggests that there is an associated risk [370, 423, 451] which may 
be weak [371]. The cell proliferation response by SKOV-3 cells to adiponectin at 20 ng/ml 
and 100 ng/ml suggests an opposite response to, say, Ishikawa endometrial cells, in that the 
hitherto unrecognised stimulatory activity of adiponectin was exhibited, but at a higher 
concentration of adiponectin on SKOV-3 than on Ishikawa cells. 
There was an increased response to insulin in VEGF secretion (relative to proliferation) 
in SKOV-3 cells despite the fact that no change in proliferation was observed. This may be 
due to insulin’s role in facilitating the movement of energy molecules, leaving SKOV-3 cells 
in nutrition deficit. This might lead to increased VEGF secretion despite there being no effects 
on cell proliferation. VEGF secretion by cells cultured with adiponectin exhibited the usual 
reversal relative to proliferation that was commonly observed during this project.  
4.3.4. Summary 
In overweight patients, low adiponectin levels have been observed to be strongly 
associated with increased cancer cell numbers [452] and in adipose tissue VEGF production 
was increased and adiponectin apparently has a direct inhibitory effect on VEGF secretion 
and angiogenesis in endothelial cells [453]. In contrast, other studies have found that 
adiponectin has a stimulatory effect on human umbilical vein endothelium cell (HUVEC) 
growth and VEGF secretion [379]. Thus, from these findings, it may be suggested that 




Further emphasising the complexity of the hormone systems is the variation of 
responses when a variety of cell lines were studied. Thus, there was a cell-type dependent 
component to the effects of the hormones. It is uncertain whether this is a result of the 
genotype and/or whether there are other tissue-specific factors. The former seems more likely 
to at least partly explain details of the responses. This is because Ishikawa cells and HEC-1A 
cells, both endometrium-derived, exhibited differences in response to, for example, 20 ng/ml 
adiponectin. Extrapolation of these results may indicate that the regulation of tumour 
development in vivo will be a complex matter affected by concentrations of numerous growth 
factors as well as other oncogenic entities.  
The roles of obesity in generating the levels of these compounds and modulating their 
activities are fundamental to understanding the increased risk of endometrial cancer, and other 
cancers, for overweight individuals. 
This is the first study to use a series of cell lines with a group of hormones that are 
dysregulated in obesity. The study design revealed, for the first time, variations in overall 
response patterns to the hormone factors and differences between cell lines. It can be noted 
that the results parallel clinical observations. In particular, these obesity-related hormones did 
not affect the proliferation in the ovarian cell line (SKOV-3) but did so in the other two. 
Whether some of the changes in cell number might have been a result of the hormones 
modifying the level of apoptosis was examined. Similarly to Ishikawa cells (Chapter 3), cells 
of the other endometrial-derived cell line, HEC-1A, also lacked a robust apoptosis response to 
the hormones. In regard to apoptosis levels, MCF-7 was the most responsive of the cells 
studied. All four hormones, including adiponectin and both 20 and 100 ng/ml, induced 
increased apoptosis in the breast cells compared to control cells. In concert with the cell 
number response, SKOV-3 cells did not significantly modify apoptotic behaviour in the 
presence of the four hormones, although mean values were arithmetically varied. Thus, in 
general, it may be suggested that the apoptosis responses of cancer cells are at least partly 
dependent on factors other than the obesity-related hormones in the panel studied here. 
The patterns of VEGF secretion as they relate to proliferation in the same treatment 




4 cell lines – Ishikawa, HEC-1A, MCF-7, SOKV-3, and 5 hormone treatments - leptin, 
insulin, IGF-I, adiponectin 20 ng/ml and adiponectin 100 ng/ml) a qualitative categorisation 
(i.e. increase or no change or decrease induced by a hormone treatment) was made for each 
response of a pair of proliferation and VEGF secretion responses. Approximately three-
quarters (14/20, 70%) were inverse or absent (8 were [proliferation INCREASED & VEGF 
secretion DECREASED]; 2 were [proliferation DECREASED & VEGF secretion INCREASED]; 4 





Increase 2 3 2 
No change  4  
Decrease 1  8 
  Decrease    No change Increase 
  Cell Number 
Table 4.1 The Table notes the number of pairs of responses regarding the the 
direction of change in cell number related to the concurrent effect on VEGF 
secretion. The numerals are numbers of pairs with the designated relationship as 
explained in the text. Note the more than 2-fold predominance of pairs (in bold) 
that have no change for both parameters or opposite direction of change 
((2+4+8=14), compared to pairs with similar direction of change (3+2+1=6). 
Cochran-Mantel-Haenszel test: p=0.033 
These responses were consistent with a previous observation that a sensed deficiency in 
the cell (metabolic reduction of proliferation by oxaliplatin) induced a compensatory response 
such as increased VEGF secretion [413]. Conversely, a low level of drug (oxaliplatin) that 
had low chemotoxicity resulted in less cellular secretion of the survival factor, VEGF [454]. 
The observations in this study were consistent with that notion and expand the concept to 
noting that cancer cells can also recognise a stressful condition associated with hormone 
ligands and modulate the survival response accordingly (Cochran-Mantel-Haenszel test: 
p=0.033). It is plausible that conservation of energy underlies this relationship [455]. 
However, exceptions were observed and there were six pairs that did not fit this pattern (3 
were [proliferation NO CHANGE & VEGF secretion INCREASED], and 2 were [proliferation 




secretion DECREASED]) which indicates that predicting clinical outcomes will require complex 
modelling of VEGF control [456, 457].  
This project reports observations that obesity-related hormones can act directly at the 
level of the cancer cell. At times, there is conflict between conclusions from in vivo 
monitoring and in vitro culture effects. Such observations may be partly due to paracrine 
pathways that function in cancer development [458]. In such cases, the circulating peripheral 
blood levels are of secondary relevance. Additionally, full conclusions cannot be drawn from 
the simple response to the hormone alone. The potential for interactions between hormones 
was documented in the previous chapter. Also, it has been observed that leptin can regulate 
breast cancer initiation, growth and metastatic progression via interaction with various growth 
factors including oestrogen, insulin, IGF-I, angiogenic pathways and inflammatory cytokines 
[459]. This implies caution should be shown in extrapolating unmodified interpretations to 
physiological conditions. Further, growth, apoptosis and VEGF secretion as targets for the 
hormones were determined, but other functions may also be affected, such as metastatic 
potential and the risk of recurrence [386, 460]. 
Thus, the results point to tissue type or cell line-dependent oncogenic potential of the 
studied hormones i.e. leptin, insulin, IGF-I and adiponectin, that may be related to genetic 
variability between the cell lines or pathophysiological organs. It must be acknowledged that 
the results found in the in vitro cell lines experiments may not always translate directly to the 
in vivo models. In this study, some preliminary data were obtained suggesting that hormones 
that are affected by obesity will influence cancer cells in definite conditions. It is noteworthy 
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5 Leptin signalling pathways in modulating proliferation in Ishikawa 
cells 
5.1. Introduction  
Leptin exerts its biological actions through the activation of its receptors. Leptin 
receptors (Ob-Rs) belong to the class I cytokine receptor super-family and their signal 
transduction pathways are associated with the phosphatidylinositol 3-kinase (PI-3K) / protein 
kinase B (Akt) / mammalian target of rapamycin (mTOR) pathway [461] and the Janus kinase 
family and signal transducers and activators of transcription-3 (JAK/STAT3) pathway [462]. 
The regulation of these pathways [463, 464] by leptin with regard to proliferation in an 
endometrial cancer cell line (Ishikawa) was investigated in this chapter. 
Signalling activity of JAK/STAT3 is triggered by the binding of leptin to its cell 
membrane receptors. This leads to receptor dimerisation, which appears mandatory to 
complete the signalling process [465, 466]. Cytoplasmic tyrosine kinases' expression of the 
JAK/STAT system are induced by the activation of class I cytokine receptors [72, 467].  
Homodimerization of leptin receptors occurs after the ligand, leptin, binds to the 
extracellular domain of the receptor (Ob-Rb). Ob-Rb then activates the JAK/STAT3 pathway 
[45] with the  binding of leptin to Ob-R leading to phosphorylation of tyrosine amino acid 
residues at the JAK domain inside the cell. The phosphorylated tyrosine sites act as docking 
locations for the SH2 and SH3 domains of the STATs [468, 469]. After binding to the 
phosphorylated intracellular domain site of JAKs STAT3 protein becomes phosphorylated 
forming p-STAT3. After activation, STAT3 proteins dimerise and move to the nucleus [470]. 
Intranuclear STAT3 recognises STAT3-specific DNA-binding elements [471] and binds to 
target gene(s) [338] which eventually leads to leptin-induced increase of cell proliferation in 
endometrial cancer [470, 472].  
The PI-3K/Akt/mTOR pathway has been linked to the pathophysiology of several 
neoplastic diseases [461, 473]. Activation of this pathway can be a result of defects in PI-3K 




upstream regulatory steps such as receptor tyrosine kinases [461, 473]. PI-3K gene mutations 
have been reported in type I endometrial cancer [473, 474] and data from genomic studies 
support activation of the PI-3K pathway in endometrial cancer [331]. In vitro pre-clinical 
studies have also reported that endometrial cancer cell proliferation inhibition can be 
interrupted by PI-3K pathway stimulation [475]. Clinical trials using target agents have 
produced results that support a role for PI-3K/Akt/mTOR mediated signalling in endometrial 
carcinoma [476, 477].  
It is well established that leptin uses the PI-3K/Akt/mTOR pathway to increases cancer 
cell proliferation. Hence, PTEN can act as cancer suppressor by converting PIP3 to PIP2, and 
thus it acts as a modulator of leptin activity and exhibits more suppressive activity in HEC-1A 
cells where PTEN is wild type and active than in Ishikawa cells in which has PTEN is 
mutated and inactive. During leptin activation, PTEN acts as facilitator in phosphorylation of 
Akt and increases cell proliferation via the PI-3K/Akt/mTOR pathway [476, 477]. 
Although many articles treat these pathways as separate but parallel, some suggest that 
these two pathways, PI-3K/Akt/mTOR and JAK/STAT3, may overlap [53, 164, 373, 375]. 
Thus, there may be potential for cross-talk between these two pathways in endometrial cancer 
and such activity might then have implications for prevention or treatment of endometrial 
cancer.  
In this project, it was previously demonstrated that leptin, an obesity-related hormone, 
modulated Ishikawa cell behaviour. This chapter, therefore, will investigate the hypothesis 
that leptin stimulates the activation of both PI-3K/Akt/mTOR and JAK/STAT3 pathways, and 
that both pathways are involved in leptin activation and modulation of cell growth in Ishikawa 




5.2. Results  
To study whether the effects of leptin on stimulating cell growth utilise PI-
3K/Akt/mTOR signalling cascade, the PI-3K inhibitor LY294002 was used to probe the 
pathway. After performing preliminary studies to determine the optimimum concentration for 
inhibitor, an LY294002 concentration of 20 μM was selected for these experiments. 
 
Figure 5.1 (A) cell numbers and (B) VEGF secretion in Ishikawa cells of 
untreated cells (Ctrl), cells treated with PI-3K inhibitor, LY294002 (20 μM), 
leptin 50 ng/ml (Leptin), and a combination of leptin and LY249002 
(Leptin+LY294002). n = 3. Data were analysed using one-way ANOVA. ** p < 
0.01 and *** p < 0.001 compared to control. Data are expressed as means ± 
S.E.M. Stars without connections indicate comparison to control incubation. The 
data are identical to previous figure. 
As shown in Figure 5.1, and consistent with results in chapter 3, leptin alone 
significantly increased cell numbers of the Ishikawa cell line. However, LY294002 
significantly reduced cell numbers of leptin-treated Ishikawa cells compared to leptin alone. 
Although without leptin stimulation, LY294002 alone did not show a measurable effect 
compared to controls (Figure 5.1A). Secretion of VEGF from controls and LY294002 alone 




However, the combination of leptin and LY294002 did not show a further reduction of VEGF 
compared to cells stimulated by leptin alone (Figure 5.1B). These data suggest that leptin 
activates growth activity in the Ishikawa cell line via a PI-3K molecule, but not alteration of 
VEGF secretion.  
The regulation of VEGF associated with the activity of adenosine mono phosphate 
kinase (AMPK) is well described [478, 479]. Thus, the activation of leptin on AMPK may 
indirectly regulate VEGF secretion. Thus, the expressions of AMPK and p-AMPK in the 
presence of leptin were also investigated with Western blots (Figure 5.2) that were quantified 




Figure 5.2 Protein expression of AMPK and p-AMPK for untreated cells (Ctrl) 
and cells treated with leptin (50 ng/ml). GAPDH is the reference protein. 
     
Figure 5.3 Densitometry of (A) AMPK and (B) p-AMPK expression for 
untreated cells (Ctrl), and cells treated with leptin (50 ng/ml). n = 3. Data were 
analysed using logarithmic analysis and Student's t-test (two-tailed). Data are 




As shown in Figure 5.3, leptin stimulation of Ishikawa cells did not change total 
expressin of AMPK or phosphorylated AMPK (p-AMPK) protein. This result indicates that in 
these circumistances AMPK may not be associated with leptin-activated pathways.  
Next, the expression and activities of the protein kinase B, Akt in the signalling 
pathways were investigated to determine whether the reduction in cell numbers induced by 
LY294002 was associated with the phosphorylation and activation of Akt. This possibility 
was investigated by assessing the total protein expression of Akt and the phosphorylated form 
(p-Akt) in the absence and presence of LY294002 using Western blots and densitometer 
measurement of the bands. 
 
Figure 5.4 Akt and p-Akt protein expression for untreated cells (Ctrl), Ishikawa 
cells treated with LY294002 alone, cells treated with leptin (50 ng/ml) (Lep50), 
and cells treated with a combination of leptin and LY294002 (20 µM) 
(Lep50+LY20). GAPDH is the reference protein. 
 
Figure 5.5 Densitometry of (A) Akt and (B) p-Akt protein expression for untreated 
Ishikawa cells (Ctrl), LY294002, Leptin, and a combination. n = 3. Data were 
analysed using logarithmic analysis and one-way ANOVA. * p < 0.05, ** p < 0.01 
and *** p < 0.001 compared to controls. Data are expressed as means ± S.E.M. 




As shown in Figure 5.4 and Figure 5.5A, leptin increased the total expression of Akt, 
and this effect was inhibited by the presence of LY294002.  
Similarly, the level of p-Akt was increased in the presence of leptin and significantly  
reduced by the PI-3K inhibitor LY294002 (Figure 5.4 and Figure 5.5B). The results suggest 
that PI-3K mediation of the leptin-stimulation pathway via Akt proteins is likely to be crucial.     
Whether the effect of leptin on cell proliferation is also mediated through the mTOR, a 
downstream protein from the PI-3K/AKT mediated route, was then determined. To ascertain 
this role, an mTOR blocker, everolimus [480] was introduced at a concentration of 2 µM to 
leptin-stimulated Ishikawa cells. As shown in Figure 5.6, everolimus significantly reduced the 
cell number of leptin-treated cells but it did not demonstrate a similar effect on non-stimulated 
cells. Overall, data may suggest a classical PI-3K/Akt/mTOR pathway triggered by the 
stimulation of leptin is essential for cell proliferation of Ishikawa cell line.  
 
Figure 5.6 Cell numbers were determined after treatment with mTOR inhibitor, 
everolimus (Everolimus) (2 μM), leptin 50 ng/ml (Leptin), and a combination of 
leptin and everolimus (Leptin+Everolimus) or remained untreated cells (Ctrl). n = 
3. Data were analysed using one-way ANOVA. ** p < 0.01, and *** p < 0.001 
compared to control. Data are expressed as means ± S.E.M. The data are identical 




To ascertain the effects of mTOR inhibitor on Akt protein activation and 
phosphorylation, the expression of Akt and p-Akt proteins in the absence and presence of 
mTOR inhibitor, everolimus, and leptin were investigated. As shown in Figure 5.7, Ishikawa 
cells did not exhibit any difference in Akt and p-Akt protein expression in the presence of 
everolimus compared to Akt and p-Akt protein expression for leptin alone (Figure 5.7). These 
data suggest that mTOR is a downstream protein of the PI-3K/Akt activated pathway acting 
after Akt. 
  
Figure 5.7 Densitometry of (A) Akt and (B) p-Akt protein expression for 
untreated Ishikawa cells (Ctrl), everolimus, leptin, and a combination. n = 3. Data 
were analysed using logarithmic analysis and one-way ANOVA. ** p < 0.01 and 
*** p < 0.001 compared to controls. Data are expressed as means ± S.E.M. The 
data are identical to previous figure. 
It is well known that leptin can activate JAK/STAT pathway and elicit cell growth. To 
investigate the effect of leptin on Ishikawa cancer cell growth via the JAK/STAT3 pathway, 





Figure 5.8 (A) cell numbers and (B) VEGF secretion in Ishikawa cells of 
untreated cells (Ctrl), cells treated with Tyrphostin AG490 (100 μM) and Leptin 
alone, Leptin+JAK inhibitor, Tyrphostin AG490, at 1 μM (Leptin+Tyrphostin1), 
10 μM (Leptin+Tyrphostin10) and 100 μM (Leptin+Tyrphostin). n = 3. Data 
were analysed using one-way ANOVA. ** p < 0.01, and *** p < 0.001 compared 
to control. Data are expressed as means ± S.E.M. The data are identical to 
previous figure. 
As shown in Figure 5.8A, leptin increased cell numbers compared to the control. 
Tyrphostin AG490 (100 μM) alone had no effect on growth of Ishikawa cells. Tyrphostin 
AG490 significantly reduced leptin-stimulated growth potential in a concentration-dependent 
manner with 100 μM Tyrphostin AG490 producing the largest reduction in Ishikawa cell 
number, an effect which was significant compared to cell numbers in the presence of leptin 
alone and control incubations. For this reason, 100 μM Tyrphostin AG490 was used in the 
following experiments.  
These results showed that, along with the PI-3K/Akt/mTOR pathways, leptin is also 
able to trigger cell proliferation of Ishikawa via the JAK protein. It is also important to note 
that Tyrphostin AG490 alone, or acting in combination with leptin, does not impact secretion 




stimulates cell proliferation by using the JAK protein, which consequently activates Akt as 
well as STAT3 the downstream protein.  
To investigate the possibility of a link between the JAK and PI-3K/Akt/mTOR 
pathways, the expression of PI-3K pathway intermediate molecules such as Akt and p-Akt 
were examined in the presence of JAK inhibitor Tyrphostin AG490.  
 
Figure 5.9 Akt and p-Akt protein expression of untreated cells (Ctrl), Ishikawa 
cells treated with Tyrphostin AG490 (Tyrphostin) (100 µM), cells treated with 
leptin (50 ng/ml) (Leptin) alone, and cells treated with a combination. GAPDH is 
the reference protein. 
 
Figure 5.10 Densitometry of (A) Akt and (B) p-Akt protein expression for 
untreated Ishikawa cells (Ctrl), Tyrphostin AG490 (JAK inhibitor), Leptin, and a 
combination. n = 3. Data were analysed using logarithmic analysis and one-way 
ANOVA. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to controls. Data 




Figure 5.9 and Figure 5.10A show significant increases in total Akt protein expression 
in the presence of leptin compared to the control while a significant reduction in Akt protein 
expression occurred when cells were exposed to a combination of leptin and Tyrphostin 
AG490 compared to incubation with leptin alone. Moreover, addition of inhibitor alone also 
led to the reduction of Akt protein expression.  
Similarly, as shown in Figure 5.9 and Figure 5.10B, p-Akt increased significantly in the 
presence of leptin. Exposing Ishikawa cells to the JAK inhibitor Tyrphostin AG490  alone or 
in combination with leptin reduced p-Akt significantly compared to p-Akt protein expression 
of control and incubation with leptin, respectively. This data may suggest that Akt protein was 
also stimulated via the JAK protein, and is therefore a potential mediator that links PI-3K/Akt 
interaction with the JAK activation pathway.  
It is well established that the STAT3 protein is a downstream regulatory molecule from 
JAK. In order to confirm the effect of the stimulation of JAK molecule on STAT3, the protein 
expression of STAT3 and p-STAT3 in the presence of Tyrphostin AG490 was also studied.  
 
Figure 5.11 STAT3 and p-STAT3(Ser727) protein expression in Ishikawa cells 
treated with Leptin (50 ng/ml) and Tyrphostin AG490 (100 µM) alone, and a 





Figure 5.12 Densitometry of (A) STAT3 and (B) p-STAT3(Ser727) protein 
expression for untreated Ishikawa cells (Ctrl), Tyrphostin AG490, Leptin, and a 
combination. n = 3. Data were analysed using logarithmic analysis and one-way 
ANOVA. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to controls. Data 
are expressed as means ± S.E.M. Stars without connections indicate comparison 
to control incubation. The data are identical to previous figure. 
Figure 5.11 and Figure 5.12A show significant reductions in total STAT3 protein 
expression in the presence of Tyrphostin AG490 compared to leptin-treated cells and the 
control. Additionally, as shown in  Figure 5.11 and Figure 5.12B, a reduction in 
phosphorylated STAT3 protein occurred after Ishikawa cells were exposed to the combination 
of leptin and Tyrphostin AG490 compared to Ishikawa cells treated with leptin alone. Figure 
5.12A also shows that Tyrphostin AG490 inhibits basal STAT3 expression and leptin-induced 
STAT3 to the same level. In addition, Figure 5.12B shows that there is a significant  reduction 
of leptin-induced phosphorylation compared to leptin alone.  
Next, it was determined whether the PI-3K pathway is inhibited by LY294002 when the 
JAK/STAT3 pathway was still active and STAT3 is expressed. Alternatively, if LY294002 
inhibits total STAT3 expression, then PI-3K may have a direct stimulatory effect on STAT3 





Figure 5.13 STAT3 and p-STAT3 expression in Ishikawa cells treated with 
Leptin (50 ng/ml) and PI-3K inhibitor LY294002 (20 μM) alone, and a 
combination. GAPDH is the reference protein. 
 
Figure 5.14 Densitometry of (A) STAT3 and (B) p-STAT3(Ser727) protein 
expression for untreated Ishikawa cells (Ctrl), LY294002, leptin, and a 
combination. n = 3. Data were analysed using logarithmic analysis and one-way 
ANOVA. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to controls. Data 
are expressed as means ± S.E.M. Stars without connections indicate comparison 
to control incubation. The data are identical to previous figure. 
Figure 5.13 and Figure 5.14A show an increased expression of STAT3 in leptin-treated 
cells compared to control. Similarly, Figure 5.13 and Figure 5.14B show an increase in 
STAT3 phosphorylated at Ser727 in the presence of leptin compared to control. Addition of 




control. These data may suggest that, leptin-induced cell proliferation in Ishikawa cells 
activates a complex interaction of the PI-3K/Akt/mTOR with the JAK/STAT proteins. 
5.3. Discussion  
In these experiments, it was demonstrated that leptin-stimulated cell growth of the 
endometrial cancer cell line Ishikawa was inhibited by both a PI-3K inhibitor and also by a 
JAK inhibitor. This suggests that leptin induces cell growth in Ishikawa cells through two 
different pathways, PI-3K/Akt/mTOR and JAK/STAT3. The proposed pathways are shown in 
diagrammatical form in Figure 5.15, constructed on the basis of the observations in this 
chapter. The pathways show JAK as the upstream molecule for PI-3K/Akt/mTOR pathway as 
















Figure 5.15 Proposed pathways involved in the action of leptin on regulation of proliferation of Ishikawa endometrial cancer cells. 
(A) before addition of inhibitors and (B) after the addition of the inhibitors.  
The proposed mechanism involves two pathways, the PI3K/Akt/mTOR pathway (in red) and the JAK/STAT3 pathway (in green). 
The points of activity of the pharmacological modulators used in this study are shown in black. The observations are consistent with 
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Leptin exerts its effect on cancer cells via activation of specific pathways inside the cell 
leading to increased DNA transcription in the nucleus and increased proliferation and tumour 
growth. PI-3K/Akt/mTOR and JAK/STAT3 are major downstream pathways which have 
been identified as being involved in leptin action during endometrial cancer cell proliferation 
[461, 462, 482].  
The first pathway is PI-3K/Akt/mTOR which is well known for its hyperactivation in 
many cancers. In order to investigate the involvement of PI-3K/Akt/mTOR pathway in 
leptin's stimulatory effect [461, 482] on endometrial cancer cell growth, the PI-3K inhibitor 
LY294002 was used. Addition of LY294002 to leptin significantly reduced endometrial 
cancer cell numbers compared to leptin alone (Figure 5.1) which is consistent with the decline 
in phosphorylated form of Akt (p-Akt) compared to leptin alone (Figure 5.4 and Figure 5.5B). 
The results suggest that PI-3K and Akt are key proteins in leptin-induced growth stimulation 
which is in line with findings of others [373, 461, 473, 483].  
To ascertain the role of mTOR activation that followed PI-3K and Akt activation, the 
mTOR inhibitor everolimus was used. Everolimus did not modulate cell numbers in non-
treated control incubations (Figure 5.6). This suggests that Ishikawa cells may use 
JAK/STAT3 or another pathway to maintain basal proliferation. However, addition of 
everolimus to leptin led to a reduction in leptin’s stimulatory effect on cells and this suggests 
that mTOR protein is also a downstream step that is associated with activation of the PI-
3K/Akt/mTOR pathway by leptin (Figure 5.6). However, the presence of mTOR inhibitor 
everolimus did not affect the leptin-induced activation and phosphorylation of Akt protein 
significantly (Figure 5.7) but did alter cell numbers (Figure 5.6). This confirmed that Akt is 
upstream from mTOR. Everolimus is known to inhibit the phosphorylation of mTOR, and so 
inhibit cell proliferation. These findings are similar to published data and together suggest that 
leptin initiates a cell signalling cascade in endometrial cancer cells that causes tumour 
progression via the stimulation of PI-3K/Akt/mTOR pathway [373, 374, 461, 473]. In 
addition, the JAK/STAT3 pathway can be activated by leptin. The binding of leptin to its 




receptor. JAK becomes phosphorylated and that in turn phosphorylates STAT3 to p-STAT3 
which dimerises with another STAT3 and moves to the nucleus to initiate a transcription 
process [45, 468-470, 472, 484].  
To ascertain if this pathway is involved in the growth of endometrial cancer cells in the 
presence of leptin, a JAK inhibitor, Tyrphostin AG490, was used. Alone, Tyrphostin AG490 
reduced cancer cell numbers compared to control cell number, and in combination with leptin 
it inhibited the leptin stimulation effect on Ishikawa cells (Figure 5.8). Activation of 
JAK/STAT3 pathway by leptin has been reported to stimulate ovarian cancer cell growth and 
Tyrphostin AG490 was reported to abolish the leptin effect on ovarian cancer cells [339]. In 
this study, Ishikawa cells exhibited a similar response to the presence of Tyrphostin AG490 
(Figure 5.8). Blocking JAK activity with Tyrphostin AG490 led to significantly reduced 
expression of STAT3 and p-STAT3 (Figure 5.11 and Figure 5.12). Tyrphostin AG490 also 
inhibited the baseline expression of STAT3 and p-STAT3 suggesting that in Ishikawa cells 
the JAK/STAT3 pathway is active in maintaining basal levels of cell proliferation (Figure 
5.11 and Figure 5.12).  
In this study, the PI-3K inhibitor, LY294002, inhibited expression of both total STAT3 
and phosphorylated STAT3 (Figure 5.13 and Figure 5.14), and, conversely, the JAK inhibitor 
also reduced activation of Akt (Figure 5.9 and Figure 5.10A). This raises the question as to 
whether PI-3K is a protein upstream from both STAT3 and Akt or whether activation of 
STAT3 is only by JAK. These results indicated at least a connection between these two 
pathways.  
Here, the relationship between JAK pathway and PI-3K pathway in endometrial cancer 
cell line Ishikawa was investigated. The expression of Akt and p-Akt proteins as 
intermediates of PI-3K/Akt/mTOR pathway in the presence of JAK inhibitor, Tyrphostin 
AG490, was determined. Interestingly, Tyrphostin AG490 reduced expression of Akt and p-
Akt (Figure 5.9, and Figure 5.10). This suggests that JAK influences the PI-3K/Akt/mTOR 
pathway and STAT3 phosphorylation at the same time. On the other hand, the PI-3K inhibitor 
LY294002 inhibited increases in STAT3 protein expression induced by leptin to levels similar 




Figure 5.14A). It has been observed that Ishikawa cells phosphorylate STAT3 specifically at 
Ser727 instead of Tyr705 which is the site phosphorylated in cervical cells in the presence of 
leptin [484]. It has also been established that PI-3K also activates STAT3 phosphorylation 
specifically at Ser727 location [485, 486]. Two antibodies were used to detect expression of 
p-STAT3 proteins. The first was against p-STAT3(Tyr705), which is specific for JAK-
mediated phosphorylation. The second was against p-STAT3(Ser727), which is specific for 
PI-3K pathway stimulation [484].  
The absence of p-STAT3 phosphorylation at Tyr705, an effect specific for the kinse 
activity of JAK, caused by the presence of leptin in Ishikawa cells was reported previously 
[484]. Sharma et al. and others showed the presence of leptin resulted in phosphorylation of 
STAT3 at Tyr705 residue within 3 minutes, with this being reduced after 15 minutes of 
exposure. This expression regulates gene expression and leads to cell division being abolished 
within 24 hours post-treatment [51, 487]. This effect may have also occurred in my 
experiments at early exposure times. However, the continued exposure of Ishikawa cells to 
leptin beyond 24 hours may result in the Ishikawa cells developing alternative pathways 
through which to continue the proliferation. Hence, exposure to the stimulatory agent leptin 
for 48 hours did not show any expression of p-STAT3(Tyr705) although expression of p-
STAT3(Ser727) was very obvious after 48 hours post-treatment. This may suggest that 
Ishikawa cells recruit another p-STAT3 residue, Ser727, which is specific for PI-3K, to 
continue the proliferation process via another pathway which is specific to this protein and in 
this case is PI-3K/STAT3. 
In other words, p-STAT3(Ser727) was detected and its expression was reduced 
significantly in cells treated with a combination of leptin and LY294002 compared to those 
cells treated with only leptin (Figure 5.13 and Figure 5.14B). The results are consistent with 
findings that reported that Ishikawa cells did not express p-STAT3(Tyr705) protein but 
revealed only p-STAT3(Ser727) protein in the presence of leptin [484]. Moreover, a PI-3K 
inhibitor, LY294002, partially reduced the leptin stimulation effect on total STAT3 to control 
levels (Figure 5.13 and Figure 5.14A) but reduced significantly the p-STAT3 expression 
(Figure 5.13 and Figure 5.14B). Thus, the results suggest that by blocking PI-3K a cancer cell 




Tyr705 is not active in Ishikawa cells but p-STAT3(Ser727) is receptive to PI-3K action to 
stimulate STAT3 activity. In addition, Figure 5.11 and Figure 5.12A show that Tyrphostin 
AG490 inhibits basal STAT3 expression and leptin-induced expression to the same level. 
Moreover, Figure 5.7 and Figure 5.12B show a strong reduction of leptin-associated 
phosphorylation. These reductions were further than with PI-3K inhibitor, LY294002. Thus, 
there may be some LY294002-independent inhibition occurring, possibly via direct JAK to 
STAT3 interaction.  
In summary, Sharma et al. suggested that in the presence of leptin, cells expressed p-
STAT3(Tyr705) at very early times of exposure (3 minutes), and this effect vanished within 
24 hours [51]. However, continuous exposure of Ishikawa cells to leptin for more than 24 
hours may cause the cells to utilise an alternative mechanism to continue proliferation. This 
may explain the observation of the expression of Ser727 residue on p-STAT3 in order for 
cells to continue to proliferate. This may occur via other pathways, possibly PI-3K, which is 
specific to this protein. However, a comprehensive understanding of the underlying 
mechanisms is essential to unravel the overlap between the pathways. 
The observations above suggest that the interaction between the pathways JAK/PI-
3K/STAT3 is a time-dependent process. Carino and collegues  also investigated the effects of 
leptin on benign and cancerous endometrial epithelial cells [488]. They suggested that leptin 
is a key molecule for the activation of JAK and downstream signalling proteins (MAPK and 
PI-3K) in endometrial cancer cell lines (An3Ca, SK-UT2 and Ishikawa). They demonstrated 
that inhibition of JAK with a specific tyrosine kinase inhibitor (AG490) in the presence of 
leptin led to decreased phosphorylation of leptin-induced p-STAT3 and MAPK (p-ERK1/2). 
However, inhibition of JAK alone did not affect the basal levels of phosphorylated MAPK or 
Akt [488]. 
JAK is a protein upstream of both PI-3K and STAT3(Ser727) in endometrial cancer 
cells. Thus, inhibiting JAK should lead to inhibition of both pathways. Further, PI-3K may 
have a direct stimulatory effect on STAT3 activation and phosphorylation. The work 
presented in this chapter is the first to provide such evidence in Ishikawa cells of the novel 




occurred in the presence of JAK inhibitor, Tyrphostin AG490. Consequently, inhibition of 
JAK may lead to suppression of STAT3 and p-STAT3 expression by either interference with 
the effect of JAK on PI-3K and/or on a direct activity of JAK on STAT3.  
A time course study to investigate the sequence of the activation of STAT3 and 
phosphorylation for both residues, Tyr705 and Ser727, would be useful for finding the 
appropriate  time to inhibit the stimulatory action of leptin on Ishikawa cancer cell line.  
Other studies suggested that following phosphorylation of JAK induced by leptin 
binding to its cellular receptor, other signalling pathways such as PI-3K pathway in ovarian 
cancer are triggered via MAP kinase activation [374] or via activation of MEK/ERK1/2 
pathway [373]. However, it has been suggested that in myeloproliferative neoplasmas (MPN) 
[375] and in hypothalamus [53] JAK is the upstream protein of PI-3K and the activation of 
PI-3K by JAK is via insulin receptor substrate (IRS). IRS may be involved in the endometrial 
cancer pathway also. However, in this study the presence of IRS was not determined. This 
study nevertheless extends evidence of the involvement of a JAK/PI-3K pathway to 
endometrial cancer cells.  
These results in endometrial cancer cells again support findings of others [53, 164, 373-
375] in ovarian cancer cells, myeloproliferative neoplasms and hypothalamus in regard to the 
stimulatory effect of JAK on PI-3K in endometrial cancer cells. In this chapter, evidence was 
provided that the two pathways may be involved in leptin stimulatory effect on endometrial 
cancer growth and are not differently separated or parallel pathways. JAK/STAT3 and PI-
3K/Akt/mTOR pathways apparently had cross-talk and JAK is the upstream protein in 
endometrial cancer cells.  
The observations suggest that the effect of leptin on Ishikawa cells is time dependent 
and JAK blockade may be an interesting area for further research as a therapeutic target in 
















6 Adiponectin signalling pathways in Ishikawa cells 
6.1. Introduction 
Adiponectin exerts its effect on the cancer cell via two protein receptors (AdipoR1 and 
AdipoR2). These AdipoRs are proteins that have an intracellular N terminal and extracellular 
C terminal region, characteristics which make the AdipoRs different from G protein-coupled 
receptors [1]. AdipoR1 and AdipoR2 were previously reported to be found in the cell 
membrane and in the cytoplasm of cells in normal and malignant endometrial tissue [2][35], 
and have different affinities to adiponectin isoforms [1]. AdipoR1 has high affinity for a 
globular adiponectin isoform (GAd) and low affinity for a full-length isoform (FAd), while 
AdipoR2 has moderate affinity for both GAd and FAd isoforms [1].  
Binding of adiponectin to one or both of the receptors triggers a series of signalling 
events inside cells that include the activation of adenosine monophosphate (AMP) protein 
kinase (AMPK) [3]. In this project, biological activities of adiponectin associated with the 
activation of the PI-3K/Akt/mTOR, JAK/STAT3 pathways and AMPK protein were 





6.2.1. Modulation of adiponectin receptors 
The levels of AdipoR1, and AdipoR2 in the Ishikawa cell line were investigated in the 
presence of adiponectin at two different concentrations, 20 ng/ml (Adp20) and 100 ng/ml 
(Adp100).  GAPDH is the reference protein in the Western blotting studies. As shown in 
Figure 6.1 and Figure 6.2 adiponectin at 20 ng/ml or at 100 ng/ml did not alter the protein 
level of AdipoR1 and AdipoR2 when compared to the control.  
 
Figure 6.1 The level of AdipoR1 and AdipoR2 in untreated Ishikawa cells, cells 
treated with Adp20, and Adp100. GAPDH is the reference protein. 
 
Figure 6.2 Densitometry of (A) AdipoR1 and (B) AdipoR2 expression for 
Ishikawa cells untreated (Ctrl) and treated with Adp20 and Adp100. n = 4. Data 
were analysed using logarithmic analysis and one-way ANOVA. Data are 




Adiponectin has been observed to exhibit biological activities opposite to the activity of 
leptin in that adiponectin can inhibit cancer cell proliferation [489]. However, the influence of 
adiponectin on expression of leptin receptors in cells remains unknown. For this reason, it 
may be worthwhile investigating whether adiponectin can change the amount of leptin 
receptor. Ishikawa cells were exposed to Adp20 and Adp100; proteins from each condition 
were analysed by Western blots. 
 
Figure 6.3 Expression of leptin receptor (Ob-Rb) in untreated cells, and cells 
treated with Adp20 and Adp100. GAPDH is the reference protein. 
 
Figure 6.4 Densitometry of Ob-R expression for Ishikawa cells untreated (Ctrl) 
and treated with Adp20 and Adp100. n = 3. Data were analysed using logarithmic 
analysis and one-way ANOVA. Data were denoted as statistically significant (*) 
when p < 0.05 compared to controls. Data are expressed as means ± S.E.M. 
It is very interesting that the level of Ob-Rb was significantly increased in Adp20 
stimulated cells. However, this increase was not observed in cells treated with Adp100 




6.2.2. Effects of adiponectin on adenosine monophosphate kinase (AMPK) 
The binding of adiponectin to its receptors has been observed to induce the activation of 
AMPK, which in turn regulates cellular functions including VEGF secretion [478, 479]. As 
such, it would be profitable to know whether adiponectin at 20 ng/ml and 100 ng/ml can elicit 
similar effects on the total level of AMPK protein and its active form (phosphorylated 
AMPK, p-AMPK) in Ishikawa cells.  
 
Figure 6.5 Expression of AMPK and p-AMPK in untreated cells, and cells 
treated with Adp20 and Adp100. GAPDH is the reference protein. 
 
Figure 6.6 Densitometry of (A) AMPK and (B) p-AMPK expression in Ishikawa 
cells untreated (Ctrl) and treated with Adp20 and Adp100. n = 3. Data were 
analysed using logarithmic analysis and one-way ANOVA. * p < 0.05, and ** p < 
0.01 compared to controls. Data are expressed as means ± S.E.M. The data are 




As shown in Figure 6.5 and Figure 6.6, the presence of 20 ng/ml adiponectin increased 
the levels of AMPK and p-AMPK significantly compared to controls. However, the protein 
levels of AMPK and p-AMPK were not changed in the presence of 100 ng/ml adiponectin. 
In the previous chapter, the cellular activities of leptin associated with the PI-
3K/Akt/mTOR and JAK/STAT3 pathways were described. Furthermore, two experimental 
inhibitors (LY294002 and Tyrphostin AG490) were used to examine these pathways that 
might be responsible for leptin’s growth promoting effect. Here, the same inhibitors were 
employed to investigate whether adiponectin could also activate PI-3K/Akt and JAK/STAT3 
signalling cascade.  
6.2.3. The effect of adiponectin on cell numbers and VEGF secretion 
The targets of the pathways that were established above were compared to results of 
experiments that examined function. The effects on cell number and VEGF secretion of 
adiponectin at both its growth-promoting concentration (20 ng/ml) and its apparent anti-
cancer concentration (100 ng/ml) for Ishikawa cells were examined. 
First, the effect of Tyrphostin AG490 was determined and the effects of LY294002 on 
adiponectin modification of cell number and VEGF secretion were assessed. The results 
showed that growth promoting and VEGF secreting effects of Adp20 were lowered by the 
presence of Tyrphostin AG490 (Figure 6.7). This may suggest that JAK mediated pathway 






Figure 6.7 Ishikawa (A) cell numbers and (B) VEGF secretion of untreated cells 
(Ctrl), cells treated with Tyrphostin AG490, Adp20, and in combination. n = 3. 
Data were analysed using one-way ANOVA. ** p < 0.01, and *** p < 0.001 
compared to control. Data are expressed as means ± S.E.M. The data are identical 








Figure 6.8 Ishikawa (A) cell numbers and (B) VEGF secretion of untreated cells 
(Ctrl), cells treated with LY294002, Adp20 and in combination. n = 3. Data were 
analysed using one-way ANOVA. * p < 0.05, and *** p < 0.001 compared to 
control. Data are expressed as means ± S.E.M. Stars without connections indicate 
comparison to control incubation. The data are identical to previous figure. 
To investigate this unique function of Adp20 activating Akt protein, the PI-3K inhibitor 
was used to treat Ishikawa cells and cell numbers were determined. The secretion of VEGF 
was also studied. As shown in Figure 6.8A, Adp20 significantly elevated cell numbers 
compared the control, and LY294002 compromised Adp20 growth promoting effect. A 
similar pattern is observed in the secretion of VEGF (Figure 6.8B). These findings suggest 
that Adp20 promotes cell proliferation and VEGF level via PI-3K protein. On the other hand 
the effects of Adp100 were not affected by either Tyrphostin AG490 or LY294002 (Figure 






Figure 6.9 Ishikawa (A) cell numbers and (B) VEGF secretion of untreated cells 
(Ctrl), cells treated with Tyrphostin AG490, Adp100 and in combination. n = 3. 
Data were analysed using one-way ANOVA. ** p < 0.01, and *** p < 0.001 
compared to control. Data are expressed as means ± S.E.M. Stars without 







Figure 6.10 Ishikawa (A) cell numbers and (B) VEGF secretion of untreated cells 
(Ctrl), cells treated with PI-3K inhibitor, LY294002 (20 μM), adiponectin 100 
ng/ml (Adp100), and a combination. n = 3. Data were analysed using one-way 
ANOVA. ** p < 0.01, and *** p < 0.001 compared to control. Data are expressed 
as means ± S.E.M. Stars without connections indicate comparison to control 
incubation. The data are identical to previous figure. 
These results, overall, indicate that the signalling pathways activated by adiponectin are 
dose-dependent effects. 
6.2.4. Effects of adiponecin on PI-3K/Akt pathway 
The association of adiponectin with the PI-3K/Akt/mTOR pathway was investigated. 
Ishikawa cells were treated with the two different concentrations, Adp20 and Adp100, and 
protein levels of Akt and the phosphorylated Akt (p-Akt) were documented using Western 






Figure 6.11 Protein levels of Akt and p-Akt in untreated cells, and cells treated 
with Adp20 and Adp100. GAPDH is the reference protein. 
 
Figure 6.12 Densitometry of (A) Akt and (B) p-Akt expression for Ishikawa cells 
untreated (Ctrl) and treated with Adp20 and Adp100. n = 3. Data were analysed 
using logarithmic analysis and one-way ANOVA. * p < 0.05 compared to 
controls. Data are expressed as means ± S.E.M. The data are identical to previous 
figure. 
Figure 6.11 and Figure 6.12A show a significant increase of total Akt protein and p-Akt 
protein in the presence of Adp20 but there was no change in Adp100 stimulated cells.   
It is interesting to note that, as shown in Figure 3.9, Adp20 significantly increased cell 
numbers in the Ishikawa cell culture. It is likely that Adp20 promotes growth activity via the 




It is very important to understand whether Adp20-stimulated cell growth may be 
associated with the activity of Akt protein, which lies downstream from PI-3K in the 
signalling pathway. Therefore, to ascertain this, proteins from Ishikawa cells were again 
subjected to Western blotting.  
 
Figure 6.13 Expression of Akt and p-Akt in Ishikawa cells in untreated cells, and 
cells treated with Adp20, LY294002 and a mixture of both inhibitors. GAPDH is 
the reference protein. 
 
Figure 6.14 Densitometry of (A) Akt and (B) p-Akt expression for Ishikawa cells 
untreated (Ctrl) and treated with Adp20, LY294002 and in combination. n = 3. 
Data were analysed using logarithmic analysis and one-way ANOVA. * p < 0.05 
and *** p < 0.001 compared to controls. Data are expressed as means ± S.E.M. 
Stars without connections indicate comparison to control incubation. The data are 




As shown in Figure 6.13 and Figure 6.14, adiponectin at 20 ng/ml increased the 
expression of Akt and this was reduced back to the control level by LY294002. A similar 
effect was observed with the phosphorylated form of Akt, as shown in Figure 6.14B. These 
results suggest that the proliferation-promoting effect of adiponectin 20 ng/ml was mediated 
via the PI-3K/Akt pathway. 
To examine if Adp100 could produce a similar Akt stimulating effect as shown by 
Adp20. It is very interesting to notice that Adp100 failed to increase the level of Akt and p-
Akt, Figure 6.16. These findings suggest that the PI-3K/Akt/mTOR pathway may not be 
involved in the biological activity of 100 ng/ml adiponectin in Ishikawa cells.  
 
Figure 6.15 Expression of Akt in Ishikawa cells in untreated cells, and cells 
treated with adiponectin at 100 ng/ml (Adp100), PI-3K inhibitor, LY294002 (20 
µM) and a combination. GAPDH is the reference protein. 
 
Figure 6.16 Densitometry of (A) Akt and (B) p-Akt expression for Ishikawa cells 
untreated (Ctrl) and treated with Adp20, LY294002, and in combination. n = 12. 
Data were analysed using logarithmic analysis and one-way ANOVA. Data are 





6.2.5. Effects of adiponectin on an association of PI-3K with AMPK 
The expression of AMPK protein was also examined in the presence of Adp20 alone 
and in combination with LY294002. 
 
Figure 6.17 Protein expression of AMPK and p-AMPK in Ishikawa cells in 
untreated cells, and cells treated with Adp20, LY294002 and in combination. 
GAPDH is the reference protein. 
 
Figure 6.18 Densitometry of  (A) AMPK and (B) p-AMPK expression for 
Ishikawa cells untreated (Ctrl) and treated with Adp20, LY294002 and in 
combination. n = 4. Data were analysed using logarithmic analysis and one-way 
ANOVA. * p < 0.05 and ** p < 0.01 compared to controls. Data are expressed as 
means ± S.E.M. Stars without connections indicate comparison to control 




Figure 6.14, Figure 6.17 and Figure 6.18, show that the presence of PI-3K inhibitor, 
LY294002, abolished the stimulatory effect on AMPK of Adp20, leading to a reduction of the 
expression of AMPK and phosphorylated AMPK. This may suggest that PI-3K acts on 
AMPK, and may regulate the activation and phosphorylation of AMPK. 
6.2.6. Effects of adiponectin on an association of PI-3K with JAK/STAT3 
In Chapter Five, it was suggested that PI-3K could act upstream from STAT3 following 
leptin binding. For that reason, it is worthwhile to investigate whether STAT3 is activated by 
adiponectin in the presence of LY294002. Here the expression and activation of STAT3 
protein in response of Adp20 and LY294002 alone and combination of both were 
investigated. The results indicate that LY294002 reduced the total levels of STAT3 and p-
STAT3 in a Adp20-stimulating condition (Figure 6.20). The effect of Adp100 on total STAT3 
and p-STAT3 were also assessed. However, Adp100 had no effect on the levels of STAT3 or 
p-STAT3 in any tested conditions (Figure 6.21, Figure 6.22).  
 
Figure 6.19 Protein expression of STAT3 and p-STAT3 in Ishikawa cells in 
untreated cells, and cells treated with Adp20), LY294002 and in combination. 





Figure 6.20 Densitometry of (A) STAT3 and (B) p-STAT3 expression for 
Ishikawa cells untreated (Ctrl) and treated with Adp20, LY294002 and in 
combination. n = 4. Data were analysed using logarithmic analysis and one-way 
ANOVA. * p < 0.05 and ** p < 0.01 compared to controls. Data are expressed as 
means ± S.E.M. The data are identical to previous figure. 
 
Figure 6.21 Protein expression of STAT3 in Ishikawa cells in untreated cells, and 







Figure 6.22 Densitometry for (A) STAT3 and (B) p-STAT3 expression for 
Ishikawa cells untreated (Ctrl) and cells treated with Adp100, LY294002 and in 
combination. n = 3. Data were analysed using logarithmic analysis and one-way 
ANOVA. ** p < 0.01 compared to controls. Data are expressed as means ± 
S.E.M. The data are identical to previous figure. 
Taken together, the results shown in Figures 6.13 to 6.20 suggest that Ishikawa cells 
stimulated with 20 ng/ml adiponectin can activate the PI-3K, Akt, AMPK, and STAT3 
proteins. However, these activations are limited in Adp100-treated cells (Figure 6.22). 
It is also important to understand the Adp20 stimulating effects in Ishikawa cells, 
possibly occurs via the activation of JAK protein. To examine this possibility the JAK 
blocker, Tyrphostin AG490, was included in cells that were stimulated with Adp20. 
 Ishikawa cells were exposed to Adp20, Tyrphostin AG490, and a combination of 
Adp20 and blocker and the expression of the intermediary molecules that are involved in the 
JAK/STAT3 pathway were determined including Akt (Figure 6.23, Figure 6.24), AMPK 





Figure 6.23 Protein expression of Akt and p-Akt in Ishikawa cells in untreated 
cells, and cells treated with Adp20, Tyrphostin AG490 and in combination. 
GAPDH is the reference protein. 
 
Figure 6.24 Densitometry of (A) Akt and (B) p-Akt expression for Ishikawa cells 
untreated (Ctrl) and cells treated with Tyrphostin AG490, Adp20 alone, and in 
combination. n = 3. Data were analysed using logarithmic analysis and one-way 
ANOVA. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to controls. Data 






Figure 6.25 Protein expression of AMPK and p-AMPK in Ishikawa cells in 
untreated cells, and cells treated with Adp20, TY AG490 and in combination. 
GAPDH is the reference protein. 
 
 
Figure 6.26 Densitometry of (A) AMPK and (B) p-AMPK expression in 
Ishikawa cells untreated (Ctrl) and cells treated with Tyrphostin AG490, Adp20 
alone, and in combination. n = 3. Data were analysed using logarithmic analysis 
and one-way ANOVA. * p < 0.05 and ** p < 0.01 compared to controls. Data are 





Figure 6.27 Protein expression of STAT3 and p-STAT3 in Ishikawa cells in 
untreated cells, and cells treated with Adp20, TY AG490 and in combination. 
GAPDH is the reference protein. 
 
Figure 6.28 Densitometry of (A) STAT3 and (B) p-STAT3 expression for 
Ishikawa cells untreated (Ctrl) and cells treated with Tyrphostin, Adp20 alone 
and in combination. n = 3. Data were analysed using logarithmic analysis and 
one-way ANOVA. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to 
controls. Data are expressed as means ± S.E.M. The data are identical to previous 
figure. 
The results confirmed that the presence of JAK inhibitor, Tyrphostin AG490, 
significantly reduced the Adp20-stimulated expression of Akt (Figure 6.23, and Figure 6.24), 
AMPK (Figure 6.25, and Figure 6.26), and STAT3 (Figure 6.27, and Figure 6.28) proteins. 




untreated cells. This suggests that Adp20 may also activate JAK/PI-3K/Akt pathway and 







Adiponectin is secreted exclusively by white adipose tissue (WAT) [143, 177] and has 
been shown to have anti-tumorigenic effects on tumour growth [143, 490]. Also obesity, as 
defined by BMI, is negatively correlated with the circulating concentrations of this adipokine 
hormone, adiponectin. It has been suggested that the development of obesity-related 
malignancies, including endometrial cancer [491], may be linked to the lowered adiponectin 
concentrations encountered in that condition [169, 173, 174, 179, 411].  
This project has revealed that adiponectin demonstrates an anticancer effect on Ishikawa 
cells at concentration of 100 ng/ml (Adp100). However, adiponectin has an opposite, 
tumorigenic effect at a concentration of 20 ng/ml (Adp20). This effect has not previously been 
reported for adiponectin. Experiments investigated how this unusual and varied response was 
transduced. 
Untreated Ishikawa cells expressed AdipoR1 and AdipoR2 proteins (Figure 3.8). The 
presence of Adp100 had no effect on the expression of AdipoR1 and AdipoR2 protein 
expression at 48 hours post-treatment (Figure 6.2) compared to untreated Ishikawa cells. 
However, the expression of Ob-R leptin receptor protein was investigated in the presence of 
Adp20 and Adp100. As shown in Figure 6.4, the lower adiponectin concentration increased 
the expression of leptin receptors significantly compared to control. This suggests that low 
adiponectin levels may modulate Ob-R and hence the effect of leptin on endometrial cancer 
cells. However, there was no change in Ob-R protein expression (Figure 6.4) induced by high 
adiponectin. 
In many aspects, adiponectin 20 ng/ml activity is closely similar to the action of leptin 
on endometrial cancer cells with regard to increasing endometrial cancer cell numbers (Figure 
3.4 and Figure 3.9).  
Previous studies identified the activation of adenosine monophosphate-activated protein 
kinase (AMPK) [376, 377] as a pathway mediating adiponectin activity. Indeed, adiponectin 




exposing cancer cells to treatment with adiponectin enhances AMPK activation in 
endometrium [30] as well as colon [365-367], breast [380, 381, 409], prostate [143, 367], and 
liver [349]. However, in the current study, the presence of higher adiponectin concentrations 
for 48 hours incubation did not activate the phosphorylation of AMPK protein.  
Moreover, this study demonstrates for the first time that cross-talk exists between 
AMPK and JAK/PI-3K/Akt/mTOR in the presence of low adiponectin. The results suggest 
that following adiponectin ligand binding, JAK activates PI-3K which in turn stimulates 
AMPK and Akt expression and phosphorylation. AMPK activated by PI-3K in the presence 
of adiponectin may explain the increase in VEGF secretion in endometrial cancer cells [478, 
479]. It appears that VEGF secretion is controlled separately from cell proliferation because 
VEGF secretion by leptin is not mediated by PI-3K. Nevertheless PI-3K is involved in 
activity of adiponectin at 20 ng/ml.  
The difference between the presence of leptin and adiponectin at 20 ng/ml concentration 
may be exemplified by the secretion of VEGF from Ishikawa cells that is associated with 
AMPK protein activation and phosphorylation. Leptin induced a reduction in VEGF secretion 
although Ishikawa cells did not exhibit a significant change in expression of AMPK or p-
AMPK proteins in the presence of leptin compared to untreated cells (Figure 5.2, Figure 5.3), 
which in this case does not involve PI-3K/Akt/AMPK pathway. However, 20 ng/ml 
adiponectin significantly increased AMPK and p-AMPK expression (Figure 6.6), consistent 
with other observations [478, 479].  
The results overall indicate there is a complex array of pathways that are involved in 
regulating VEGF secretion. According to these data, the following schema for the adiponectin 
signalling pathway is proposed (Figure 6.29). Here, it was demonstrated that the population of 
leptin receptors may be involved in endometrial cancer cell growth that is modulated by 
adiponectin. Also, PI-3K is upstream of AMPK and Akt and modifies the phosphorylation of 





Figure 6.29 Depicted is a proposed set of signalling pathways associated with 
adiponectin (20 ng/ml) in endometrium adenocarcinoma (Ishikawa) cells 
consistent with the observations. Adiponectin activated the PI-3K pathway, which 
in turn led to (i) increased expression of Akt and its phosphorylation; (ii) 
increased expression of AMPK and its phosphorylation; (iii) an increase in 
STAT3 synthesis and its phosphorylation. Additionally, involvement of JAK 










Insulin and IGF-I: proliferation and 





7 Insulin and IGF-I: proliferation and VEGF secretion signalling 
pathways in Ishikawa cells 
7.1. Introduction 
Insulin is one of several obesity-related growth factors that may be associated with 
cancer cell proliferation and survival [387, 428]. Insulin resistance occurs in a variety of 
conditions such as obesity, polycystic ovary syndrome (PCOS) [492], type 2 diabetes mellitus 
and hypertension, and may also be associated with increased endometrial cancer risk [429, 
493]. Insulin exhibits an important impact on endometrial carcinoma cells [429] and serum 
insulin levels are correlated with progression of endometrial adenocarcinoma [494]. It is 
possible that hyperinsulinemia associated with obesity underlies this relationship in different 
types of cancer [494-496]. The binding of insulin to its receptors (InsR) generates a series of 
reactions commencing with the phosphorylation of the insulin receptor and its substrate (IRS) 
proteins, which then activate downstream molecules such as the PI-3K/Akt/mTOR pathway 
[391, 393-395]. 
The insulin-like growth factor system is also known to be associated with increased 
body weight, diabetes, and hyperinsulinemia [206, 497]. The receptor for IGF-I, IGF-IR, is a 
trans-membrane tyrosine kinase receptor that has several functional features in common with 
InsR [120, 121, 125]. IGF-I ligand binding induces auto-phosphorylation of IGF-IR [498]. 
This in turn results in the activation of signalling pathways, which, like insulin, include the 
PI-3K/Akt/mTOR signalling cascade [498]. The expression levels of IGF-IR are also 
significantly higher in endometrium adenocarcinoma than in the normal endometrium [499]. 
 It was previously noted that insulin and IGF-I promoted proliferation of Ishikawa cells 
(Figure 3.15, Figure 3.21). Thus, this chapter studies the effects of insulin and IGF-I on the 
PI-3K/Akt/mTOR pathway to determine whether there was a potential association of InsR and 
IGF-I with proliferation in the Ishikawa endometrial cancer cell line [392]. Further, it has also 
been observed that both insulin and IGF-I reduced VEGF secretion from Ishikawa cells 




and IGF-I-regulated VEGF secretion in these cells, the relationship of VEGF and AMPK 





7.2.  Results 
7.2.1. The effect of insulin on signalling proteins 
It has been suggested that insulin’s promotion of tumour cell proliferation and survival 
involves the phosphatidylinositol 3-kinase (PI-3K)/Akt pathway [500-502]. Therefore, the 
responses of Akt and p-Akt to insulin were investigated. As shown in Figure 7.1 and Figure 
7.2, insulin significantly increased the expression and phosphorylation of Akt. This increase 
in Akt and p-Akt confirms the involvement of PI-3K/Akt/mTOR pathway in cell signalling 
behaviour in the presence of insulin. 
 
Figure 7.1 Protein expression of Akt and p-Akt in untreated Ishikawa cells (-) 
and cells treated with 580 ng/ml insulin. GAPDH is the reference protein. 
 
Figure 7.2 Densitometry of the amount of (A) Akt and (B) p-Akt proteins for 
cells treated with 580 ng/ml insulin and untreated cells (Ctrl). n = 3. Data were 
analysed using logarithmic analysis and Student's t-test (two-tailed). * p < 0.05 




It is believed that AMPK is involved in the stimulatory pathway of VEGF secretion 
[379, 478, 479]. Therefore, the levels of both AMPK and p-AMPK were investigated in 
Ishikawa cells by Western blotting. The inhibition of AMPK expression and phosphorylation 
that occurred in the presence of insulin (Figure 7.3, Figure 7.4) may be a contributing factor to 
the reduction in VEGF secretion from Ishikawa cells.  
 
Figure 7.3 AMPK and p-AMPK proteins expression in untreated Ishikawa cells 
(-) and cells treated with 580 ng/ml insulin. GAPDH is the reference protein. 
 
Figure 7.4 Densitometry of (A) AMPK and (B) p-AMPK expression in untreated 
Ishikawa cells and cells treated with insulin. n = 3. Data were analysed using 
logarithmic analysis and Student's t-test (two-tailed). * p < 0.05 compared to 





7.2.2. Effect of insulin like growth factor-1 on signalling proteins  
The effect of treatments with IGF-1 on signalling proteins were also investigated. Akt 
protein expression was investigated to ascertain whether signalling molecules that IGF-I 
activates include the PI-3K/Akt/mTOR pathway. Figure 7.5, and Figure 7.6 show that there 
was a significant increase of Akt protein expression and phosphorylation in the presence of 
IGF-I compared to the control. 
 
Figure 7.5 Protein expression of Akt and p-Akt in untreated Ishikawa cells (-) 
and cells treated with 100 ng/ml IGF-I. GAPDH is reference protein. 
 
  
Figure 7.6 Densitometry of (A) Akt and  (B) p-Akt expression in untreated 
Ishikawa cells (Ctrl) and cells treated with 100 ng/ml IGF-I . n = 3. Data were 
analysed using logarithmic analysis and Student's t-test (two-tailed). * p < 0.05 
and *** p < 0.001 compared to controls. Data are expressed as means ± S.E.M. 





AMPK protein expression was also investigated in order to determine whether IGF-I 
activates this pathway, as this may also be associated with secretion of VEGF from Ishikawa 
cells. As shown in Figure 7.7 and Figure 7.8, the presence of IGF-I decreased expression of 
AMPK, and this reduction was significant for p-AMPK compared to the control.  
 
Figure 7.7 Protein expression of AMPK and p-AMPK in untreated Ishikawa cells 
(-) and Ishikawa cells treated with IGF-I (100 ng/ml). GAPDH is reference 
protein. 
 
Figure 7.8 Densitometry of (A) AMPK and (B) p-AMPK expression for 
untreated cells (Ctrl) and cells treated with IGF-100. n = 3. Data were analysed 
using logarithmic analysis and Student's t-test (two-tailed). *  p < 0.05 compared 







In this chapter, it was shown that both insulin and IGF-I activated the PI-3K/Akt 
pathway in Ishikawa cells, and down-regulated AMPK expression and phosphorylation. 
Unfortunately, because of time limitations, it was not possible to investigate the contribution 
of JAK/STAT3 pathway in the activation process of insulin and IGF-I in Ishikawa cells nor 
the effect of the inhibitors that were used in the previous chapters. 
The PI-3K/Akt/mTOR pathway is widely associated with cell proliferation. 
Consequently, it is reasonable to suggest that the observed increase of Ishikawa cancer cell 
numbers induced by both insulin and IGF-I (Figure 3.15, Figure 3.21) may be related to the 
endocrine regulation of this pathway (Figure 7.1, Figure 7.2, Figure 7.5, Figure 7.6). These 
results are consistent with other studies [399, 496, 502] in tissue cell lines such as HEC-1A, 
colorectal and myoblast cell lines in which it has been proposed that insulin increases cancer 
cell proliferation via the PI-3K/Akt pathway. 
Increases in Akt and p-Akt expression may have led to the inhibition of the activation of 
AMPK, thus disturbing the cellular energy balance that is partly regulated by AMPK [455, 
503] and suppresses the breakdown of ATP to AMP which in turns activates the kinase 
protein. Thus, cancer cells may divert energy expenditure while the proliferation process 
occurs [455]. 
Because AMPK has a central role in upregulating VEGF secretion and hence the 
presence of insulin reduced the expression of AMPK and p-AMPK and reduced VEGF 
secretion from HEC-1A cells [397]. Bermont et al. treated HEC-1A cells with 10 nM insulin 
for up to 24 hours and observed a high VEGF level in the conditioned medium compared to 
untreated ones due to low insulin concentration. In this study, the insulin concentration used 
was ten-fold higher (100 nM) than in Bermont's study [397] which also tested hypoxia [345] 
which shares with insulin the ability to regulate the expression of some stress-induced genes 




The effects of insulin and IGF-I on Akt activation and phosphorylation were similar to 
those of leptin (Chapter 5). However, neither insulin nor IGF-I replicated the action of leptin 
on AMPK activation. This suggests that the down-regulation of AMPK protein expression in 
endometrial cancer cells observed in this chapter might possibly occur via different 
intracellular complexes than those recruited by leptin. This aspect will require further 
investigation.  
The other signalling protein investigated was AMPK. Treatment with insulin or IGF-I 
led to reduced levels of AMPK and p-AMPK. It might be speculated that the high 
concentrations of insulin and IGF-I for 48 hours and the non-hypoxic environment reduced 
the stress on the cells, which in turn reduced AMPK activation and led to inhibit VEGF 
secretion from the Ishikawa cells. Thus, the reduction of AMPK and p-AMPK protein 
expression might be associated with the reduced VEGF secretion from Ishikawa cells that was 
previously observed (Figure 3.16, Figure 3.22). To my knowledge, this is the first study that 
reveals the potential for a negative mechanistic association between either insulin or IGF-I 
and VEGF secretion from endometrial cancer cells.  
It is suggested that there is an inverse association between Akt and AMPK activation 
and the presence of insulin and IGF-I. Cancer cell proliferation requires significant amounts 
of energy to maintain the processes of growth and division associated with proliferation. 
Thus, the increase in expression of Akt, a mediator of the cell proliferation process, partly 
silences AMPK phosphorylation and reduces VEGF secretion and saves energy.  
There is a strong reason to conduct a study using a series of pharmacological inhibitors 
such as LY294002, everolimus and Tyrphostin AG490 to further investigate the signalling 
pathways that are involved in the responses of Ishikawa cells to the presence of insulin and 
IGF-I, just as were conducted with leptin and adiponectin. Unfortunately, however, because 
of the time limits, I was not able to conduct such a study, and I consider this for future study.  
These observations show that insulin and IGF-I have parallel effects on both cell 
number and VEGF secretion in Ishikawa cells and, further, that the effects of the two 
hormones on the signalling molecules that were investigated are similar. However, in the light 




Figure 4.5) to have differential growth effects on different types of cancer cell lines which did 
not parallel insulin, it would be informative in future to expand this study of mechanisms to 


















There is a strong interest in the connection between obesity and an increased risk of the 
onset of cancer. This thesis has been an investigation into aspects of this relationship, and 
possible links between cancer progression and obesity-related hormones are reported. These 
hormones were leptin, insulin, IGF-I and adiponectin. 
In pre-clinical studies these hormones exhibit a spectrum of biological activities in 
regards to their actions on different types of cancers. There have, however, been only a 
limited number of studies in which these hormones have been systematically tested with 
gynaecological cancers. Interest in this study has focused on endometrial cancer and a well 
differentiated endometrial cancer cell line, Ishikawa, was chosen to be the centre of the study. 
This cell line is widely used in pre-clinical studies of endometrial cancer [504-506]. For 
comparison and controls alternative cell lines were also included. These lines were a second 
endometrial cancer cell line, HEC-1A, a breast cancer cell line, MCF-7, and an ovarian cancer 
cell line, SKOV-3.  
The four obesity-related hormones included in this study are secreted by at least three 
different tissues, namely the white adipose tissue which secretes leptin and adiponectin, the 
pancreatic β-cells which secrete insulin and the liver which is responsible for the secretion of 
IGF-I. The effects of these hormones on the Ishikawa cell line were determined through 
different approaches. Cell numbers, which were determined as an indication of cell 
proliferation, the level of apoptosis, the secretion of VEGF as a putative tumorigenic marker, 
and protein expression of selected signalling molecules were all measured. Also, 
immunohistochemistry and Western blotting were utilised to complement the other 
methodologies. The effects of these hormones were individually studied, and combinations of 





The working hypothesis in this study was that leptin, insulin and IGF-I would promote 
cancer growth, and in particular the growth of endometrial cancer, along with the secretion of 
VEGF, while adiponectin would inhibit these tumorigenic processes.  
As hypothesised, it was observed that leptin, insulin and IGF-I increased Ishikawa 
endometrial cancer cell proliferation in a manner that was influenced by the hormone 
concentration. Similar increases in proliferation were also found in HEC-1A cells and MCF-7 
cells, with the exception of insulin which failed to promote cell proliferation in the latter cell 
line. Notably, the ovarian cell line, SKOV-3, exhibited different behaviour. These results all 
agree with extensive reports in the literature that these hormones all induce cell proliferation, 
with leptin known to cause proliferation in Ishikawa, HEC-1A, and MCF-7  [157, 507-509], 
insulin to generate increased cell numbers in Ishikawa, HEC-1A and MCF-7 [510-513], and 
IGF-1 also known to induce increased cell proliferation.in HEC-1A, MCF-7 [514, 515]. On 
the other hand, the hormone adiponectin exhibited effects that varied with concentration such 
that both anti-cancer activity was observed with a reduction in cell number caused by 100 
ng/ml adiponectin while pro-tumorigenic activity was observed with an increase in cell 
number when only 20 ng/ml was used. The details of the effects of adiponectin were also cell 
line-dependent. Adiponectin at both 20 and 100 ng/ml significantly reduced the proliferation 
of HEC-1A cells but adiponectin did not have these effects on MCF-7 cells. In SKOV-3 cells, 
100 ng/ml adiponectin increased cell proliferation while 20 ng/ml adiponectin had not effect 
on proliferation.  
In this study, the effects of adiponection acting alone showed concentration-dependent, 
differential effect on cell growth. The observations of a tumorigenic effect of 20 ng/ml 
adiponectin, a concentration which has the ability to increase proliferation of Ishikawa cells, 
is novel and runs counter to published studies on the effects of adiponectin which reduces 
endometrial and MCF-7 cancer risk [402-404, 516]. It is possible to speculate that this 
unusual effect might be due to stimulation of multiple stimulatory pathways, as has been 
suggested in other systems [137, 379]. Thus, this novel observation extends the properties of 
adiponectin in endometrial cancer to an association with tumorigenic as well as the previously 
observed anti-tumorigenic characteristics [402]. Further, that 20 ng/ml adiponectin has the 




oncogenic responses that result from obesity because concentration of adiponectin in this 
range are biologically relevant. Adiponectin is found in the highest concentration of all 
hormones in human plasma [131] with a range from 3 to 30 µg/ml which accounts for up to 
0.05% of total plasma proteins [142, 143]. In contrast to other hormones, adiponectin serum 
levels are found to be higher in lean women compared to obese (13.3 + 1.8 and 8.6 + 0.8 
mg/L) respectively [83]. 
There is still discussion regarding the place of obesity in risk of ovarian cancer. Clinical 
studies have concluded that for ovarian cancer patients BMI is higher and adiponectin 
concentrations are lower [450], thus suggesting the link to ovarian cancer [370]. In vitro, this 
study showed that the SKOV-3 cells had no proliferative response to leptin, insulin and IGF-I 
which is in a manner consistent with literature observation [372]. These observations are also 
consistent with the fact that ovarian cancer risk is not increased by obesity, although meta-
analyses suggest that there is an associated risk [370, 423, 451] which may be weak [371]. 
The results obtained in this study which show limited effects of the proliferative hormones on 
the SKOV-3 ovarian cancer cell line are consistent with, at most, a low increased risk due to 
obesity. Alternatively, if there is an increased risk it is not mediated via the endocrinological 
factors investigated in this study. Thus, the initial hypothesis was only partly confirmed in 
that SKOV-3 cells did not respond to the presence of the stimulatory obesity-related 
hormones, leptin, insulin and IGF-I. However, the cell proliferation response by SKOV-3 
cells to adiponectin at 20 ng/ml and 100 ng/ml suggests an opposite response to Ishikawa 
endometrial cells, in that the hitherto unrecognised stimulatory activity of adiponectin was 
exhibited, but at a higher concentration of adiponectin on SKOV-3 than on Ishikawa cells.  
Interpreting the results presented here is complex. The results suggest, for example, that 
the low adiponectin concentrations and high leptin concentrations that are found in obese 
women with endometrial cancer [209, 411, 412] could have an additive effect because, as 
shown in Chapter 3, both have stimulatory effects on proliferation. However, later 
experiments in which combinations of leptin and low concentrations of adiponectin were 
tested together indicated that the proliferative effects of these hormones were not additive. 
Further, although individual treatments with insulin and IGF-I also increased endometrial 




when in combination with adiponectin gave different results. These observations are a 
warning about making simple speculations concerning the activities of hormones in vivo. The 
implication is that in a pathophysiological environment, manipulating the concentration of a 
single hormone will not necessarily reduce tumorigenicity because the overall effect in vivo is 
not a simple mathematical equation, as found in vitro, but rather a complex network 
controlled by multiple, redundant pathways. In the case of obesity, a reduction in BMI will 
modulate the endocrine environment in a complex way, but this may have the overall effect of 
reducing the risk of endometrial cancer, although results may be expected to vary between 
individual women. 
Also unexpected were the effects of the different hormones on the secretion of VEGF, a 
protein that stimulates the formation of new blood vessels and is critical for tumorigenesis 
[517, 518] .This project revealed that the presence of the tumorigenic hormones leptin, 
insulin, and IGF-I often reduced VEGF secretion from the cells. Thus, the results partially 
refuted the original hypothesis. In contrast, both 20 and 100 ng/ml adiponectin significantly 
increased VEGF secretion from Ishikawa cells. Again, the effects of adiponectin on VEGF 
were also the reverse of the original hypothesis. Typically, therefore, the effects of a hormone 
on cell proliferation and on VEGF secretion were most often in opposite directions in vitro.  
It is possible to speculate on why this inverse relationship between proliferation and 
VEGF secretion occurs in culture cells. It is possible that cell signalling events occur that 
indicate that the local environment contains satisfactory nutrition. In that case, a subsequent 
signal might reduce VEGF secretion because increased vascularisation is unnecessary: 
reducing VEGF production would mean that the cell could conserve its energy expenditure. A 
sensor based on energy balance could regulate this effect, perhaps through detecting the. 
AMP/ATP ratio [519, 520]. Thus, it is possible that because of the increased ratio of ATP to 
AMP, the expression of AMP kinase is reduced, and that this leads to lower secretion of 
VEGF by the cells.  
Thus, AMPK is believed to play a crucial role in regulating VEGF secretion. Indeed, 
AMPK expression was elevated in this study in the presence of adiponectin along with 
increased VEGF secretion. However, leptin did not have an apparent effect on AMPK 




p-AMPK activity in association with lowered VEGF secretion. The variation of the 
association between AMPK expression and VEGF secretion indicates that the hormonal 
effects on VEGF secretion might be mediated via more than just AMPK protein regulation, 
possibly incorporating the energy-regulating capacity of AMPK [519].  
Although numerous studies have reported increases in VEGF secretion following 
treatments with the hormones leptin [521-523], insulin [524-526] and IGF-I [527, 528] this 
study clearly did not observe increases in all cases. It is possible that the experimental design 
and M199 culture conditions used, which involved FBS-free conditions, a low glucose 
concentration (normal level) and the absence of oestrogen supplementation, have an effect on 
cell proliferation and might have enabled exposure of the proposed, underlying  energy-
related process. Thus, with reduced glucose in the media, the energy supply was lower and 
energy conservation becomes important, and so in most cases in this study, energy 
expenditure was prioritised to proliferation over VEGF secretion. This is a situation that may 
correspond to some in vivo circumstances when, for example, vascular supply is poor, and in 
vivo other, non-endocrinological VEGF-stimulating pathways may be activated. 
Cell signalling pathways that are involved in the activities of leptin, adiponectin, insulin 
and IGF-I were studied in this study, with those of leptin and adiponectin investigated in the 
most detail. The PI-3K/Akt pathway is involved in cell proliferation [511, 529]. These 
experiments demonstrated that leptin stimulation of Ishikawa cell growth was inhibited by a 
PI-3K inhibitor, LY294002. A JAK inhibitor, Tyrphostin AG490, also suppressed the leptin 
stimulation of endometrial cancer cell growth. For these reasons, JAK may be a regulatory 
protein for the PI-3K/Akt/mTOR pathway [53, 375, 447] in endometrial cancer cells. Akt and 
p-Akt expression were also enhanced by treatments with 20 ng/ml adiponectin which 
stimulated cell growth, and 100 ng/ml adiponectin which did not enhance Akt expression nor 
promote cell division. STAT3 protein also appears to be an intermediate molecule in the 
pathways of JAK and PI-3K. There was, as a result, evidence to suggest there is cross-talk 
between PI-3K/Akt/mTOR and JAK/STAT3 pathways which are associated with cell growth 
in endometrial cancer. No other papers have reported such interactions in endometrial cancer, 
as different from observations of the paths acting in parallel. Interactions have been reported 




studies on other organs [53, 375, 447]. The involvement of pathways that are conceptually 
different may be an important redundancy in tumour survival.  
A previous study [35] indicated that endocrine ligand receptors are located on cell 
membrane, and perhaps in cytoplasm, but failed to provide evidence for this such as images. 
Using the optical sectioning imaging capacity of the ApoTome system, the collection of Z-
stacks confirmed for the first time that the receptors for the endocrine ligands are present in 
these cancer cell lines, and that they are located in the cytoplasm and nucleus. The separation 
or convergence of signalling following receptor occupancy by the ligand is potentially a point 
of regulation in cancer responses to a hormone, and might be relevant in the variations in 
proliferative responses to the hormones studied here. 
In the present study, treatment with insulin and IGF-I increased expression of Akt and 
phosphorylated Akt, suggesting that Ishikawa cells use the PI-3K/Akt as a pathway for 
hormones to increase cell number. Further study is required to dissect the point(s) at which 
the different signalling pathways PI-3K/Akt/mTOR and JAK/STAT3 interact, and which 
molecules are involved when hormones, which did not act identically when combined with 
adiponectin, are acting together. When extrapolating these results to the in vivo situation it is 
important to note that leptin receptor expression was modulated by adiponectin. This 
observation indicates the potential for interactions to occur between hormones through 
modulating the responsiveness of the second hormone by affecting its receptor expression. 
Thus, a full understanding of the in vivo milieu is dependent on defining the interactions 
between the different components of hormonal signalling and reception. The literature is 
generally deficient of these sorts of investigations, although several studies have investigated 
the two WAT-derived hormones, leptin and adiponectin, because they have putatively 
opposite effects, leptin increased cancer cell proliferation while adiponectin reduced cancer 
cell proliferation [530-532]. Other hormones will also interact and such studies are a logical 
extension of the current project. 
Other pathway studies that included, for example, the Erk pathway [52, 533] would be 
an expansion to this project that might yield valuable data because it acts as a mediator 
between stimulatory pathways such as MEK and MAPK pathways in endometrial cancer. 




fundamental signals involved in tumour progression, and the signalling redundancies that are 
present that provide survival paths for the growth and development of a cancer. A deeper 
characterisation of the signalling processes that are modified by the presence of a second or 
even a third ligand would begin to provide the basis for a model on which to build 
hypotheses. 
VEGF secretion is believed to centrally require AMPK [478]. PI-3K is located upstream 
of AMPK and activates the phosphorylation of AMPK. However, AMPK is possibly not the 
only regulator of VEGF secretion in the experimental conditions used in this study because 
there was no detected effect of leptin on AMPK expression in spite of leptin’s modulation of 
VEGF secretion. Additionally, because the reduction in VEGF induced by leptin is relatively 
small, the relative insensitivity of the Western blot densitometry measurements might mean 
that changes in AMPK activation and phosphorylation could not be detected in this instance. 
Also, the higher adiponectin concentration (100 ng/ml) did not enhance AMPK and p-AMPK 
expression despite this higher adiponectin concentration resulting in increased VEGF 
secretion from Ishikawa cells. These results suggest that VEGF is signalled via multiple, 
different pathways and that the concentration of adiponectin plays a role in choosing the 
relative activation of these pathways. 
Adiponectin may exert its effects on endometrial cancer cells via cross-talk with leptin 
pathways [534]. Also, the identity of this proposed signalling link between increased 
proliferation and decreased VEGF secretion remains to be determined, although other data 
that suggest a positive correlation between cell proliferation and VEGF secretion suggests that 
there may be a vital survival response component based on an energy sensor  [489, 535]. 
Therefore, there may be value in undertaking experiments in different culture media 
containing a range of constituents or with a range of concentrations of FBS. 
Emphasising the further complexity of the hormone systems was the variation in 
responses when the other cell lines were studied. In other words, there was a cell-type 
dependent component to the effects of the hormones. It is uncertain whether this is a result of 
the genotype and/or whether there are tissue-specific factors. The former seems likely to 
explain, at least partially, the differences in the responses of Ishikawa cells and HEC-1A cells, 




response to, for example, 20 ng/ml adiponectin which increased Ishikawa cells proliferation, 
while with HEC-1A cell proliferation was reduced. These results indicated that the regulation 
of tumour progression in vivo will be a complex matter affected by concentrations of 
numerous growth factors as well as other oncogenic entities.  
The differences in this study between the effects of adiponectin at 20 ng/ml and 100 
ng/ml provide a ready example of the importance of details, with the role of concentration 
revealed in these new and intriguing results in multiple ways: 
(a) In some case the results of the two concentrations were similar. They both did not alter 
proliferation of MCF-7 but increased proliferation of SKOV-3 cells at high 
concentration, and both decreased proliferation of HEC-1A cells. The two 
concentrations tended to be always equally active on VEGF secretion - they increased 
VEGF secretion from both Ishikawa cells and HEC-1A and both had no effect on MCF-
7 or SKOV-3 cells. Also adiponectin at neither 20 ng/ml nor 100 ng/ml concentration 
altered adiponectin receptor expression.  
(b) In other cases adiponectin at 20 ng/ml was active but at 100 ng/ml was not - adiponectin at 
20 ng/ml had a positive effect on signalling molecules AMPK, Akt and STAT3 whereas 
adiponectin at 100 ng/ml had no effect. Similarly adiponectin at 20 ng/ml increased 
leptin receptor expression in Ishikawa cells, adiponectin at 100 ng/ml did not.  
(c) Conversely, in Ishikawa cells on leptin-associated increase of proliferation, adiponectin at 
100 ng/ml had a decreasing effect but adiponectin at 20 ng/ml had none and in the 
otherwise unresponsive SKOV-3 cells adiponectin at 100 ng/ml increased proliferation.  
(d) Opposite effects were observed in Ishikawa proliferation (adiponectin at 20 ng/ml 
increased proliferation, 100 ng/ml was associated with a small decrease in 
proliferation). So can I say that adiponectin is actually acting as an anti-cancer hormone, 
as described by some researchers?. Further studies are required. 
Identifying the roles of obesity in generating these compounds and in modulating their 
concentrations and activities is fundamental to understanding the increased risk of 
endometrial, breast and ovarian cancer in overweight individuals. The systematic approach 
taken to examining the effects in the selected four cell lines provides new findings and offers 




hormones having a role in cancers that occur and proliferate in the dysregulated environment 
that is a result of obesity. In particular, it was interesting to note the lower sensitivity to 
obesity-related hormones by the ovarian SKOV-3 cell line compared to endometrial and 
breast lines.  
However, an expanded series of ovarian cancer lines should be investigated to 
determine whether these finding can be replicated across a wider range of mutations and 
cancer subtypes. Reviewing the results here – that the hormones have more effect on three of 
the cell lines but not so much on the ovarian cell line-raises the intriguing possibility that 
there are tissue-related properties. There is a wide range of ovarian cell lines available, and 
undertaking a project on only ovarian lines would be a useful study and would seem to offer a 
most interesting and efficient approach. Nevertheless, it would be profitable to also 
investigate other endometrial and breast cell lines.  
Further insights would also be gleaned by studying the RNA expression of relevant 
genes after being exposed to the hormones. Thus, the endpoint in this project has provided 
excellent entry points for further experiment, but digging deeper will provide a different sort 
of information on points of regulation at translation or transcription control. 
The experiments undertaken in this project indicate that the dysregulated endocrine 
environment associated with obesity has the potential to support the progression of tumours. 
The results revealed parts of the network that makes up the mechanism processes recruited by 
the hormones studied. On the other hand, the observations also pointed to the necessary 
involvement of other entities, which were not studied here, for the full engagement of the 






8.1. Limitations of the study 
It is acknowledged that this study used only a small number of endometrial cancer cell 
lines which might not represent the complete diversity of endometrial cancer genotypes. In 
addition the conclusions that can be drawn from the experiments with both breast cancer and 
ovarian cancer cell lines remain preliminary, although the results obtained in this study do 
open the door to future studies. Furthermore, it must also be acknowledged that results found 
in in vitro cell lines do not always translate directly to in vivo models, where the milieu will 
include various concentrations of many other cellular factors and hormones that may 
influence the response of the cancer cells. Such variations and combination cannot really be 
replicated in the experimental conditions in the laboratory.  
I used 2D as representative of the actions of these hormones on cancer cell lines. Using 
3D cell model, explant models and genetically modified mice could add more value to this 
study but because of time constraints, I could not conduct all these experiments.  Results from 
2D cell monolayer is an early indication of very important knowledge that could lead to 
further investigation of the roles of obesity-related hormones in the stimulation of PI-3K and 
JAKs pathways in animal models. Moreover, 2D models provide useful information – most of 
our knowledge of e.g. pathways, receptor activation, etc has come from 2D in vitro 
incubations. 
Even with these limitations, however, the results from this study remain exciting and 







8.2. Future studies 
i) Of highest priority will be the replication of these experiments in other endometrial 
cancer cell lines as well as in non-cancerous normal cells in order to confirm the 
general attributes of the observations and for comparison. 
 
ii) The details of the proposed energy sensor, linking between increased proliferation and 
decreased VEGF secretion, remain to be determined. Thus, there may be value in 
undertaking experiments in culture media that provide a range of metabolic stress 
(e.g. hypoxia) and energy supply (e.g. glucose concentrations) in order to justify the 
relationships between low and high adiponectin concentrations, and increased VEGF 
secretion from cancer cell lines. Moreover, signalling pathway experiments covering 
the action of 20 ng/ml adiponectin and PI-3K activation and the expression of AMPK 
should be completed. These findings open the door for further studies that will 
provide information on translation or transcription control. Further, details of the 
intriguing oncogenic and inhibitory pathways activated by 20 ng/ml adiponectin 
would also be gleaned by studying RNA expression.  
 
iii) Expansion of the project into in vivo conditions would also provide additional 
information enabling a fuller description of oncogenic processes as well as providing 
a comparison between in vitro and in vivo microenvironments. Alternatively, clinical 
studies might be undertaken in which measurements of hormones in obese women 
with cancer are compared to other phenotypes including diabetes. 
iv) Treating the endometrial cancer cell line, Ishikawa, with normal chemotherapy 
treatment such as Paclitaxel, Carboplatin, Doxorubicin and Cisplatin drugs that used 
on patients to investigate the effects of these drugs on cell proliferation and 
expression of receptors. 
v) There are several models in animals with defined genotypes, perhaps including the 
obese Zucker rat that can be used to explore the roles of the hormones in cancer 




coupled to orthotopic implantation of tumour cells, with these experiments leading to 
further insights. 
vi) It is noteworthy that all four cancer cell lines have oestrogen receptors [432, 536, 537]. 
To investigate whether these receptors are involved in positive or negative action on 
cancer cell proliferation, experiments with an oestrogen receptor negative cell line, or 
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Figure 10.1. Comparison of Ishikawa cell growth in the presence of leptin at 
selected concentrations in two media, M199 and DMEM-F12 which have with 
different glucose concentrations. M199 has 5.5 mM and DMEM-F12 has 17.1 









42 kDa  
Figure 10.2. Random samples for Western blot full molecular weight membrane. 
The samples in first membrane were Ctrl, Leptin, Adp20, Adp100, Insulin and IGF-
I. In second membrane Ctrl, Leptin, Adp100, Insulin, IGF-I, Leptin+Adp100, 







Image sectioning microscope 







The optical section thickness was 0.5 µm for each image. Red = the identified receptor, Blue = nuclei, and Green = cell membrane (actin). All images 












































































































Peptides used as blocker for receptors 
        
Figure 10.3. Immunohistochemical images for receptors of leptin, adiponectin 
and insulin before and after addition of blockers. For Ob-R and InsR, the primary 
antibodies concentration were 1/500, and for IGFR was 1/200. Secondary 






Material and Methods protocols 
Western blot 
Sample preparation 
 Supernatant medium was removed and cells were washed with 0.5 ml PBS and lysed 
with 100 μl RIPA lysis buffer prepared from constituents - (50 mmol/ Tris base (2-Amino-2-
(hydroxymethyl)-1,3-propanediol, Roche, Cat. No. 708976, Indianapolis, IN, USA), 
150 mmol/l NaCl (Sodium chloride, Merck, Cat. No. K 33591704506, Darmstadt, Germany), 
5 mmol/l ethylenediaminetetraacetic acid, 0.1% sodium dodecyl sulfate (SDS) (BDH, Cat. 
No. 44244, UK), 1% NP-40 (acetyl phenol ethylene oxide, Sigma-Aldrich, Cat. No. N-6507), 
0.5% sodium deoxycholate, 1 mM NaVO4, 10% glycerol (Sigma-Aldrich, Cat. No. G 6279-1 
litre), and 1 protease inhibitor tablet, pH 7.4). Cell culture plates were left on ice for 20 
minutes. Cells were scraped off from the bottom of the wells using a pipette tip and the cell 
lysate was transferred to an Eppendorf tube and the total protein concentration in a cell lysate 
was measured by Bio-Rad DC protein assay kit (Cat. No. 500-0113, 500-0114 and 500-0115, 
Hercules, CA, USA). 
SDS gel preparation 
Working solutions for SDS-GEL 
2M Tris-HCl (pH 8.8), 100 ml.  
Tris base (24.2 g) was added to 50 mL Milli-Q water, then concentrated HCl (Sigma-
Aldrich) was added slowly to reach pH 8.8 and distilled water was added to a total volume of 
100 ml and stored at room temperature. 
1M Tris-HCl (pH 6.8), 100 ml.  
Tris base (12.1 g) was added to 50 mL Milli-Q water. Concentrated HCl was added 





2M Tris-HCl (pH 7.4), 100 ml.  
Tris base (24.2 g) was added to 50 ml Milli-Q water then pH adjusted by adding 
concentrated HCl slowly to reach pH 7.4 and water was added to a total volume of 100 ml. 
The solution was stored at room temperature. 
10% SDS (w/v), 100 ml.  
SDS (10 g) was added to 100 ml Milli-Q water and stored at room temperature. 
50% glycerol (v/v), 100 ml.  
100% glycerol (50 ml) was added to 100 ml Milli-Q water. Solution was stored at room 
temperature. 
10x sample buffer.  
Tris-HCl pH 6.8 (600 µl), 5 ml of 50% Glycerol, 2 ml of 10% SDS, and 2 ml of 1% 
bromophenol was added to 5.4 ml Milli-Q water to a total volume of 10 ml. The solution was 
stored at -20°C. 
Stock solutions for SDS-GEL 
Solution B, 100 ml.  
75 ml of 2 M Tris-HCl (pH 8.8) (1.5 M) was added to 4 ml 10% SDS (0.4%) and Milli-
Q water was added to a total volume of 100 ml and stored at 4°C. 
Solution C, 100 ml.  
50 ml of 1 M Tris-HCl (pH 6.8) (0.5 M) was added to 4 ml 10% SDS (0.4%) and Milli-
Q water was added to a total volume of 100 ml and stored at 4°C. 
10% ammonium persulphate, 5 ml.  
Ammonium persulphate (Boehringer, Cat. No. 100 190, Phoenixville, PA, USA) (0.5 g) 




Electrophoresis buffer, 1 litre.  
Tris base 25 mM (3 g), glycine (Sigma-Aldrich, Cat. No. G 8898-1 Kg) 192 mM (14.4 
g), and SDS (1 g) were dissolved in Milli-Q water to a total volume of 1 litre and stored at 
room temperature. 
Transfer buffer, 1 litre.  
Tris base (1.93 g) and glycine (9 g) were dissolved in Milli-Q water to a total volume of 
1 litre and stored at 4ºC. 
Tris-Buffer-Saline plus Tween-20 (TBS-T).  
NaCl 140 mM (8.18) g was dissolved in 10 ml of 2 M Tris-HCl pH (7.4) 20 mM. Then 
Milli-Q water was added to a total volume of 1 litre.  The solution was autoclaved and cooled. 
Tween-20 (Sigma-Aldrich, Cat. No. P 5927-500 ml) (1 ml) was added and stored at room 
temperature. 
SDS-PAGE Separating Gel (10%), preparing 2 gels.  
4.17 ml of Milli-Q water were added to 2.5 ml of solution B (see paragraph above) then 
Acrylamide/Bis 40% (N,N’-methylene-bis-acrylamide, Bio-Rad, Cat. No. 161-0148) (3.33 
ml) was added. Then ammonium persulphate 10% (50 µl) also was added. TEMED (5 µl) was 
added and mixed before pouring the solution in the apparatus. Water was added to the top of 
the glass and the apparatus left in a 37°C incubator for 1 hour to polymerise. 
SDS-PAGE Separating Gel (12%), preparing 2 gels.  
3.5 ml of Milli-Q water were added to 2.5 ml of solution B then 4 ml of acrylamide/bis 
40%, 50 µl of ammonium persulphate 10% and TEMED 5 µl were added directly before 
pouring the solution into the apparatus. Addition of water continued to the top of the glass. 
The apparatus was placed in a 37°C incubator for 1 hour to polymerise. 
SDS-PAGE stacking Gel (7%), prepare 2 gels.  
2 ml of Milli-Q water were added to 1 ml of solution C then acrylamide/bis 40 % (1 
ml), ammonium persulphate 10 % (40 µl), TEMED (5 µl) were added and mixed together 




proper position on the top of the glass and the apparatus was left at room temperature for 30 
minutes to polymerise. 
Preparation of cell lysate for SDS-GEL 
Sample buffer (10 µl of 10x) was added to each 100 µl of cell lysate. Tubes were boiled 
at 100°C for 10 minutes then cooled down and the tubes were placed on ice. When tubes 
reached room temperature they were centrifuged at 8040g for 7 minutes. Samples were kept 
on ice until loading. The samples were stored in a freezer for further experiments.  
The samples containing 10 μg of the total proteins were loaded in each well of SDS-
GEL as shown below.  
MW ladder Ctrl S 1 S2 S3 S4 S5 S6 S7 Dye 
The marker contained 4 µl Precision Plus protein Dual color standard (Bio-Rad, Cat. 
No. 161-0374) and 1 µl Magic Mark Western standard (Invitrogen, Cat. No. P/N LC5602) 
and were added to the gel well. 
Following gel electrophoresis, proteins were electrophoretically transferred to 
polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Cat. No. 162-0177) in ice cold 
transfer buffer at 100 Volt for 1 hour. Then membranes were blocked with the blocker 
solution that was appropriate for each antibody (Table 2.1) for 1 hour at room temperature. 
Specific immuno-detections were carried out by incubation with relevant primary antibodies. 
The PVDF membranes were incubated with relevant primary antibodies overnight at 
4°C. After three washes with TBS-T buffer, the membranes were incubated for 90 minutes 
with secondary antibody (horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse 
immunoglobulin G) (Table 2.1), diluted 1:10,000 in TBS-T at room temperature. Antigens 
were revealed using ECL developing solution (Amersham, ECL Prime Western Blotting 
Detection Reagent, ge-9466588; GE Healthcare, Little Chalfont, UK). 
The presence of proteins was imaged and captured using UVITEC Cambridge / Alliance 
4.7 device and measured by UV band software programme. 
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